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“Gesuperviseerde looptherapie is een 
veilige en de meest kosteneffectieve 
behandeling voor patiënten met claudicatio 
intermittens. Idealiter richt gesuperviseerde 
looptherapie zich naast het vergroten van 
de loopafstand, balans en spierkracht op 
(ongezonde) leefstijlfactoren. Stimuleren 
van fysieke dagelijkse activiteit, stoppen 
met roken en een verantwoord eetpatroon 
worden zo onderdeel van de algemene 
‘claudicatiobehandeling’. Dergelijke aanpak 
moet zorgen voor een meer duurzame 
behandeling van deze patiëntengroep.”
Lindy Gommans
Supervised Exercise Therapy  for Intermittent Claudication 
 
subgroups, gait and physical activity
Lindy Nicolaas Maria Gommans
 


Supervised Exercise Therapy  
 
for Intermittent Claudication 
 
subgroups, gait and physical activity
Lindy Nicolaas Maria Gommans
Colofon
Author:   Lindy Nicolaas Maria Gommans
Cover design en lay-out:  Miranda Dood, Mirakels Ontwerp
Printing:  Gildeprint - The Netherlands
ISBN:   978-90-9029455-1
© L.N.M. Gommans, 2015
All rights reserved. No part of this publication may be reproduced or transmitted
in any form by any means, without permission of the author.
Printing of this thesis was financially supported by:
ClaudicatioNet - Catharina Ziekenhuis - Maxima Medisch Centrum - Lode / Procare - McRoberts -  
The Scientific College Physical Therapy (WCF) of the Royal Dutch Society for Physical Therapy (KNGF) -  
Rabobank - Samcon - Stichting Fonds voor het Hart
Financial support by the Dutch Heart Foundation for the publication of this thesis is gratefully  
acknowledged
Supervised Exercise Therapy  
 
for Intermittent Claudication 
 
subgroups, gait and physical activity
Proefschrift
ter verkrijging van de graad van doctor
aan de Universiteit Maastricht,
op gezag van de Rector Magnificus, prof. dr. L.L.G. Soete
volgens het besluit van het College van Decanen,
in het openbaar te verdedigen
op dinsdag 22 december 2015 om 12:00 uur
door
Lindy Nicolaas Maria Gommans
 
Geboren op 18 september 1985 
te Venlo
Promotor  
Prof. dr. J.A.W. Teijink
Copromotoren 
Dr. M.R.M. Scheltinga (Máxima Medisch Centrum, Veldhoven)
Dr. K. Meijer
Beoordelingscommissie
Prof. dr. M.H. Prins (voorzitter)
Prof. dr. H. ten Cate
Prof. dr. I.C. Heyligers
Prof. dr. ir. N. Verdonschot (Radboud Universitair Medisch Centrum, Nijmegen)

Supervised exercise therapy for intermittent claudication
TABLE OF CONTENTS
Chapter 1
Chapter 2
Chapter 3
Chapter 4
Chapter 5
Chapter 6
Chapter 7
General introduction and outline of thesis.
Adapted from “Attitudes to supervised exercise therapy”, Br J Surg. 
2015 Sep;102(10):1153-5.
The effect of supervision on walking distance in patients 
with intermittent claudication: a meta-analysis.  
Eur J Vasc Endovasc Surg. 2014 Aug;48(2):169-84.
Safety of supervised exercise therapy in patients with 
intermittent claudication.
J Vasc Surg. 2015 Feb;61(2):512-518.
Gender differences following supervised exercise  
therapy in patients with intermittent claudication. 
J Vasc Surg. 2015 Sep;62(3):681-8.
Effect of diabetes on outcomes of supervised exercise 
therapy for intermittent claudication.  
Submitted to J Vasc Surg.
The minimally important difference of absolute and 
functional claudication distance in patients with 
intermittent claudication. 
Accepted in Eur J Vasc Endovasc Surg.
Minimal correlation between physical exercise capacity  
and daily activity in patients with intermittent claudication. 
Accepted in J Vasc Surg.
p.12
p.26
p.60
p.88
p.110
p.128
p.144
Table of contents
Chapter 8
Chapter 9
Chapter 10
Chapter 11
Chapter 12
Intermittent claudication prolongs stance phase 
during walking. 
Submitted to Eur J Vasc Endovasc Surg.
Altered joint kinematics and increased electromyographic 
muscle activity during walking in patients with intermittent 
claudication. 
Accepted in J Vasc Surg.
Summary & general discussion 
Samenvatting & algemene discussie
Valorisatie 
Dankwoord
List of publications
Curriculum vitae
p.164
p.184
p.206
p.232
p.256
p.266
p.272
p.275
 
1
CHAPTER 1
General introduction and outline of 
the thesis 
  
Adapted from “Attitudes to supervised exercise  
therapy”, Br J Surg. 2015 Sep;102(10):1153-5.
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1 PERIPHERAL ARTERIAL DISEASE
Peripheral arterial disease (PAD) is a chronic atherosclerotic disease resulting in 
obstruction or occlusion of the large peripheral arteries.1 Symptoms of lower extremity 
PAD are classified according to Rutherford and range from mild, moderate and severe 
claudication (stage 1-3) respectively, to pain at rest and/or at night (stage 4) or ulceration 
or necrosis (stage 5-6).1 Major amputation of the affected limb is required in less than 1% 
of the patients per year.2 Conversely, the majority of patients with PAD are asymptomatic 
(stage 0). 
Risk factors associated with PAD are similar to those classically identified for coronary 
and cerebrovascular diseases.3 However, the relative importance of these factors may be 
different in PAD. Numerous reports have now confirmed that advanced age, tobacco use 
and diabetes mellitus are the most important risk factors for developing PAD.4 
The prevalence of PAD is approximately 15% among people aged >69 years.4 A 
conservative estimate revealed that worldwide some 202 million individuals are having 
PAD.5 In high-income countries, PAD prevalence is equal between men and women. 
In aging populations where cigarette smoking persists and the incidences of diabetes 
mellitus, hypertension and obesity continue to grow, PAD prevalence is expected to 
increase in the upcoming years.5 As a result, growing numbers of PAD patients will 
increasingly drain (inter)national health care resources. 
INTERMITTENT CLAUDICATION
Intermittent claudication (IC) is the most common clinical manifestation of PAD. It was 
found that up to 40% of PAD population suffers from IC.1 IC can be defined as muscle 
pain/discomfort in the lower limbs during exercise that is relieved after a short period of 
rest.1 Obstruction of the arterial blood supply to the leg muscles limits augmented blood 
flow when required during exercise. As a consequence, a mismatch between oxygen and 
muscle metabolic demand leads to cramps and pain in calf, thigh, and/or buttock. 
The range of symptom severity and consequent effects on daily function and quality 
of life may vary widely among IC patients.6 Moreover, concomitant conditions such as 
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1cardiopulmonary disease, arthritis and obesity can markedly limit exercise capacity. The 
presence of IC is associated with serious health risks as an approximately 20% five-year 
mortality rate is reported, most commonly due to cardiovascular causes.1 
TREATMENT FOR INTERMITTENT CLAUDICATION
IC treatment should consist of two modules, cardiovascular risk management including 
lifestyle modification and symptomatic therapy. The first aims to prevent the onset of 
cardiovascular events (i.e. myocardial infarction, stroke) and related comorbidity and 
mortality in this high risk patient group. Cardiovascular risk management consists of 
antiplatelet and statin therapy and optimal treatment of hypertension and diabetes. 
Lifestyle modification ideally focusses on smoking cessation, weight reduction, a balanced 
diet and increased daily physical activity level. Many of these recommendations for risk-
factor modification in PAD/IC were extrapolated from literature on secondary prevention 
in coronary artery disease. Evidence specific to PAD regarding these measures is largely 
lacking. Similarly, high-quality trials on the effect of health-behavior changes techniques 
in IC patients are required.7
The first-line symptomatic treatment of IC is conservative. According to contemporary 
international guidelines, supervised exercise therapy (SET) should be provided to all 
patients with IC.4, 8 SET comprises of regular training under supervision of a physical 
therapist (in the Dutch situation), or any other exercise specialist. Although the optimal 
content and frequency of SET are unclear9, most frequently described programs consist 
of interval-based (treadmill) walking to a near-maximum pain level. A combination with 
both cardiopulmonary endurance and strength training at a minimum of three times per 
week (30-60 minutes per session) for at least 12 weeks is advised.10
SET for IC is a refinement of a basic exercise therapy as originally described in 
1898 by a German neurologist Wilhelm Erb.11 In 1966, a randomized clinical trial by 
Larsen et al. demonstrated a significantly improved maximum walking distance in the 
intervention group (instructed to take an extra daily walk of at least one hour) versus 
controls (receiving a placebo medical treatment of lactose tablets).12 Nowadays, SET has 
repeatedly proven to be the most effective among conservative therapies with respect to 
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1 decreasing IC symptoms, increasing walking capacity and improving quality of life.13, 14 
Moreover, a 12-week SET program showed to reduce the overall cardiovascular mortality 
by 52% and morbidity by 30%.15 SET is in essence an ‘athletic’ training, albeit on a much 
more limited scale than generally practiced by elite athletes. However, the potential 
biomechanical mechanisms underlying the effect of SET are largely exercise-related 
and include enlargement of existing collateral vessels, exercise-induced angiogenesis, 
enhanced nitric oxide endothelium-dependent microcirculation vasodilatation, 
improved skeletal muscles bioenergetics and better hemorheology.4, 16
If SET fails to achieve satisfying results, invasive techniques may be considered such 
as a percutaneous transluminal angioplasty (PTA) or vascular surgery (i.e. bypass).8 A 
stent may for instance be inserted to ensure the vessel’s patency. Good results of these 
invasive interventions for IC are reported.17 However, effects on walking capacity and 
quality of life are similar for either SET or invasive revascularization after long-term 
follow-up.18, 19 These results are not unexpected as restoration of the peripheral circulation 
itself does not provide the necessarily behavioral change.20 Moreover, the irrevocable 
risks associated with invasive procedures (i.e. bleeding, infection, thrombo-embolic 
events) and associated substantial costs need to be considered when deciding to perform 
an intervention. 
ATTITUDES TO SUPERVISED EXERCISE THERAPY
Despite the substantial evidence on the (cost-)effectiveness of SET21-25 and the 
contemporary guideline recommendations, SET is largely underused26 and most IC 
patients still do not receive SET.26 A recent analysis of invoice data from a Dutch health 
insurance company found that only 14% of the patients with IC were initially referred for 
SET.27 Interestingly, in January 2015 The New York Times highlighted the inappropriate 
use of invasive interventions for patients with IC.28 This article questioned conflicts of 
interest and motives of doctors performing these interventions in view of the potential 
harm for patients and unnecessary costs for the healthcare system. 
There seem to be three categories of reasons why this cost-effective treatment 
is not widely adopted yet.29, 30 First, there is resistance among patients as effort and 
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1responsibility are required rather than undergoing a ‘fast fix’ for their discomfort. 
However, decisions regarding therapy are nowadays a shared responsibility (‘shared 
decision making’). Second, resistance in clinicians themselves. Self-interest of doctors 
performing interventions that involve fee-for-service is undoubtedly a contributor. Next 
to the powerful influence of the medical devices industry who repeatedly underscore 
the argument of an immediate effect, underline ever-increasing long-term patencies, 
and continue to lobby and sponsor scientific meetings. Moreover, outdated arguments 
for performing an invasive intervention, instead of prescribing SET, are still prevailing 
among clinicians. However, it must be appreciated that the CLEVER study (Claudication: 
Exercise Versus Endoluminal Revascularization) in symptomatic aortoiliac stenosis 
provided clear evidence that improvement in functional status and quality of life 
following PTA and stenting or SET were comparable after a 18 months follow-up.18 
Results of the SUPERvised Exercise Therapy or Endovascular Revascularization for 
Intermittent Claudication due to an Iliac Artery obstruction (SUPER) trial have to be 
awaited to provide further insight on this subgroup of IC patients. Third and foremost 
important category, is the ongoing resistance of politicians, health policy makers and 
insurers who persist to ignore SET and fail to stimulate measures for SET access and 
reimbursement. In most countries of the world, as the Netherlands is a rare exemption, 
SET programs are not readily available.26, 31 As a result, even clinicians who fully endorse 
SET as initial treatment for IC may end up performing invasive interventions if their 
patients cannot find a qualified SET practitioner or SET appears to be not reimbursed by 
their health care insurer. Surprisingly, for a tenfold expensive invasive intervention no 
budgetary restrictions exist. In addition, incipient SET initiatives, in the UK for example, 
are prevented from coming to fruition by a lack of funding.32 
GENERAL AIM OF THE THESIS
This thesis aims to enhance knowledge on various aspects of SET in patients with IC. In 
the first part, current barriers and misconceptions regarding the indications for SET in 
certain subgroups are elucidated. In the second part, various aspects of gait pattern in 
IC and correlations between physical exercise capacity outcomes and daily activity are 
16
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1 studied. This thesis strives to contribute in minimizing barriers for SET referral. Moreover, 
results of this thesis may facilitate the development of new rehabilitation strategies, may 
promote the initiation of studies quantifying the effects of specified supervised exercise 
regimens and may introduce potential new outcome parameters in IC. 
Specific aims of the thesis 
1. To evaluate the safety of supervised exercise therapy in patients with IC.
2. To summarize the evidence on the effect of exercise therapy with various levels of 
supervision on walking distance in IC.
3. To assess gender-specific outcomes of supervised exercise therapy in IC.
4. To study the literature on the effect of diabetes on walking distance after supervised 
exercise therapy in IC.
5. To define the minimally important difference of treadmill-based walking distances 
in IC.
6. To determine correlations between physical exercise capacity and daily activity of 
patients with IC.
7. To describe spatio-temporal parameters, kinematics and electromyographic muscle 
profiles of the gait pattern in IC.
OUTLINE OF THE THESIS
It has been suggested that some patients with IC may be unsuitable for SET as they also 
suffer from co-morbidities leading to increased safety risks.29 There is no evidence to 
support such claims, but literature addressing the safety issue in IC is lacking. Chapter 2 
describes the results of a systematic review evaluating the safety of SET by determining 
the number of (cardiovascular) adverse events during SET in patients with IC. 
Recent studies reported on the value of home-based exercise programs for patients 
with IC.34, 35 These programs might be an attractive alternative to SET, considering the 
limited availability of SET in countries other than the Netherlands. However, there is only 
‘low-level’ evidence that home-based programs improve walking capacity and quality of 
life in patients with IC.36 Therefore, a meta-analysis is provided in chapter 3 to study the 
17
General introduction and outline
1value of home-based programs by comparing results of a control group, a ‘go home, and 
walk’ advice group and a group receiving the conventional SET program. 
Prevalence of IC is equal among men and women.4 Surprisingly, no study has 
addressed the possible gender-specific response to SET in terms of absolute walking 
distances or perceived walking (dis)ability yet. This paucity of data is likely due to a 
consistent female underrepresentation in randomized controlled trials. However, the 
idea of gender-specific responses to SET in patients with IC is sensible considering data 
from cardiac rehabilitation where gender-specific programs are readily discussed.37 In 
line with a recent scientific statement of the American Heart Association releasing a ‘call 
to action’ for more research into gender-based differences of patients with PAD38, chapter 
4 describes an analysis on the response of men and women with IC to SET. 
Diabetes mellitus (DM) is a strong risk factor for the development of PAD.39 DM 
is known to affect almost each vascular bed and it is associated with an impaired 
microvascular function in patients with IC. Moreover, IC patients with DM demonstrate 
reduced physical function as compared to IC patients without DM.40 It has previously been 
suggested that IC patients with comorbidities might benefit less from SET.29 However, the 
available evidence is not yet overviewed yet. In chapter 5 a review is provided aimed at 
studying the current literature on the effect of DM regarding the response of patients with 
IC to SET. 
Effects of SET are usually evaluated in term of (improved) walking capacity by using 
a treadmill test. Walking distance however is an outcome parameter with limitations. 
Nonetheless, it is widely used in clinical trials and daily practice, as its value in assessing 
treatment effect has been well established.41, 42 Minimally important differences (MID) 
of commonly used outcome measures can aid clinicians and researchers in determining 
what numerical change indicates a clinically meaningful change from a patient’s 
perception. For treadmill-based walking distances in patients with IC, MIDs have not 
been determined yet. Therefore, MIDs for maximal and functional walking distance are 
assessed in an IC population in chapter 6. 
Recent insight suggested that improved exercise (i.e. walking) capacity does not 
automatically imply an increase in daily physical activity (PA).43 In addition, it has 
increasingly been recognized that PA is a strong predictor of morbidity and mortality in 
patients with IC.44 Whether exercise capacity outcomes could serve as a surrogate marker 
18
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1 for PA is currently unknown, as the relationship between exercise capacity and daily PA 
is still unclear. In chapter 7 the association between exercise capacity and daily PA is 
studied in patients with IC.  
It is known that patients with IC consume about 40% more oxygen during normal 
walking at a speed similar to healthy controls, possibly due to biomechanical changes.45 
A limited number of suboptimal studies included gait analysis in patients with IC.42, 43 In 
chapter 8, spatio-temporal parameters of gait in patients with IC are described. 
Subsequent electromyographic and kinematic analyses aimed at responding to a priori 
generated hypotheses are described in chapter 9. Results of these studies may lead to new 
targets in the development of SET programs for IC. 
In chapter 10, the main findings of this thesis are discussed including methodological 
aspects of the different studies, implications for clinical practice and suggestions for future 
research. A Dutch summary, discussion and valorization are provided in chapter 11. 
Finally, chapter 12 includes the acknowledgements, list of publications and curriculum 
vitae of the author.
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2ABSTRACT
Background: A number of reviews reported on the influence of exercise therapy (ET) for 
treatment of intermittent claudication (IC). However, a complete overview of different 
types of ET is lacking. The aim of this meta-analysis is to study the effect of supervision 
on walking capacity in IC. We hypothesized the presence of a positive treatment effect 
in relation to intensity of supervision and improvement of walking capacity (‘dose – 
response’ hypothesis).
Methods: A systematic search in CENTRAL, MEDLINE and EMBASE was performed 
(January 1966 to March 2013). Only randomized controlled trials (RCTs) evaluating the 
efficacy of an ET in IC were included. Type of supervision, treadmill protocol, length 
of ET, total training volume and change in walking distance were extracted. RCTs were 
categorized according to type of support: no exercise (NO-ET), walking advice (WA), 
home-based exercise (HB-ET) and supervised exercise therapy (SET). A standardized 
mean difference (SMD) between pre- and post-training maximal walking distance 
(MWD) and pain-free walking distance (PFWD) was calculated for all subgroups at six 
weeks, three and six months of follow up (FU).
Results: A total of 30 studies involving 1406 IC patients were included. The overall quality 
was moderate to good although number of included patients varied widely (20 to 304). 
Intensity of supervision was directly related to MWD and PFWD. SET was superior 
compared to other conservative treatment regimens with respect to improvement in 
walking distances at all FU moments. However, the difference between HB-ET and SET 
at six months of follow up was not significant.
Conclusion: Supervised exercise therapy for intermittent claudication is superior 
compared to all other forms of exercise therapy. Intensity of supervision is related to 
improved walking distances.
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INTRODUCTION
Worldwide, 202 million people were coping with peripheral arterial obstructive disease 
(PAOD) in the year of 2010.1 During the preceding decade, the number of affected 
individuals increased by 13.1% and 28.7% in high and low-middle income countries, 
respectively.1 These huge numbers illustrate that PAOD has become a global health 
problem affecting vast quantities of individuals. Some 50% to 80% of PAOD patients are 
symptomatic and suffer from intermittent claudication (IC), the mildest manifestation of 
symptomatic arterial obstructive disease.2 
International guidelines indicate that the treatment of IC should consist of 
cardiovascular risk management to protect patients from cardiovascular events and 
related morbidity and mortality. Moreover, supervised exercise therapy (SET) is advised to 
reduce symptoms and restore physical function.2-3 However, widespread implementation 
of SET is restricted by the combination of insufficient number of available facilities and 
issues on reimbursement, awareness and motivation.2, 4-6 To overcome some of these 
problems, a community based network for SET was implemented in the Netherlands.5 
Community based SET solves the problem of transportation time and costs for individual 
patients as well as the restricted capacity of hospital based SET.7-8 Others suggested to 
initiate exercise programs in a home-based environment and thereby diminishing the 
amount of labour-intensive supervision.9-10 A recent published trial revealed promising 
results regarding the effect of such an approach.11
Several reviews are currently available regarding the value of different conservative 
treatment options in IC.12-16 However, no meta-analysis compared SET with home-
based exercise, non-supervised regimens and a control group yet. A recently updated 
Cochrane review compared unsupervised exercise with supervised exercise concerning 
walking improvement.16 A second review that was aimed to identify components of SET 
contributing to maximal improvement of walking capacity only compared supervised 
exercise with no exercise at all.13 Despite the use of strict inclusion criteria in both 
reviews, some overlap in included trials was inevitable. Moreover, the latter reported that 
neither intensity nor duration or program content were independently associated with 
improvement of maximal or pain-free walking distance, but the role of support was not 
addressed.
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The present effort was aimed to evaluate the effect of various grades of supervision on 
walking capacity by providing a meta-analysis of existing literature concerning exercise 
programs for IC. It was hypothesized that a dose-response relationship was present 
between supervision and improvement on walking capacity. 
METHODS
Eligibility criteria
Only randomized controlled trials (RCT) on patients with IC (Fontaine II/Rutherford 
1-3) were eligible for inclusion in this meta-analysis. A RCT was included if each 
intervention group received at least one type of exercise, if type of supervision was 
different between study groups, if supervision and duration of exercise therapy (ET) 
exceeded six consecutive weeks, and if >50% of the exercise time included lower limb 
training. Outcomes had to be reported as maximal walking distance/time (MWD/T) 
or pain free walking distance/time (PFWD/T), or both. Only English or Dutch studies 
were included. Trials with a control group undergoing invasive therapy or specific drug 
treatment were excluded.
Trial selection strategy
The electronic search was conducted in MEDLINE (1966 to March 2013), EMBASE (1974 
to March 2013) and the Cochrane Central Register of Controlled Trials (CENTRAL) 
database (1966 to September 2012). The search strategy contained the following 
MeSH terms: Arteriosclerosis, Arterial Occlusive Diseases, Intermittent Claudication, 
Peripheral Vascular Diseases, Exercise, Exercise Therapy, Physical Exertion, Sports, 
Exercise Movement Techniques, Locomotion, Leisure Activities, Fitness Centers, and 
Physical Exertion. In addition, reference lists of papers identified from these searches 
were hand searched for additional trials. Three authors (LG, RS and HF) independently 
selected trials on the basis of title and abstract. A definite selection was based on a full-
text evaluation of the report. Disagreement between the reviewers was discussed and 
resolved by consensus.
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Risk of bias assessment
The included articles were assessed with the Cochrane scale by two authors (LG and 
RS) to determine methodological quality and to assess the risk of bias. Blinding of 
staff and patients during exercise programs is not possible and was therefore not taken 
into account. Study quality was determined using a table of risk of bias on the basis of 
a checklist of design components including random sequence generation, allocation 
concealment, incomplete outcome data and selective reporting (appendix I). Adequacy of 
each category was assessed as ’low’, ’unclear’, or ’high’ risk, as suggested in the Cochrane 
Collaboration Handbook.17
Data collection and processing
Trial data were extracted by three authors (LG, HF and RS) using a standardized data 
extraction form that was checked by a fourth author (SH). Study characteristics, year 
of publication, study location and type of supervision were collected as well as patient 
group characteristics including mean age and sex, number of patients in each group and 
walking distances (maximal walking distance (MWD) and pain free walking distance 
(PFWD), pre- and post-training). Authors were contacted for additional information in 
case of ambiguity or missing data.
When maximal or pain-free walking time were reported, conversion into distances 
(meters) was performed by multiplying the time spent on the treadmill with the given 
walking speed (m/s). If standard errors (SE) were available (and authors did not reply or 
declined our request to send unpublished data), we converted these values into standard 
deviations (SD). In articles reporting non-parametric data, the SD was calculated by 
dividing the interquartile range (IQR) by 1.35 as suggested by the Cochrane Handbook.17 
Labeling of supervision
Two authors (RS and LG) independently categorized treatment arms per study by 
classifying the type of supervision given per arm. The following groups were defined:
Control group - No Exercise Therapy (NO-ET): Participants were mainly advised to 
consolidate current levels of activities, while some additionally received best medical 
treatment (BMT). Supervised walking exercise or a walking advice was not provided 
during the treatment period. 
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Walking Advice (WA): Participants were actively advised by a physician, nurse or physical 
therapist to increase activity levels by walking, defined as a “go home and walk” advice. 
However, supervision or monitoring was absent.
Home-based Exercise Therapy (HB-ET): Participants were advised to increase physical 
activity that was monitored by keeping a walking diary, by pedometers or by using 
physical activity monitors. They were stimulated by regular telephone calls or were visited 
at home. Active monitoring by a physician, nurse or physiotherapist was limited to a 
maximum of two moments per week.
Supervised Exercise Therapy (SET): Participants were treated with a SET regimen with 
or without an additional walking advice. The training was hospital- or community-
based under supervision of a physical therapist or other trained medical personnel. The 
program consisted of a least two supervised sessions per week.
Statistical analysis 
The main outcome was difference in walking distances (MWD and PFWD) after 
treatment (i.e. NO-ET, WA, HB-ET and SET) compared to baseline measures. Results are 
presented as standardized mean difference (SMD) with 95% confidence intervals (CIs), 
at 6 weeks, 3 and 6 months follow-up. SMD expresses the size of the intervention effect 
in each study relative to the variability observed in that study. It is used as a summary 
statistic when studies assess the same outcome but measure it in a variety of ways17, as 
in our meta-analysis by the use of different treadmill protocols. We used a DerSimonian 
and Laird random-effects model to pool continuous data of each group.18 We examined 
statistical heterogeneity with Cochran’s test and I2 statistic measured. Studies with an 
initial supervised period followed by an unsupervised follow-up period were analyzed 
separately in a sensitivity analysis.
Differences in SMD between the subgroups were investigated as a means to evaluate 
the presence of a dose-response relation. Testing for subgroup differences based on 
random-effects models are preferable to those based on fixed-effects, due to the high risk 
of false-positive results in a fixed-effect model.19 Therefore, we only applied a random-
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effects model as previously described. A test for subgroup differences as described by 
Borenstein was used.20 
Review Manager Software of the Cochrane Collaboration (version 5.2, Cochrane 
Collaboration) was used for SMD calculation, pooled effect estimation, test for 
heterogeneity and determination of differences between SMDs of the subgroups. A two-
sided p-value <0.05 was considered statistically significant. Graphs were created with 
Graphpad Prism 6 (GraphPad Software Inc, La Jolla, USA). 
RESULTS
Study selection
In the MEDLINE and EMBASE search, 2544 studies were identified. Another 240 
potentially relevant studies were found by a search using the CENTRAL library whereas 
the hand search yielded another 8 eligible studies. After removing duplicates and selection 
based on title and abstract, a total of 108 studies underwent full text reviewing. A total of 
78 studies was excluded by failing to meet predefined criteria. Eventually, 28 RCTs met all 
inclusion criteria. A flow chart of the trial selection is depicted in figure 1.
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Figure 1. Flow chart of trial selection
2,544 records identified in MEDLINE 
and EMBASE databases 
2,792 records 
2,595 records excluded: not relevant
28 studies included
80 full-text articles excluded:
• No usable outcome measures
• No RCT
• No difference in supervision
• Less than 50% walking
• Control group with drugs or 
surgical intervention
• Review or meta-analysis
8 records identified by hand search 240 records identified in the CENTRAL library
Removal of 89 duplicates 
2,703 records screened on title and 
abstracts
108 full-text articles reviewed 
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Study characteristics
A total of 1406 participants (68% males, mean age 68 years) were studied (table 1). All 
trials were conducted between 1974 and 2012 in eight different countries. The NO-ET 
group was formed on the basis of data derived from sixteen trials containing a total of 
262 participants (table 1). The WA group was formed on the basis of ten trials with a total 
of 302 participants (table 1). Walking instructions were generally provided at baseline. 
Patients were mostly advised to continue to walk to near maximal pain. One study 
provided patients with an additional brochure26, while patients were educated using video 
material in another.10 Two studies stipulated that patients did not receive any life-style 
coaching or risk factor management.11, 31 The HB-ET group consisted of 140 participants 
obtained from six trials (table 1). Subjects received similar walking advice as the WA 
group, although regimens were supplemented with weekly (telephone) contact.9-11, 21-23 In 
two studies, participants had to log their exercise9, 11, while in a third study participants 
received SET once a week.10 
All trials used a SET regimen as comparator (n=702) except for one study which 
compared a home-based exercise regimen with a group receiving a walking advice.10 
In seven trials, subjects were treated twice a week with SET26, 28-29, 34-35, 45, 47, while in the 
remaining trials SET was given three times a week (table 2). The length of the ET programs 
varied between 6 and 52 weeks with nine, twenty and sixteen trials lasting 6 weeks, 3 and 
6 months, respectively (table 2). One trial consisted of a WA group, a HB-ET group and 
a SET group; all three arms were included.11 A graded treadmill protocol was used in 23 
trials, while the remaining 7 trials used a fixed protocol (table 1). Outcome was based on 
a conversion from a time to distance format in eight studies.
Risk of bias assessment
The risk of bias is presented in appendix II. Of the included trials, 83% reported random 
sequence generation whereas a mere 27% used allocation concealment. The outcome 
assessor was blinded for intervention in 23% of the trials. In 57% correct handling of 
incomplete outcome measures was reported, while description of all outcome measures 
was provided in 93% of the trials. The overall quality of included trials was rated as 
moderate to good.
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Effect of interventions
Six weeks
Sixteen studies reported data on MWD and 13 on PFWD at 6 weeks of follow up. No studies 
were found that investigated the effect of home-based exercise on walking distances at 6 
weeks of follow up. A non-significant effect on MWD was present for both the NO-ET 
and WA programs, while on PFWD both programs groups showed a significant increase 
in SMD. The SET regimen demonstrated a significant increase in SMD of 0.90 (95% CI: 
0.67 – 1.13) and 0.94 (95% CI: 0.64 – 1.24) for MWD and PFWD, respectively (figure 
2). Significant differences between groups were only found when comparing with the 
SET group (figure 2). Heterogeneity was absent for all groups on MWD and PFWD (All: 
I2<15%; P>.32).
Three months
Results of MWD were reported in 8, 6, 5 and 20 trials for NO-ET, WA, HB-ET and SET 
groups, respectively. PFWD was described in 6, 3, 5 and 13 trials for the subsequent 
groups. A significant increase in MWD was found for the WA, HB-ET and SET programs, 
whereas only the SET program revealed a significant effect for PFWD too (figure 3). The 
SET program showed a significant difference compared to all other groups. MWD was 
also significantly higher in the HB-ET compared to the NO-ET group. There was no 
heterogeneity for all groups on MWD and PFWD (All: I2<18%; P>.29) except for the SET 
group (MWD: I2=83%; P<.001, PFWD: I2=87%; P<.001).
Six months
Results of MWD were reported in 6, 5, 1 and 9 trials for NO-ET, WA, HB-ET and SET 
groups, respectively. PFWD was described in 2, 3, 1 and 4 trials, respectively. A non-
significant increase in MWD and PFWD compared to baseline measurements was found 
for the NO-ET. For the WA and SET group however, the increase in MWD and PFWD 
was significant. Between groups analysis showed a significant differences in MWD and 
PFWD in the SET and WA group (figure 4). 
In six trials the follow up period was longer than the actual exercise 
program.9, 21-22, 29, 34-35 Results of these trials were added to the 6-month results and were 
used in the sensitivity analysis (figure 5). In this analysis, MWD was described in 8, 6, 4 
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and 15 trials for NO-ET, WA, HB-ET and SET groups, while PFWD was found in 4, 4, 4 
and 10 trials, respectively (figure 5). SET results were superior with a SMD of 0.96 (95% 
CI: 0.76 – 1.16) and 0.89 (95% CI: 0.65 – 1.14) for MWD and PFWD, respectively. SET 
results were also significantly better compared to the NO-ET and WA group, regarding 
both outcomes. Homogeneity was observed for all groups on both outcomes (All: 
0%<I2<62%; P>.07). 
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NO-ET: no exercise; WA: walking 
advice; HB-ET: home-based exercise 
training; SET: supervised exercise 
training; SMD: standardized mean 
difference; n: number of participants 
for respectively MWD and PFWD, se-
parated by forward slash (/). Error bars 
correspond to 95% CI of calculated 
SMD. * = significant difference (P<.05) 
compared to NO-ET; § = significant 
difference (P<.05) compared to WA; 
# = significant difference (P<.10) 
compared to NO-ET; + significant dif-
ference (P<.05) compared to baseline 
value.
Figure 2. Maximal (MWD) and pain-free walking distances (PFWD) for the different support 
types at 6 weeks of follow up
NO-ET: no exercise; WA: walking 
advice; HB-ET: home-based exercise 
training; SET: supervised exercise 
training; SMD: standardized mean 
difference; n: number of participants 
for respectively MWD and PFWD, se-
parated by forward slash (/). Error bars 
correspond to 95% CI of calculated 
SMD. * = significant difference (P<.05) 
compared to NO-ET, § = significant 
difference (P<.05) compared to WA, 
^ = significant difference (P<.05) 
compared to HB-ET; +  = significant 
difference (P<.05) compared to 
baseline value. 
Figure 3. Maximal (MWD) and pain-free walking distances (PFWD) for the different support 
types at 3 month of follow up 
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NO-ET: no exercise; WA: walking 
advice; HB-ET: home-based exercise 
training; SET: supervised exercise 
training; SMD: standardized mean 
difference; n: number of participants 
for respectively MWD and PFWD, se-
parated by forward slash (/). Error bars 
correspond to 95% CI of calculated 
SMD. * = significant difference (P<.05) 
compared to NO-ET, § = significant 
difference (P<.05) compared to WA, 
^ = significant difference (P<.05) 
compared to HB-ET, # = significant 
difference (P<.10) compared to NO-ET; 
+ = significant difference (P<.05) 
compared to baseline value. 
Figure 4. Maximal (MWD) and pain-free walking distances (PFWD) for the different support 
types at 6 month of follow up
NO-ET: no exercise; WA: walking 
advice; HB-ET: home-based exercise 
training; SET: supervised exercise 
training; SMD: standardized mean 
difference; n: number of participants 
for respectively MWD and PFWD, se-
parated by forward slash (/). Error bars 
correspond to 95% CI of calculated 
SMD. * = significant difference (P<.05) 
compared to NO-ET, § = significant 
difference (P<.05) compared to WA, 
^ = significant difference (P<.05) 
compared to HB-ET, # = significant 
difference (P<.10) compared to NO-ET; 
+ = significant difference (P<.05) 
compared to baseline value. 
Figure 5. Maximal (MWD) and pain-free walking distances (PFWD) for the different support 
types at 6 month of follow up: sensitivity analysis
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DISCUSSION
The aim of this meta-analysis was to study the effect of supervision on improvement 
of walking distance in patients with intermittent claudication (IC). Our findings 
demonstrated a superior role of supervised exercised therapy (SET) as significant effect 
sizes >0.8 for all the follow up periods were found. These effects are generally considered as 
‘large’.48 Moreover, the results of SET were significantly better compared to the three other 
types of ET. Although we failed to demonstrate significant differences between all groups 
mutually, a dose-response trend as present with increasing supervision resulting in larger 
walking distances, most evident for the PFWD, at six month of follow up. The results as 
found in our study indicate that exercise programs supplemented with supervision have 
significant beneficial effects on walking capacity, which is in line with existing data.13, 16
One may question the additional value of just another meta-analysis as various other 
reviews were published in the previous decade.12-16 For instance, Fahkry et al.13 described 
the effectiveness of SET on walking distances although they failed to include the factor 
supervision in their overview. By extending the number of included trials we were 
confident that the results were genuine. By doing so, the total number of participants was 
increased by 50%. Moreover, the present study is the first to include three conservative 
treatment arms including a control group facilitating a more extensive comparison. 
Secondly, it was judged that evaluation of the factor support was required. Thirdly, the 
alternative method of calculation used in our review allowed for evaluating the four 
individual groups as well as comparing them. Since calculation of SMDs was based on 
group pre- en post-training values, significant differences reflect the actual effect of any 
treatment. In addition, significant differences in SMDs between groups represent the 
difference in effect between groups. 
One would intuitively think that a dose response relationship would be present 
between intensity of support and increased walking performance, since a comparison 
between SET and non-supervised regimens already demonstrated the additional value 
of supervision.16 Obvious or not, a dose response relation was never identified. We 
demonstrated a clear dose response trend in our review, but since not all differences 
between groups were statistically significant we failed in revealing a genuine relationship. 
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Conversely, failing to identify such a relation does not necessarily mean that there is none. 
Moreover, comparing statistical significance levels of the results is misleading, given the 
low power and variation in number of participants per subgroup. However, we included 
the largest number of participants so far17, and as such, this finding may have profound 
consequences on structure of these and future programs.  
Despite the overwhelming evidence supporting the use of supervised exercise 
programs for IC12-13, 16, and the class I recommendation by three leading international 
guidelines2-3, 49, uncertainty surrounds the relative contribution of all components of an 
optimal SET program.13 Moreover, the most optimal length of a SET program is a matter 
of debate. Gardner et al. described a tendency of middle-term length programs (12-26 
weeks) leading to greater improvement in MWD and PFWD compared to shorter (<12 
weeks) or longer (>26 weeks) programs.31 They also concluded that walking distances 
increased rapidly within the first 2 months of exercise rehabilitation.31 With respect to 
the support component, our meta-analysis confirms these findings, as the effect after 3 
months of SET (SMD 1.28; 95% CI 0.94-1.62) was larger compared to the effect after 
6 months of training (SMD 0.96; 95% CI 0.76-1.16). Moreover, the SET results after 6 
months of follow-up were not significantly different from the HB-ET group suggesting 
that extra supervision does not result in better outcomes after a long period of training 
and demonstrating the potential value of HB-ET.
Consequently, a 3 months SET program appears most preferable, but given the limited 
utilization of SET in daily practice50-51 and lessons learned in the worldwide available 
cardiac rehabilitation programmes, ongoing program modifications could possibly lead 
to a more viable supervised exercise schedule for patients with IC. After 3 months of 
training, SET may be replaced by a home-based program as our extensive meta-analysis 
demonstrated a equivalent effect of SET and HB-ET after six months. HB-ET may be 
more cost-effective by limiting expensive supervision and reducing issues regarding 
to training facilities. Interestingly, monitor options for HB-ET could be extended by 
incorporating eHealth and mHealth technologies.4, 50 Such technologies may increase 
adherence and consequent effectiveness. Future research should therefore focus on cost-
effectiveness of home-based programs revealing the optimal mixture of home-based and 
supervised training.
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Some limitations of this meta-analysis should be addressed. First, the methodological 
quality of original RCTs is not always optimal, in particular the questionable allocation 
concealment and lack of blind outcome assessment. As a consequence, the effect of 
SET may have been overestimated in individual studies. However, knowledge about 
appropriateness of patients for SET is not available yet, making favorable allocation 
unlikely. Moreover, the use of standardized exercise testing procedures and quantitative 
outcome measures may compensate for the lack of blind outcome assessment. Second, 
sample size of some studies was limited (<10 participants per treatment arm) which may 
have resulted in imprecise effect estimates. Thirdly, we chose to calculate SMDs in order 
to be able to compare more than two groups. Therefore, interpretation of the overall 
intervention effect can be difficult as it is reported in units of standard deviation rather 
than in meters. However, in reality the intervention effect is a difference in means and not 
a mean of differences.17 On the other hand, conversion to SMDs allowed us to compare 
walking distances which were assessed with different treadmill tests. Fourthly, a large 
diversity has been observed in the HB-ET group regarding the supervision strategy (e.g. 
diary, pedometers or physical activity monitors), frequency and length of the programs. 
The sample size of this group was also considerably smaller compared to the other three 
groups. These effects may potentially have contributed to an inaccurate effect assessment 
and may also explain the absence of a significant difference between the WA and HB-ET 
group. Fifthly, outcomes were measured by using a treadmill test. Patients in the SET 
group may have been favored as they were accustomed to train on a treadmill leading to 
a potential overestimation of the results of SET. Last, results of the present meta-analysis 
may also be explained in part by a difference in extend of support or a difference in 
training regimen (e.g. outdoor walking in the WA group compared to mainly indoor 
walking in the SET group). However, this potential bias is inherent to the retrospective 
methodology as groups were not identical in terms of training program. An interesting 
contribution to this discussion is provided by a recent study that found no difference 
in walking performance when comparing to different training regimens.52 Therefore, the 
exact effect of training type on walking distance is not identified yet. 
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CONCLUSION
SET is superior compared to other forms of ET in patients with IC. Increased supervision 
tends to lead to a larger improvement on walking distance. At six months of follow-up 
however, efficacy of home-based programs may be equal to SET. Future research should 
focus on identifying an optimal mixture of supervised and home-based programs. 
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APPENDIX I  Methodological quality of trials included in meta-
analysis
Author and year Random 
sequence 
generation
Allocation 
concealment
Blinding of 
participants 
and 
personnel
Blinding of 
outcome 
assesment
Incomplete 
outcome  
assessment
Selective 
reporting
Other 
bias
Cheetham40 + ? - + + - +
Collins9 + ? - ? + + ?
Dahllöf45 ? ? - ? + + ?
Gardner11 + ? - ? + + +
Gardner34 + + - ? + ? ?
Gardner24 + + - ? + + ?
Hiatt42 + - - ? ? + +
Hiatt43 + - - ? + + +
Hobbs21 + ? - ? ? + ?
Hobbs44 + ? - ? + + +
Hodges26 + ? - ? - + +
Kakkos41 + ? - ? + + ?
Langbein47 + ? - ? ? + +
Mika48 + ? - + ? + +
Mika49 + ? - + ? + +
Mika30 + ? - ? ? + +
Nicolai23 + + - + + + ?
Parr29 + ? - ? ? + +
Patterson25 ? ? - ? ? + ?
Regensteiner10 ? ? - ? + + +
Sanderson28 + + - ? + + +
Savage39 ? ? - ? + + +
Schlager27 + + - + ? + +
Schlager51 + ? - + + + +
Stewart6 + + - ? + + ?
Treat-Jacobson38 ? ? - - + + +
Tsai46 + ? - + ? + +
Wood50 + ? - ? ? + ?
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APPENDIX II Overview of excluded studies after full-text review
Author and year Journal Reasons for exclusion
Degischer, 2002 Vasc Med. 2002;7(2):109-15 No RCT
Nielsen, 1977 Ugeskr Laeger. 1977;139(46):2733-6 Language
Arosio, 2001 Life Sci. 2001;69(4):421-33 Research with drug treament
Collins, 2003 Med Sci Sports Exerc. 2003;35(3):384-93 Less than 50% walking
Gardner, 2002 J Cardiopulm Rehabil. 2002;22(3):192-8 Data already used in other publication
Gibellini, 2000 Int Angiol. 2000;19(1):8-13 Less than 6 weeks of training
Lepantalo, 1991 Clin Rehabil. 1991;5:65-9 No difference in supervision between groups
McDermott, 2004 J Cardiopulm Rehabil. 2004;24(3):187-96 Different patient population
Nawaz, 2001 J Vasc Surg. 2001;33(2):392-9 Only cycling
Taft, 2001 Eur J Vasc Endovasc Surg. 2001;22(2):114-23 No outcome measures on walking
Taft, 2004 Eur J Vasc Endovasc Surg. 2004;27(1):24-32 No outcome measures on walking
Tisi, 1997 Eur J Vasc Endovasc Surg. 1997;14(5):344-50 Less than 6 weeks training
Bronas, 2011 J Vasc Surg. 2011;53(6):1557-64 Data already used in other publication
Ciuffeti, 1994 Int Angiol. 1994 Mar;13(1):33-9 Research with drug treament
Collins, 2005 J Cardiovasc Nurs. 2005;20(3):177-85 Data already used in other publication
Fahkry, 2011 Arch Phys Med Rehabil. 2011;92:1066-73 Data already used in other publication
Fowler, 2002 Aust J Physiother 2002;48(4):269-75 No outcome measures on walking
Gardner, 2005 J Vasc Surg. 2005;42(4):702-9 No difference in supervision between groups
Greenhalgh, 2008 Eur J Vasc Endovasc Surg. 2008;36(6):680-8 No difference in supervision between groups
Grizzo, 2011 Vasa. 2011;40(5):390-7 No difference in supervision between groups
Krause, 1974 Munch Med Wochenschr. 1974;116(8):385-8. Different research scope
Kruidenier, 2011 J Vasc Interv Radiol. 2011;22(7):961-8 Patients underwent invasive therapy
Leon, 2005 Clin J Sport Med. 2005;15:285-6 No outcome measures on walking
Manfredini, 2008 Circ J. 2008;72(6):946-52 No difference in supervision between groups
Meneses, 2011 J. Vasc. Nurs. 2011;29, 81-86 Different research scope
Murphy, 2012 Circ. 2012;125(1):130-9 Research with invasive therapy
Pinto, 1997 J Aging Phys Act. 1997;5:311 Data already used in other publication
>>
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Ritti-Dias, 2010 J Vasc Surg. 2010;51(1):89-95 No difference in supervision between groups
Spronk, 2009 Radiol. 2009;250(2):586-95 Research with invasive therapy
Steiner, 2009 Eur Heart J. 2009;30(984):985 Data already used in other publication
Tebbutt, 2011 Phys Ther. 2011;97:244-249 Less than 50% walking
Tew, 2009 Clin Sci. 2009;117(12):405-13 Less than 50% walking
Van Asselt, 2011 Eur J Vasc Endovasc Surg. 2011; 41, 97-103 No outcome measures on walking
Walker, 2000 J Vasc Surg. 2000;31(4):662-9 Less than 50% walking
Wood, 2006 Clin Sci. 2006;111(6):401-9 No outcome measures on walking
Zwierska, 2005 J Vasc Surg. 2005;42(6):1122-30 Less than 50% walking
Mazari, 2012 Br J Surg. 2012;99(1):39-48 Research with invasive therapy
Mohler, 2011 Vasc Med. 2011;16(5):346-53 No exercise intervention
Cousin, 2011 Ann Phys Rehabil Med. 2011;54(7):429-42 No RCT
Duscha, 2011 Arterioscler Thromb Vasc 
Biol. 2011;31(11):2742-8
No outcome measures on walking
Szymańska, 2011 Ortop Traumatol Rehabil. 2011;13(3):279-92 No difference in supervision between groups
Malagoni, 2011 Circ J. 2011;75(9):2128-34 No outcome measures on walking
Villemur, 2011 Ann Phys Rehabil Med. 2011;54(5):275-81 Language
Nordanstig, 2011 Eur J Vasc Endovasc Surg. 2011;42(2):220-7 Research with invasive therapy
Vitale, 2011 Pharmacol Res. 2011;63(4):278-83 Different research scope
Franz, 2010 Vascular. 2010;18(6):325-35 No RCT
Hiatt, 2011 J Cardiopulm Rehabil Prev. 2011;31(2):125-32 Research with drug treament
Allen, 2010 Free Radic Biol Med. 2010;49(6):1138-44 Different research scope
Casto-Sanchez, 2010 Med Clin (Barc). 2010;134(3):107-10 Language
Martinez, 2009 J Vasc Nurs. 2009;27(1):2-7 Different research scope
Andreozzi, 2008 Int Angiol. 2008;27(5):401-7 No RCT
Spronk, 2008 J Vasc Surg. 2008;48(6):1472-80 Data already used in other publication
Carlon, 2008 Monaldi Arch Chest Dis. 2008;70(2):76-83 Language
Gardner, 2008 J Cardiopulm Rehabil Prev. 2008;28(4):258-65 Research with drug treament
Saxton, 2008 Eur J Vasc Endovasc Surg. 2008;35(5):607-13 No outcome measures on walking
Wang 2007 Clin Rehabil. 2007;21(7):579-86 Research with drug treament
>>
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Nylaende, 2007 Vasc Med. 2007;12(4):275-83 Research with invasive therapy
Bendermacher, 2007 J Vasc Surg. 2007;45(6):1192-6 No RCT
Andreozzi, 2007 Int Angiol. 2007;26(1):12-7 No outcome measures on walking
Slørdahl, 2005 Scand Cardiovasc J. 2005;39(4):244-9 No difference in supervision between groups
McGuigan, 2001 J Gerontol A Biol Sci Med Sci. 
2001;56(7):B302-10
No difference in supervision between groups
Cachovan, 2001 Angiology. 2001;52(6):381-91 Research with drug treament
Belcaro, 2000 Angiology. 2000;51(8 Pt 2):S15-26 Research with drug treament
Ubels, 1999 Diabetes Care. 1999;22(2):198-201 Different patient population
Perkins, 1996 Eur J Vasc Endovasc Surg. 1996;11(4):409-13 Different patient population
Regensteiner, 1996 J Vasc Surg. 1996;23(1):104-15 Data already used in other publication
Hiatt, 1996 J Appl Physiol. 1996;81(2):780-8 No outcome measures on walking
Streminski, 1992 Vasa. 1992;21(4):392-402 Language
Scheffler, 1991 Vasa Suppl. 1991;33:350-2 Language
Lundgren, 1989 Clin Sci (Lond). 1989;77(5):485-93 No outcome measures on walking
Mannario, 1989 Angiology. 1989;40(1):5-10 No outcome measures on walking
Diehm, 1989 Vasa Suppl. 1989;28:26-30 No data on effect of exercise intervention
Kiesewetter, 1987 Dtsch Med Wochenschr. 1987;112(22):873-8 Language
Lepantalo, 1984 Scand J Rehabil Med. 1984;16(4):159-62 Data already used in other publication
White, 1984 JAMA. 1983 Jun 24;249(24):3355-6 No actual research data
Sandri, 2005 Circ. 2005;111:3391-9 Less than 6 weeks training
Gelin, 2001 Eur J Vasc Endovasc Surg. 2001;22(2):107-13 Different follow up time
Crowther, 2008 Vasc Surg. 2008;47(2):303-9 Different follow up time
RCT = randomized controlled trial.
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ABSTRACT
Background: Supervised exercise therapy (SET) is recommended as primary treatment 
for patients with intermittent claudication (IC). However, there is concern regarding the 
safety of SET, as IC patients are at risk for untoward cardiovascular events. The Dutch 
physical therapy guideline advocates cardiac exercise testing prior to SET if indicated. 
Perceived uncertainties concerning safety may contribute to the underutilization of SET 
in daily practice. The objective of this review is to analyze the safety of supervised exercise 
training in patients with IC.
Methods: Two authors independently studied clinical trials investigating SET. Data was 
obtained from Medline, EMBASE and CENTRAL libraries. Complication rates were 
calculated and expressed as number of events per number of patient-hours. A subanalysis 
was executed to evaluate the usefulness of cardiac screening prior to SET.    
Results: Our search strategy revealed 2,703 abstracts. A total of 121 articles was selected 
of which 74 met inclusion criteria. Studies represent 82,725 hours of training in 2,876 IC 
patients. Eight adverse events were reported, six of cardiac and two of non-cardiac origin, 
resulting in an all-cause complication rate of 1 per 10,340 patient-hours. 
Conclusion: SET can safely be prescribed in patients with IC as an exceedingly low all-
cause complication rate was found. Routine cardiac screening prior to commencing SET 
is not required. Our results may diminish perceived uncertainties regarding safety and 
will possibly increase the use of SET in daily practice.
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INTRODUCTION
Some 50 to 80% of patients with peripheral arterial disease (PAD) are symptomatic and 
suffer from intermittent claudication (IC).1 IC is defined as muscle discomfort in the lower 
limb(s) elicited by exercise that resolves following a short period of rest.1 IC is associated 
with significant disability, reduced quality of life2-3 and an increased risk of death.4 A 
recent study found a significant difference in survival when patients with and without 
PAD were compared. For instance, the all-cause and cardiovascular mortality rates were 
24% and 7.7% in PAD patients versus 9.5% and 2.4% in patients without, respectively.5 
The unfavorable prognosis associated with PAD is dominated by the concomitant 
presence of cerebral and coronary artery disease (CAD) due to generally accepted risk 
factors (smoking, hypertension, diabetes mellitus, hyperlipidemia).6-8 The estimated 
overall prevalence of atherosclerotic CAD in PAD is 72%, with an obstructive nature 
in 61 to 98% in certain subgroups.9, 10 The Quebec Cardiovascular Study reported that 
the risk on fatal and nonfatal cardiovascular events in men with IC was twice as high 
compared to men without known cardiovascular disease (CVD).11 
International guidelines state that treatment of IC should consist of a multimodal 
approach including cardiovascular risk reduction in combination with symptomatic 
treatment.1, 7 First choice symptomatic treatment, demonstrated by level I evidence, is 
daily exercise with supervision (i.e. supervised exercise therapy: SET).12-17 Apart from 
symptomatic improvement, a 12-week SET program also reduced overall cardiovascular 
mortality and morbidity by 52% and 30%, respectively.18 Although it is generally accepted 
that SET should be part of the initial treatment for each patient with IC, this therapeutic 
tool is seriously underused in clinical practice.19-21 A study among surgeons in the United 
Kingdom revealed that only 24% of IC patients had access to SET.21 Moreover, a large 
variation in the proportion of eligible patients referred to such an exercise program was 
found. Lack of knowledge on referral criteria was also observed in a recent nationwide 
survey among Dutch vascular surgeons. Approximately 70% of the interviewed surgeons 
were convinced that coexisting cardiopulmonary comorbidity and/or aortoiliac stenosis 
or occlusion were relative contra-indications for participation in a SET program.20 These 
doubts are strengthened by a worry among physical therapists providing SET as they fear 
the onset of cardiovascular events that may possibly occur during exercise. Moreover, 
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physical therapists guidelines advocate cardiac screening prior to SET22, although 
evidence to support such a strategy is currently lacking. On the contrary, SET is often 
described as well tolerated whereas cardiovascular complications were rarely found in 
two studies.23-24 The aim of the present study is to analyze the safety of SET in patients 
suffering from IC in terms of onset of untoward (cardiovascular) events.
METHODS
Participants
We included studies that investigated the role of SET in patients diagnosed with IC 
(Fontaine II/Rutherford 1-3). 
Types of studies
Eligible studies examined SET alone, or in a comparison model with other treatment 
modalities (e.g. endovascular treatment, vaso-active medication or non-supervised 
exercise therapy). Both randomized and non-randomized studies were included. 
Although treadmill walking is considered an important component of a SET program, 
uncertainty remains regarding the most effective content of such a program.25 All types 
of SET programs were therefore included (e.g. pole-striding and strength training). The 
search was limited to studies in human and articles written in Dutch, German or English. 
No limitation to date of publication was considered. 
Search strategy
We performed a search in MEDLINE (1966 to June 2013) using the following (MeSH) 
terms: ‘peripheral arterial diseases’, ‘peripheral vascular diseases’, ‘intermittent claudication’, 
‘peripheral arter* occlus*’, ‘claudica*’, ‘isch* limb*’, ‘exercise’, ‘exercise therapy’, ‘exercise 
movement techniques’, ‘walk*’, ‘runni*’, ‘exerc*’, ‘train*’, ‘treadmill’. Additional articles 
were found by matching a previous search of CENTRAL (1966 to September 2012) 
and EMBASE (1974 to June 2013) and removing duplicates. Additionally, we searched 
bibliographies of included articles. After screening titles and abstracts, two reviewers (LG 
and HF) independently selected articles, based on a full-text evaluation. Disagreement 
between reviewers was discussed and resolved by consensus. 
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Data extraction and management
The following data were extracted by two authors (LG and HF) using a standardized 
data extraction form: details of study population, country, research setting, number of 
participants, number of drop-outs/lost to follow up, reasons for drop-out, age, gender, in- 
and exclusion criteria, description of the supervised exercise protocol, frequency, duration, 
content, all types of reported complications related to SET and the use of cardiopulmonary 
exercise testing. In order to exclude the potential influence of medication, only results 
obtained from participants in the placebo control group of RCTs were included. If studies 
did not explicitly report possible occurrence of adverse events, we used information on 
the number of drop-outs and reasons for drop-out. Studies which contained drop-outs 
due to medical causes were excluded. An email was sent to authors reporting unclear data 
regarding SET related complications or reasons for drop-out, in order to obtain details on 
the occurrence of untoward events. Studies of authors who did not respond to this mail 
were also excluded. 
Statistical analysis and data synthesis
Data were analyzed using SPSS for Windows 18.0 (SPSS Inc., Chicago, Illinois). The 
total number of patient-hours was calculated as the number of patients multiplied 
with number of training sessions corrected for mean duration of each session. When 
information on exact duration of training sessions was lacking, an approximation of 30 
minutes was assumed. Adverse events were characterized as cardiac or non-cardiac, and 
as fatal or nonfatal. The role of cardiac screening was studied by performing a subanalysis. 
We calculated separated event rates based on the use of cardiopulmonary exercise testing 
(CPET) prior to SET. 
RESULTS
Study selection
A total of 2,703 records was identified resulting in the study of 121 relevant articles. 
Overall, 74 studies (appendix I) with a total number of 2,876 IC patients met inclusion 
criteria (figure 1). Patients represented 82,725 patient-hours of SET. 
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* = Insufficient data is defined as: 1. missing data on complications during SET; 2. incomplete data on reasons for drop-
out; or 3. non-response on email request as a final attempt to obtain information.
Figure 1. Flow chart of study selection
Study characteristics
The majority of SET studies were performed in Western Europe and North America. 
Mean age ranged from 54 to 76 years, whereas more males than females were participating 
(table 1). Frequently reported patient exclusion criteria were IC presenting with pain at 
rest or critical ischemia, exercise capacity limited by symptoms of angina, congestive 
heart failure, chronic obstructive pulmonary disease or arthritis and poorly controlled 
2,703 potentially relevant records identified: 
titles and abstracts were screened
121 potentially relevant articles:
full text reviewed
74 studies included in review
2,574 records excluded: 
not relevant
65 articles excluded:
Systematic review or meta-analysis (5)
Different research scope (6)
Insufficient data* (10)
Language (2)
No supervised exercise therapy (19)
Preliminary results or duplicate data (23)
18 articles added by hand search
65
Safety of supervised exercise therapy
3
hypertension. Exercise programs consisted of treadmill training (n=49), mixed exercise 
therapy (n=8), circuit training (n=11), strength training (n=2), arm ergometry (n=2) 
or pole-striding (n=2). Duration of the exercise programs ranged from 2 weeks to 12 
months. Training frequencies varied from one to seven times a week, 30-120 minutes per 
day (table 2).
Table 1. Demographic characteristics (n=2,876)
Mean (range)
Age, years 64 (54-76)
Men, % 71 (30-100)
Countrya (n)
Europe 44
Asia 2
North-America 18
South-America 4
Oceania 5
Africa 1
a = number of studies performed in listed continents
Main outcome measurement
Some 35 of the 74 studies explicitly reported on potential adverse events. Another 32 
studies reported either no drop-outs or drop-outs without medical cause. The remaining 
7 studies were included after positive e-mail conformation. Eight adverse events of 
cardiac (n=6) and non-cardiac (n=2) origin were reported (table 3). The total all-cause 
event rate was 1 per 10,340 patient-hours. Total cardiac and non-cardiac event rates were 
1 per 13,788 and 1 per 41,363 patient-hours, respectively (table 4). 
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Table 2. Characteristics of included studies 
Supervised exercise program
Author and year  
of publication
Country N Mean 
age
% 
male
Duration 
(weeks)
Frequencya
(per  week)
Content
(main 
component)
Adverse 
events
Andreozzi 2008 Italy 74 65 91 6 3 Treadmill None 
Andreozzi 2007 Italy 22 67 100 6 3 Treadmill None 
Arosio 2001 Italy 12 65 NR 2 7 Treadmill None 
Badger 2007 Ireland 8 70 NR 6 2 Treadmill None 
Beckitt 2012 UK 27 68 98 12 2 Circuit training None 
Beckitt 2012 UK 42 66 69 12 2 Circuit training None 
Bendermacher 2007 Netherlands 93 64 63 24 2.5 Treadmill None 
Cachovan 1994 Germany 21 62 NR 4 5 Treadmill None 
Carlon 2008 Italy 41 NR NR 12 3 Treadmill None 
Cheetham 2004 UK 30 65 NR 24 1 Circuit training None 
Ciuffeti 1994 Italy 15 56 >99 12 2 Mixed exer-
cises
None 
Collins 2005 USA 27 70 98 24 3 Pole striding None 
Collins 2012 USA 103 66 93 24 3 Treadmill/pole 
striding 
None 
Collins 2011 USA 72 66 75 24 1 Walking None 
Cousin 2011 France 31 56b 97 4 5 Treadmill  None 
Crowther 2008 USA 11 71 50 52 3 Treadmill None 
Degischer 2002 Switzerland 46 68 NR 12 1 Treadmill None 
Franz 2010 USA 101 72 46 12 3 Treadmill None 
Gardner 2005 USA 77 NR 88 24 3 Treadmill  None 
Gardner 2011 USA 40 66 45 12 3 Treadmill None 
Gardner 2002 USA 31 68 NR 24 3 Treadmill None 
Gardner 2012 USA 106 67 86 24 3 Treadmill None 
Gibelline 2000 Italy 20 65 99 4 5 Treadmill None 
Greenhalgh 2008 UK 127 65 63 24 1 Treadmill None 
Grizzo Cucato 2011 Brazil 34 67 60 12 2 Circuit training None >>
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Hiatt 1996 USA 29 61 NR 20 3 Treadmill None 
Hiatt 1990 USA 25 67 100 12 3 Treadmill None 
Hiatt 2011 USA 30 66 83 24 0.29 Treadmill None 
Hobbs 2007 UK 9 NR 78 12 2 Circuit training None 
Hodges 2008 UK 14 67 NR 12 2 Treadmill None 
Jones 2012 USA 30 69 60 12 3 Treadmill None 
Kakkos 2005 UK 12 61 92 6 3 Treadmill None 
Kiesewetter 1987 Germany 15 64 70 6 5 Treadmill None 
Krause 1978 Germany 63 66 77 6 5 Mixed exercise None 
Krause 1976 Germany 55 65 74 6 5 Mixed exercise 1 myocardial 
infarction  
Kruidenier 2011 Netherlands 35 67 63 24 2.5 Treadmill None 
Lee 2007 UK 33 68 67 12 3 Circuit training None 
Leicht 2011 Australia 12 64 50 52 3 Treadmill None 
Lundgren 1989 Sweden 25 61 79 24 2 Mixed exercise None 
Mannarino 1991 Italy 10 63 67 24 2 Treadmill None 
Mannarino 1989 Italy 8 69 75 24 2 Treadmill None 
Martinez 2009 Israel 84 69 66 37 2 Treadmill None 
Mazari 2012 UK 60 69 62 12 3 Circuit training None 
McDermott 2009 USA 103 NR 52 24 3 Treadmill 1 cardiac  
arrest; 1 chest 
pain
McDermott 2004 USA 24 70 50 12 3 Treadmill 1 heart  
arrhythmias; 
1 chest pain 
McGuigan 2001 Australia 11 61 36 24 3 Circuit training None 
Mika 2011 Poland 34 64 90 12 3 Treadmill None 
Mika 2005 Poland 49 64 85 12 3 Treadmill None 
Murphy 2012 USA/Canada 43 69 49 26 3 Treadmill None 
Nawaz 2001 UK 52 69 83 6 2 Treadmill None 
Ng 2005 UK 16 NR 63 8 3 Walking None 
Nicolaï 2010 Netherlands 202 62 67 52 2.5 Treadmill None 
Parr 2009 South-Africa 17 68 30 6 3 Strength 
training 
None 
>>
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Patterson 1997 USA 27 NR 53 12 3 Mixed exercise None 
Perkins 1996 UK 26 65 NR 24 2 Mixed exercise None 
Regensteiner 1997 USA 10 NR NR 12 3 Treadmill None 
Ritti Dias 2010 Brazil 34 62 67 12 2 Strength 
training
None 
Sanderson 2006 Australia 28 66 39 6 3 Treadmill None 
Savage 2001 USA 11 68 68 12 3 Treadmill None 
Saxton 2011 UK 71 60 79 24 2 Treadmill None 
Scheffler 1994 Germany 15 69 70 4 5 Treadmill/
walking 
None 
Schlager 2011 Austria 20 66 65 24 2 Treadmill None 
Slørdahl 2005 Norway 18 66 NR 8 3 Treadmill None 
Spronk 2009 Netherlands 75 68 52 24 2 Treadmill None 
Stewart 2008 UK 30 62 67 12 2 Circuit training None 
Streminski 1992 Germany 30 69 67 4 5 Treadmill 1 increased 
heart rate/
dyspnea;     1 
worsening 
arthritis; 1 
ischialgia 
Tew 2009 UK 27 69 NR 12 2 Arm ergo-
metry 
None 
Tisi 1997 UK 22 67 69 4 1 Mixed exercise None 
Treat-Jacobson 2009 USA 37 76 33 12 3 Treadmill/arm 
ergometry
None 
Tsai 2002 Taiwan 27 68 81 12 3 Treadmill None 
Villemur 2011 France 11 72 NR 2 5 Treadmill  None 
Wang 2007 Australia 22 54 100 12 3 Treadmill None 
Winterfeld 1983 Germany 17 64 NR 12 2 Circuit training None 
Wood 2006 Australia 7 65 72 6 3 Treadmill None
NR = not reported, a= recalculated to frequency per week, b= median age
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Table 3. Overview of adverse events occurred during SET (n=8)
Number of events
Heart arrhythmias 1
Angina pectoris 2
Cardiac arresta 1
Myocardial infarctionb 1
Increased heart rate and dyspnea 1
Worsening of osteoarthritisc 1
Ischialgiac 1
a = successfully resuscitated, b = fatal outcome, c = no treatment needed
Table 4. Complication rates during SET 
Number of events Complication ratesa
All cause 8 1:10,340
Cardiac 6 1:13,788
Non-cardiac 2 1:41,363
a = expressed as 1 event per number of patient-training hours
Subanalysis on cardiac screening
Some 28 studies (26,790 patient-hours of SET; 32%) included cardiac screening before 
initiating SET, of which 23 studies used electrocardiography registration. Four of the 
eight adverse events were reported in these 28 studies. The remaining four, including a 
fatal myocardial infarction, were found in the 46 remaining studies not including cardiac 
screening (55,935 patient-hours of SET; 68%). Six studies reported results of 1,703 CPETs 
prior to SET inclusion. A total of 59 patients (3.5%) were excluded from SET participation 
based on abnormal CPET findings.
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DISCUSSION 
The aim of this review was to identify SET related complications in patients with IC as a 
means to determine its safety. To our knowledge, this is the first study addressing the safety 
issue of SET. Eight complications were described during more than 80,000 patient-hours 
of SET, resulting in an all-cause complication rate of 1 to 10,340 patient-hours. Therefore, 
the risk of complications during SET is considered exceedingly low. Focusing on major 
cardiac complications (n=2), an even lower event rate of 1 to 41,362 patient-hours was 
calculated. These results are in line with a prospective registry on complications during 
exercise for cardiac rehabilitation reporting an almost similar 1 per 49,565 patient-hours 
event rate.26 Moreover, these rates may even be considered relatively high as events that 
were reported in studies from more than three decades ago were also included. Medical 
treatment has greatly improved the overall prognosis, potentially resulting in even lower 
current event rates.
Although cardiopulmonary exercise testing (CPET) has been used over 60 years for risk 
stratification in patients with heart diseases27, this technique is no longer recommended 
as a screening tool for myocardial ischemia in people without known coronary artery 
disease (CAD) as suggested by a recent guideline of The National Institute for Health and 
Clinical Excellence (NICE).28 Prediction of a future severe cardiac event during exercise 
is very difficult, if not impossible.26 In the present review, one third of the studies (n= 
28; 32% of total patient-hours) included cardiac screening. But as an equal number of 
adverse events (n=4) was found in studies with or without cardiac screening, the results 
may indicate that cardiac screening in IC patients is indeed not useful. However, by the 
observational and retrospective design of our study firm conclusions cannot be drawn. 
Yet, given the very low complication rate, cardiac screening as a tool for a safe execution 
of SET seems clinically irrelevant. 
There is also a downside using CPET as a screening technique. As all screening tests 
do, CPET also inherently carries a risk of false positive testing. For instance, a 15% false 
positive rate is observed in patients with chest pain29, while in asymptomatic patients 
this percentage is even higher.30 A false positive test will incorrectly and unnecessary 
exclude IC patients from a first choice treatment.1, 7 In addition, false positive tests  may 
lead to unneeded (invasive) interventions (e.g. coronary angiography) with accompanied 
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morbidity, mortality and costs. On the other hand, the risk of false negative testing 
following CPET is also present as illustrated by one study.31 A cardiac arrest was reported 
during exercise although no obstructive coronary disease was found during prior testing. 
Cardiac screening may therefore create a false sense of safety. Moreover, CPET itself also 
harbors a risk of cardiac complications. About 1 to 5 complications per 10,000 tests were 
reported27, 32, a percentage that clearly exceeds any risk caused by SET. 
Some suggested that CPET is useful in detecting silent ischemia.33 As the majority of 
patients with IC will experience myocardial ischemia as anginal pain during exertion, 
some 17-47% will be asymptomatic, i.e. silent ischemia type I.34 Extensive research is 
executed in patients with diabetes mellitus, a condition associated with an even higher 
prevalence of silent ischemia.35 A difference between silent and symptomatic CAD with 
respect to prognosis was never found.34, 36, 37 Although, patients with IC may potentially 
benefit from routine CAD screening through detection of silent ischemia. However, 
considering the high prevalence of silent ischemia and assuming that these patients were 
also present in our review, a larger number of incidents would have been expected. The 
value of CPET is therefore also questionable from this perspective. 
Lastly, CPET is potentially useful as a tool allowing for training optimization. A recent 
review attempted to identify the most important exercise components resulting in an 
optimal training protocol for patients with IC. It was concluded that neither intensity 
nor duration or program content were independently associated with improvement of 
maximal or pain-free walking distance.25 Therefore, selection of SET components based 
on CPET does not seem to be a useful strategy. 
Our study has limitations associated with its retrospective methodology and the 
possibility of publication bias. Only 35 of 74 studies explicitly reported the possible 
occurrence of adverse events whereas a detailed description was sometimes lacking. 
It remains therefore uncertain whether all reported events were indeed related to SET 
and occurred during supervision. While other complications may have been missed. 
However, these are most likely minor events preventing the patient from stopping any 
activity. By our strategy of using information on drop-outs, the number of patient-hours 
was increased as was the chance on some extra uncertainty. 
Included studies were very heterogenic in terms of content of the SET program, 
and an exact description of intensity was often lacking. Therefore it was not possible 
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to identify any potential association between intensity of SET and complication risk. 
Moreover, subgroup analyses were impossible due to the small number of adverse events. 
An additional disadvantage of the present study is the fact that the vast majority of 
participants were men. Consequently, safety of SET is not demonstrated in female IC 
patients, although gender differences regarding the response to SET were never reported. 
A major methodological concern is the fact that patients with limited exercise capacity 
due to angina, heart failure, chronic obstructive pulmonary disease, arthritis, poorly 
controlled hypertension or recent myocardial infarction were excluded in some studies. 
Exclusion of these vulnerable cardiac patients may have resulted in an underestimation 
of the number of adverse events. Therefore, generalizing these results to IC patients 
with major comorbidities is hazardous. On the other hand, it must be appreciated that 
exercise training also reduces the all-cause mortality in patients with congestive heart 
failure by 11%.41 Others demonstrated in patients with stable coronary artery disease that 
a 12-month program of regular physical exercise resulted in superior event-free survival 
and exercise capacity compared to percutaneous coronary angioplasty (88% vs. 70%, 
P=.023).42 As a consequence, patients with (cardiac) comorbidity should not routinely 
be excluded from SET in daily practice. However, each patient obviously requires careful 
monitoring.
In conclusion, the present review demonstrates that SET can safely be prescribed in 
IC patients as (cardiovascular) complication rates associated with this type of therapy are 
extremely low. However, caution should be taken when applying these results on patients 
with major comorbidity. 
73
Safety of supervised exercise therapy
3
REFERENCES 
1. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Inter-Society 
Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007 
Jan;45 Suppl S:S5-67.
2. Spronk S, Bosch JL, Veen HF, den Hoed PT, Hunink MG. Intermittent claudication: 
functional capacity and quality of life after exercise training or percutaneous transluminal 
angioplasty--systematic review. Radiology. 2005 Jun;235(3):833-42.
3. Regensteiner JG, Hiatt WR, Coll JR, Criqui MH, Treat-Jacobson D, McDermott MM, et al. 
The impact of peripheral arterial disease on health-related quality of life in the Peripheral 
Arterial Disease Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) 
Program. Vasc Med. 2008 Feb;13(1):15-24.
4. Muluk SC, Muluk VS, Kelley ME, Whittle JC, Tierney JA, Webster MW, et al. Outcome 
events in patients with claudication: a 15-year study in 2777 patients. J Vasc Surg. 2001 
Feb;33(2):251-7; discussion 7-8.
5. Diehm C, Allenberg JR, Pittrow D, Mahn M, Tepohl G, Haberl RL, et al. Mortality and 
vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery 
disease. Circulation. 2009 Nov 24;120(21):2053-61.
6. Rehring TF, Sandhoff BG, Stolcpart RS, Merenich JA, Hollis HW, Jr. Atherosclerotic risk 
factor control in patients with peripheral arterial disease. J Vasc Surg. 2005 May;41(5):816-
22.
7. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 
2005 guidelines for the management of patients with peripheral arterial disease (lower 
extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative 
report from the American Association for Vascular Surgery/Society for Vascular Surgery, 
Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine 
and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice 
Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With 
Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and 
Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular 
Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am 
Coll Cardiol. 2006 Mar 21;47(6):1239-312.
74
Supervised exercise therapy for intermittent claudication
3
8. Tilloy E, Montaye M, Kee F, Bingham A, Arveiler D, Ruidavets JB, et al. Contribution of 
cardiovascular risk factors to coronary risk in patients with intermittent claudication in the 
PRIME Cohort Study of European men. Atherosclerosis. 2009 Oct;206(2):563-8.
9. Duran NE, Duran I, Gurel E, Gunduz S, Gol G, Biteker M, et al. Coronary artery disease in 
patients with peripheral artery disease. Heart Lung. 2010 Mar-Apr;39(2):116-20.
10. Sukhija R, Yalamanchili K, Aronow WS. Prevalence of left main coronary artery disease, of 
three- or four-vessel coronary artery disease, and of obstructive coronary artery disease in 
patients with and without peripheral arterial disease undergoing coronary angiography for 
suspected coronary artery disease. Am J Cardiol. 2003 Aug 1;92(3):304-5.
11. St-Pierre AC, Cantin B, Lamarche B, Auger D, Despres JP, Dagenais GR. Intermittent 
claudication: From its risk factors to its long-term prognosis in men. The Quebec 
Cardiovascular Study. Can J Cardiol. 2010 Jan;26(1):17-21.
12. Watson L, Ellis B, Leng GC. Exercise for intermittent claudication. Cochrane Database Syst 
Rev. 2008(4):CD000990.
13. Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. Cochrane Database Syst 
Rev. 2000(2):CD000990.
14. Wind J, Koelemay MJ. Exercise therapy and the additional effect of supervision on exercise 
therapy in patients with intermittent claudication. Systematic review of randomised 
controlled trials. Eur J Vasc Endovasc Surg. 2007 Jul;34(1):1-9.
15. Bendermacher BL, Willigendael EM, Teijink JA, Prins MH. Supervised exercise therapy 
versus non-supervised exercise therapy for intermittent claudication. Cochrane Database 
Syst Rev. 2006(2):CD005263.
16. Gardner AW, Parker DE, Montgomery PS, Scott KJ, Blevins SM. Efficacy of quantified 
home-based exercise and supervised exercise in patients with intermittent claudication: a 
randomized controlled trial. Circulation. 2011 Feb 8;123(5):491-8.
17. Fokkenrood HJ, Bendermacher BL, Lauret GJ, Willigendael EM, Prins MH, Teijink JA. 
Supervised exercise therapy versus non-supervised exercise therapy for intermittent 
claudication. Cochrane Database Syst Rev. 2013 Aug 23;8:CD005263.
18. Sakamoto S, Yokoyama N, Tamori Y, Akutsu K, Hashimoto H, Takeshita S. Patients with 
peripheral artery disease who complete 12-week supervised exercise training program show 
reduced cardiovascular mortality and morbidity. Circ J. 2009 Jan;73(1):167-73.
75
Safety of supervised exercise therapy
3
19. Makris GC, Lattimer CR, Lavida A, Geroulakos G. Availability of supervised exercise 
programs and the role of structured home-based exercise in peripheral arterial disease. Eur J 
Vasc Endovasc Surg. 2012 Dec;44(6):569-75; discussion 76.
20. Lauret GJ, van Dalen HC, Hendriks HJ, van Sterkenburg SM, Koelemay MJ, Zeebregts CJ, 
et al. When is supervised exercise therapy considered useful in peripheral arterial occlusive 
disease? A nationwide survey among vascular surgeons. Eur J Vasc Endovasc Surg. 2012 
Mar;43(3):308-12.
21. Shalhoub J, Hamish M, Davies AH. Supervised exercise for intermittent claudication - an 
under-utilised tool. Ann R Coll Surg Engl. 2009 Sep;91(6):473-6.
22. Jongert MWA, Hendriks HJM, van Hoek J, Klaasboer-Kogelman K, Robeer GG, Simens B, 
et al. [KNGF-Guideline Intermittent Claudication (author’s transl)]. Ned Tijdschr Fysiother. 
2003;113(6).
23. Frans FA, Bipat S, Reekers JA, Legemate DA, Koelemay MJ. Systematic review of exercise 
training or percutaneous transluminal angioplasty for intermittent claudication. Br J Surg. 
2012 Jan;99(1):16-28.
24. Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT. Exercise training for claudication. 
N Engl J Med. 2002 Dec 12;347(24):1941-51.
25. Fakhry F, van de Luijtgaarden KM, Bax L, den Hoed PT, Hunink MG, Rouwet EV, et al. 
Supervised walking therapy in patients with intermittent claudication. J Vasc Surg. 2012 
Oct;56(4):1132-42.
26. Pavy B, Iliou MC, Meurin P, Tabet JY, Corone S. Safety of exercise training for cardiac 
patients: results of the French registry of complications during cardiac rehabilitation. 
Arch Intern Med. 2006 Nov 27;166(21):2329-34.
27. Myers J, Arena R, Franklin B, Pina I, Kraus WE, McInnis K, et al. Recommendations for 
clinical exercise laboratories: a scientific statement from the american heart association. 
Circulation. 2009 Jun 23;119(24):3144-61.
28. Skinner JS, Smeeth L, Kendall JM, Adams PC, Timmis A. NICE guidance. Chest pain of 
recent onset: assessment and diagnosis of recent onset chest pain or discomfort of suspected 
cardiac origin. Heart. 2010 Jun;96(12):974-8.
29. Faisal AW, Abid AR, Azhar M. Exercise Tolerance Test: a comparison between true positive 
and false positive test results. J Ayub Med Coll Abbottabad. 2007 Oct-Dec;19(4):71-4.
76
Supervised exercise therapy for intermittent claudication
3
30. Megnien JL, Simon A. Exercise tolerance test for predicting coronary heart disease in 
asymptomatic individuals: A review. Atherosclerosis. 2009 Aug;205(2):579-83.
31. McDermott MM, Ades P, Guralnik JM, Dyer A, Ferrucci L, Liu K, et al. Treadmill exercise and 
resistance training in patients with peripheral arterial disease with and without intermittent 
claudication: a randomized controlled trial. JAMA. 2009 Jan 14;301(2):165-74.
32. Gibbons LW, Mitchell TL, Gonzalez V. The safety of exercise testing. Prim Care. 1994 
Sep;21(3):611-29.
33. Ahmed AH, Shankar K, Eftekhari H, Munir M, Robertson J, Brewer A, et al. Silent 
myocardial ischemia: Current perspectives and future directions. Exp Clin Cardiol. 2007 
Winter;12(4):189-96.
34. Zellweger MJ. Prognostic significance of silent coronary artery disease in type 2 diabetes. 
Herz. 2006 May;31(3):240-5.
35. Ditchburn CJ, Hall JA, de Belder M, Davies A, Kelly W, Bilous R. Silent myocardial ischaemia 
in patients with proved coronary artery disease: a comparison of diabetic and non-diabetic 
patients. Postgrad Med J. 2001 Jun;77(908):395-8.
36. Moskowitz RM, Chatterjee K, Parmley WW. Silent myocardial ischemia: an update. 
Med Clin North Am. 1988 Sep;72(5):1033-54.
37. Sayer JW, Timmis AD. Investigation of coronary artery disease in diabetes: is screening of 
asymptomatic patients necessary? Heart. 1997 Dec;78(6):525-6.
38. Messerli FH, Bangalore S, Yao SS, Steinberg JS. Cardioprotection with beta-blockers: myths, 
facts and Pascal’s wager. J Intern Med. 2009 Sep;266(3):232-41.
39. Schweizer J, Kaulen R, Altmann E, Nierade A, Nanning T. [Are beta-blockers generally 
contraindicated in patients with peripheral arterial occlusive disease?]. Z Kardiol. 1996 
Mar;85(3):193-7.
40. Paravastu SC, Mendonca DA, da Silva A. Beta blockers for peripheral arterial disease. 
Eur J Vasc Endovasc Surg. 2009 Jul;38(1):66-70.
41. O’Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, et al. Efficacy and 
safety of exercise training in patients with chronic heart failure: HF-ACTION randomized 
controlled trial. JAMA. 2009 Apr 8;301(14):1439-50.
42. Hambrecht R, Walther C, Mobius-Winkler S, Gielen S, Linke A, Conradi K, et al. Percutaneous 
coronary angioplasty compared with exercise training in patients with stable coronary artery 
disease: a randomized trial. Circulation. 2004 Mar 23;109(11):1371-8.
77
Safety of supervised exercise therapy
3
APPENDIX I Studies included in the review
• Andreozzi GM, Leone A, Martini R, Laudani R, Salimistraro G, Deinite G. Effectiveness and 
costs of a short-course supervised training program in claudicants: proposal for a shared 
protocol with aerobic working load. Int Angiol. 2008 Oct;27(5):401-7.
• Andreozzi GM, Leone A, Laudani R, Deinite G, Martini R. Acute impairment of the 
endothelial function by maximal treadmill exercise in patients with intermittent claudication, 
and its improvement after supervised physical training. Int Angiol. 2007 Mar;26(1):12-7.
• Arosio E, Minuz P, Prior M, Zuliani V, Gaino S, De Marchi S, et al. Vascular adhesion 
molecule-1 and markers of platelet function before and after a treatment with iloprost or 
a supervised physical exercise program in patients with peripheral arterial disease. Life Sci. 
2001 Jun 15;69(4):421-33.
• Badger SA, Soong CV, O’Donnell ME, Boreham CA, McGuigan KE. Benefits of a supervised 
exercise program after lower limb bypass surgery. Vasc Endovascular Surg. 2007 Feb-
Mar;41(1):27-32.
• Beckitt TA, Day J, Morgan M, Lamont PM. Skeletal muscle adaptation in response to 
supervised exercise training for intermittent claudication. Eur J Vasc Endovasc Surg. 2012 
Sep;44(3):313-7.
• Beckitt TA, Day J, Morgan M, Lamont PM. Calf muscle oxygen saturation and the effects of 
supervised exercise training for intermittent claudication. J Vasc Surg. 2012 Aug;56(2):470-5.
• Bendermacher BL, Willigendael EM, Nicolai SP, Kruidenier LM, Welten RJ, Hendriks E, et 
al. Supervised exercise therapy for intermittent claudication in a community-based setting is 
as effective as clinic-based. J Vasc Surg. 2007 Jun;45(6):1192-6.
• Cachovan M, Scheffler P, Gruss J, Diehm C, Rogatti W. Efficacy of a standardized physical 
training programme in intermittent claudication [author’s translation]. Wien Klin 
Wochenschr. 1994;106(16):3.
• Carlon R, Olivieri A, Benacchio L, Zanchetta M. [Short and medium term functional capacity 
after single cycle of controlled physical training in subjects with claudication]. Monaldi Arch 
Chest Dis. 2008 Jun;70(2):76-83.
• Cheetham DR, Burgess L, Ellis M, Williams A, Greenhalgh RM, Davies AH. Does supervised 
exercise offer adjuvant benefit over exercise advice alone for the treatment of intermittent 
claudication? A randomised trial. Eur J Vasc Endovasc Surg. 2004 Jan;27(1):17-23.
78
Supervised exercise therapy for intermittent claudication
3
• Ciuffetti G, Paltriccia R, Lombardi R, Lupattelli G, Pasqualini L, Mannarino E. Treating 
peripheral arterial occlusive disease: pentoxifylline vs exercise. Int Angiol. 1994;13(1):6.
• Collins EG, Langbein WE, Orebaugh C, Bammert C, Hanson K, Reda D, et al. Cardiovascular 
training effect associated with polestriding exercise in patients with peripheral arterial 
disease. J Cardiovasc Nurs. 2005 May-Jun;20(3):177-85.
• Collins EG, O’Connell S, McBurney C, Jelinek C, Butler J, Reda D, et al. Comparison of 
walking with poles and traditional walking for peripheral arterial disease rehabilitation. 
J Cardiopulm Rehabil Prev. 2012 Jul-Aug;32(4):210-8.
• Collins TC, Lunos S, Carlson T, Henderson K, Lightbourne M, Nelson B, et al. Effects of 
a home-based walking intervention on mobility and quality of life in people with diabetes 
and peripheral arterial disease: a randomized controlled trial. Diabetes Care. 2011 
Oct;34(10):2174-9.
• Cousin A, Popielarz S, Wieczorek V, Tiffreau V, Mounier-Vehier C, Thevenon A. Impact of a 
rehabilitation program on muscular strength and endurance in peripheral arterial occlusive 
disease patients. Ann Phys Rehabil Med. 2011 Oct;54(7):429-42.
• Crowther RG, Spinks WL, Leicht AS, Sangla K, Quigley F, Golledge J. Effects of a long-term 
exercise program on lower limb mobility, physiological responses, walking performance, 
and physical activity levels in patients with peripheral arterial disease. J Vasc Surg. 2008 
Feb;47(2):303-9.
• Degischer S, Labs KH, Aschwanden M, Tschoepl M, Jaeger KA. Reproducibility of constant-
load treadmill testing with various treadmill protocols and predictability of treadmill test 
results in patients with intermittent claudication. J Vasc Surg. 2002 Jul;36(1):83-8.
• Franz RW, Garwick T, Haldeman K. Initial results of a 12-week, institution-based, supervised 
exercise rehabilitation program for the management of peripheral arterial disease. Vascular. 
2010 Nov-Dec;18(6):325-35.
• Gardner AW, Montgomery PS, Flinn WR, Katzel LI. The effect of exercise intensity on the 
response to exercise rehabilitation in patients with intermittent claudication. J Vasc Surg. 
2005 Oct;42(4):702-9.
• Gardner AW, Parker DE, Montgomery PS, Scott KJ, Blevins SM. Efficacy of quantified 
home-based exercise and supervised exercise in patients with intermittent claudication: a 
randomized controlled trial. Circulation. 2011 Feb 8;123(5):491-8.
79
Safety of supervised exercise therapy
3
• Gardner AW, Katzel LI, Sorkin JD, Goldberg AP. Effects of long-term exercise rehabilitation 
on claudication distances in patients with peripheral arterial disease: a randomized controlled 
trial. J Cardiopulm Rehabil. 2002 May-Jun;22(3):192-8.
• Gardner AW, Montgomery PS, Parker DE. Optimal exercise program length for patients with 
claudication. J Vasc Surg. 2012 May;55(5):1346-54.
• Gibellini R, Fanello M, Bardile AF, Salerno M, Aloi T. Exercise training in intermittent 
claudication. Int Angiol. 2000 Mar;19(1):8-13.
• Greenhalgh RM, Belch JJ, Brown LC, Gaines PA, Gao L, Reise JA, et al. The adjuvant 
benefit of angioplasty in patients with mild to moderate intermittent claudication (MIMIC) 
managed by supervised exercise, smoking cessation advice and best medical therapy: results 
from two randomised trials for stenotic femoropopliteal and aortoiliac arterial disease. Eur J 
Vasc Endovasc Surg. 2008 Dec;36(6):680-8.
• Grizzo Cucato G, de Moraes Forjaz CL, Kanegusuku H, da Rocha Chehuen M, Riani Costa 
LA, Wolosker N, et al. Effects of walking and strength training on resting and exercise 
cardiovascular responses in patients with intermittent claudication. Vasa. 2011 Sep;40(5):390-
7.
• Hiatt WR, Regensteiner JG, Wolfel EE, Carry MR, Brass EP. Effect of exercise training on 
skeletal muscle histology and metabolism in peripheral arterial disease. J Appl Physiol. 1996 
Aug;81(2):780-8.
• Hiatt WR, Regensteiner JG, Hargarten ME, Wolfel EE, Brass EP. Benefit of exercise 
conditioning for patients with peripheral arterial disease. Circulation. 1990 Feb;81(2):602-9.
• Hiatt WR, Creager MA, Amato A, Brass EP. Effect of propionyl-L-carnitine on a background 
of monitored exercise in patients with claudication secondary to peripheral artery disease. J 
Cardiopulm Rehabil Prev. 2011 Mar-Apr;31(2):125-32.
• Hobbs SD, Marshall T, Fegan C, Adam DJ, Bradbury AW. The effect of supervised exercise 
and cilostazol on coagulation and fibrinolysis in intermittent claudication: a randomized 
controlled trial. J Vasc Surg. 2007 Jan;45(1):65-70; discussion. 
• Hodges LD, Sandercock GR, Das SK, Brodie DA. Randomized controlled trial of supervised 
exercise to evaluate changes in cardiac function in patients with peripheral atherosclerotic 
disease. Clin Physiol Funct Imaging. 2008 Jan;28(1):32-7.
80
Supervised exercise therapy for intermittent claudication
3
• Jones WS, Duscha BD, Robbins JL, Duggan NN, Regensteiner JG, Kraus WE, et al. Alteration 
in angiogenic and anti-angiogenic forms of vascular endothelial growth factor-A in skeletal 
muscle of patients with intermittent claudication following exercise training. Vasc Med. 2012 
Apr;17(2):94-100.
• Kakkos SK, Geroulakos G, Nicolaides AN. Improvement of the walking ability in 
intermittent claudication due to superficial femoral artery occlusion with supervised 
exercise and pneumatic foot and calf compression: a randomised controlled trial. 
Eur J Vasc Endovasc Surg. 2005 Aug;30(2):164-75.
• Kiesewetter H, Blume J, Jung F, Gerhards M, Leipnitz G. [Walk training and drug therapy in 
peripheral arterial occlusive disease. A randomized, prospective, placebo-controlled double-
blind study]. Dtsch Med Wochenschr. 1987 May 29;112(22):873-8.
• Krause D, Dittmar K. [Active therapeutic exercises in combination with vasoactive drug 
in intermittent claudication (author’s transl)]. MMW Munch Med Wochenschr. 1978 Jan 
20;120(2-3):69-72.
• Krause D, Dittmar K. [Combination of physiotherapeutic exercise therapy with bencyclane 
in intermittent claudication (author’s transl)]. MMW Munch Med Wochenschr. 1976 Oct 
1;118(40):1281-4.
• Kruidenier LM, Nicolai SP, Rouwet EV, Peters RJ, Prins MH, Teijink JA. Additional supervised 
exercise therapy after a percutaneous vascular intervention for peripheral arterial disease: a 
randomized clinical trial. J Vasc Interv Radiol. 2011 Jul;22(7):961-8.
• Lee HL, Mehta T, Ray B, Heng MS, McCollum PT, Chetter IC. A non-randomised controlled 
trial of the clinical and cost effectiveness of a Supervised Exercise Programme for claudication. 
Eur J Vasc Endovasc Surg. 2007 Feb;33(2):202-7.
• Leicht AS, Crowther RG, Golledge J. Influence of peripheral arterial disease and supervised 
walking on heart rate variability. J Vasc Surg. 2011 Nov;54(5):1352-9.
• Lundgren F, Dahllof AG, Lundholm K, Schersten T, Volkmann R. Intermittent claudication-
-surgical reconstruction or physical training? A prospective randomized trial of treatment 
efficiency. Ann Surg. 1989 Mar;209(3):346-55.
• Mannarino E, Pasqualini L, Innocente S, Scricciolo V, Rignanese A, Ciuffetti G. Physical 
training and antiplatelet treatment in stage II peripheral arterial occlusive disease: alone or 
combined? Angiology. 1991 Jul;42(7):513-21.
81
Safety of supervised exercise therapy
3
• Mannarino E, Pasqualini L, Menna M, Maragoni G, Orlandi U. Effects of physical training on 
peripheral vascular disease: a controlled study. Angiology. 1989 Jan;40(1):5-10.
• Martinez CA, Carmeli E, Barak S, Stopka CB. Changes in pain-free walking based on time in 
accommodating pain-free exercise therapy for peripheral arterial disease. J Vasc Nurs. 2009 
Mar;27(1):2-7.
• Mazari FA, Khan JA, Carradice D, Samuel N, Abdul Rahman MN, Gulati S, et al. Randomized 
clinical trial of percutaneous transluminal angioplasty, supervised exercise and combined 
treatment for intermittent claudication due to femoropopliteal arterial disease. Br J Surg. 
2012 Jan;99(1):39-48.
• McDermott MM, Ades P, Guralnik JM, Dyer A, Ferrucci L, Liu K, et al. Treadmill exercise and 
resistance training in patients with peripheral arterial disease with and without intermittent 
claudication: a randomized controlled trial. JAMA. 2009 Jan 14;301(2):165-74.
• McDermott MM, Tiukinhoy S, Greenland P, Liu K, Pearce WH, Guralnik JM, et al. A 
pilot exercise intervention to improve lower extremity functioning in peripheral arterial 
disease unaccompanied by intermittent claudication. J Cardiopulm Rehabil. 2004 May-
Jun;24(3):187-96.
• McGuigan MR, Bronks R, Newton RU, Sharman MJ, Graham JC, Cody DV, et al. Resistance 
training in patients with peripheral arterial disease: effects on myosin isoforms, fiber type 
distribution, and capillary supply to skeletal muscle. J Gerontol A Biol Sci Med Sci. 2001 
Jul;56(7):B302-10.
• Mika P, Wilk B, Mika A, Marchewka A, Nizankowski R. The effect of pain-free treadmill 
training on fibrinogen, haematocrit, and lipid profile in patients with claudication. 
Eur J Cardiovasc Prev Rehabil. 2011 Oct;18(5):754-60.
• Mika P, Spodaryk K, Cencora A, Unnithan VB, Mika A. Experimental model of pain-free 
treadmill training in patients with claudication. Am J Phys Med Rehabil. 2005 Oct;84(10):756-
62.
• Murphy TP, Cutlip DE, Regensteiner JG, Mohler ER, Cohen DJ, Reynolds MR, et al. 
Supervised exercise versus primary stenting for claudication resulting from aortoiliac 
peripheral artery disease: six-month outcomes from the claudication: exercise versus 
endoluminal revascularization (CLEVER) study. Circulation. 2012 Jan 3;125(1):130-9.
82
Supervised exercise therapy for intermittent claudication
3
• Nawaz S, Walker RD, Wilkinson CH, Saxton JM, Pockley AG, Wood RF. The inflammatory 
response to upper and lower limb exercise and the effects of exercise training in patients with 
claudication. J Vasc Surg. 2001 Feb;33(2):392-9.
• Ng PW, Hollingsworth SJ, Luery H, Kumana TJ, Chaloner EJ. Intermittent claudication: 
exercise-increased walking distance is not related to improved cardiopulmonary fitness. Eur 
J Vasc Endovasc Surg. 2005 Oct;30(4):391-4.
• Nicolai SP, Hendriks EJ, Prins MH, Teijink JA. Optimizing supervised exercise therapy for 
patients with intermittent claudication. J Vasc Surg. 2010 Nov;52(5):1226-33.
• Parr BM, Noakes TD, Derman EW. Peripheral arterial disease and intermittent claudication: 
efficacy of short-term upper body strength training, dynamic exercise training, and advice to 
exercise at home. S Afr Med J. 2009 Nov;99(11):800-4.
• Patterson RB, Pinto B, Marcus B, Colucci A, Braun T, Roberts M. Value of a supervised 
exercise program for the therapy of arterial claudication. J Vasc Surg. 1997 Feb;25(2):312-8; 
discussion 8-9.
• Perkins JM, Collin J, Creasy TS, Fletcher EW, Morris PJ. Exercise training versus angioplasty 
for stable claudication. Long and medium term results of a prospective, randomised trial. Eur 
J Vasc Endovasc Surg. 1996 May;11(4):409-13.
• Regensteiner JG, Meyer TJ, Krupski WC, Cranford LS, Hiatt WR. Hospital vs home-based 
exercise rehabilitation for patients with peripheral arterial occlusive disease. Angiology. 1997 
Apr;48(4):291-300.
• Ritti-Dias RM, Wolosker N, de Moraes Forjaz CL, Carvalho CR, Cucato GG, Leao PP, et 
al. Strength training increases walking tolerance in intermittent claudication patients: 
randomized trial. J Vasc Surg. 2010 Jan;51(1):89-95.
• Sanderson B, Askew C, Stewart I, Walker P, Gibbs H, Green S. Short-term effects of cycle 
and treadmill training on exercise tolerance in peripheral arterial disease. J Vasc Surg. 2006 
Jul;44(1):119-27.
• Savage P, Ricci MA, Lynn M, Gardner A, Knight S, Brochu M, et al. Effects of home versus 
supervised exercise for patients with intermittent claudication. J Cardiopulm Rehabil. 2001 
May-Jun;21(3):152-7.
• Saxton JM, Zwierska I, Blagojevic M, Choksy SA, Nawaz S, Pockley AG. Upper- versus lower-
limb aerobic exercise training on health-related quality of life in patients with symptomatic 
peripheral arterial disease. J Vasc Surg. 2011 May;53(5):1265-73.
83
Safety of supervised exercise therapy
3
• Scheffler P, de la Hamette D, Gross J, Mueller H, Schieffer H. Intensive vascular training in stage 
IIb of peripheral arterial occlusive disease. The additive effects of intravenous prostaglandin 
E1 or intravenous pentoxifylline during training. Circulation. 1994 Aug;90(2):818-22.
• Schlager O, Giurgea A, Schuhfried O, Seidinger D, Hammer A, Groger M, et al. Exercise 
training increases endothelial progenitor cells and decreases asymmetric dimethylarginine 
in peripheral arterial disease: a randomized controlled trial. Atherosclerosis. 2011 
Jul;217(1):240-8.
• Slordahl SA, Wang E, Hoff J, Kemi OJ, Amundsen BH, Helgerud J. Effective training for 
patients with intermittent claudication. Scand Cardiovasc J. 2005 Sep;39(4):244-9.
• Spronk S, Bosch JL, den Hoed PT, Veen HF, Pattynama PM, Hunink MG. Intermittent 
claudication: clinical effectiveness of endovascular revascularization versus supervised 
hospital-based exercise training--randomized controlled trial. Radiology. 2009 
Feb;250(2):586-95.
• Stewart AH, Smith FC, Baird RN, Lamont PM. Local versus systemic mechanisms underlying 
supervised exercise training for intermittent claudication. Vasc Endovascular Surg. 2008 
Aug-Sep;42(4):314-20.
• Streminski JA, de la Haye R, Rettig K, Kuntz G. [Comparison of the effectiveness of physical 
training with parenteral drug therapy in Fontaine stage IIb peripheral arterial occlusive 
disease]. Vasa. 1992;21(4):392-402.
• Tew G, Nawaz S, Zwierska I, Saxton JM. Limb-specific and cross-transfer effects of 
arm-crank exercise training in patients with symptomatic peripheral arterial disease. 
Clin Sci (Lond). 2009 Dec;117(12):405-13.
• Tisi PV, Hulse M, Chulakadabba A, Gosling P, Shearman CP. Exercise training for 
intermittent claudication: does it adversely affect biochemical markers of the exercise-
induced inflammatory response? Eur J Vasc Endovasc Surg. 1997 Nov;14(5):344-50.
• Treat-Jacobson D, Bronas UG, Leon AS. Efficacy of arm-ergometry versus treadmill 
exercise training to improve walking distance in patients with claudication. Vasc Med. 2009 
Aug;14(3):203-13.
• Tsai JC, Chan P, Wang CH, Jeng C, Hsieh MH, Kao PF, et al. The effects of exercise training on 
walking function and perception of health status in elderly patients with peripheral arterial 
occlusive disease. J Intern Med. 2002 Nov;252(5):448-55.
84
Supervised exercise therapy for intermittent claudication
3
• Villemur B, Marquer A, Gailledrat E, Benetreau C, Bucci B, Evra V, et al. New rehabilitation 
program for intermittent claudication: Interval training with active recovery: pilot study. 
Ann Phys Rehabil Med. 2011 Jul;54(5):275-81.
• Wang J, Zhou S, Bronks R, Graham J, Myers S. Supervised exercise training combined with 
ginkgo biloba treatment for patients with peripheral arterial disease. Clin Rehabil. 2007 
Jul;21(7):579-86.
• Winterfeld HJ, Siewert H, Strangfeld D, Schmidt HH. [Experiences with the application of 
physiotherapy in peripheral arterial circulatory disorders of the lower extremities (stage I 
and IIa) under ambulatory conditions]. Z Gesamte Inn Med. 1983 Apr 1;38(7):221-5.
• Wood RE, Sanderson BE, Askew CD, Walker PJ, Green S, Stewart IB. Effect of training on the 
response of plasma vascular endothelial growth factor to exercise in patients with peripheral 
arterial disease. Clin Sci (Lond). 2006 Dec;111(6):401-9.

 
4
CHAPTER 4
Gender differences following supervised 
exercise therapy in patients with 
intermittent claudication  
L.N.M. Gommans 
M.R.M. Scheltinga 
M.R.H.M. van Sambeek 
A.H.E.M. Maas 
B.L.W. Bendermacher 
J.A.W. Teijink 
 
 
J Vasc Surg. 2015 Sep;62(3):681-8.
ABSTRACT
Background: Prevalence of peripheral arterial disease is equal in men and women. 
However, women seem to suffer more from the burden of disease. Current studies on 
gender-related outcomes following supervised exercise therapy (SET) for intermittent 
claudication (IC) yield conflicting results.
Methods: A follow-up analysis on data from the 2010 ExercIse Therapy in Peripheral 
Arterial Disease (EXITPAD) study: a multicentre randomized controlled trial including 
IC patients following SET, was performed. The SET program was supervised by 
physiotherapists and included interval-based treadmill walking approximating maximal 
pain, combined with activities such as cycling and rowing. Patients usually started with 
three 30 minutes sessions a week. Training frequency was adapted during the following 
year on the basis of individual needs. Primary outcome was gender differences regarding 
the change in absolute claudication distance (ACD) following SET. ACD was defined as 
the number of meters that a patient had covered just before he/she was forced to stop 
walking because of intolerable pain. Secondary outcomes were gender differences in 
change of functional walking distance (FWD), quality of life and walking (dis)ability 
following SET. Walking distances were obtained by standardized treadmill testing 
according the Gardner-Skinner protocol. Quality of life was measured by the Short Form 
(36) Health Survey and walking (dis)ability was determined by the Walking Impairment 
Questionnaire (WIQ). Measurements were performed at baseline and after 3, 6, 9 and 12 
months. Only patients who met the 12 months follow-up measure were included in the 
analysis.
Results: A total of 113 men and 56 women were available for analysis. At baseline, groups 
were similar in terms of clinical characteristics and ACD walking distances (men: 250 
meters vs. women: 270 meters; P=.45). ACD improved for both sexes. However, ACD 
increase was significantly lower for women than for men, during the first 3 months of 
SET (men: Δ 280 meters vs. women: Δ 220 meters, P=.04). Moreover, absolute walking 
distance was significantly shorter for women compared to men after 1 year (565 meters 
vs. 660 meters, P=.032). Women also reported less on several WIQ subdomains, although 
total WIQ score was similar (men: 0.69 vs. women: 0.61; P=.592). No differences in 
quality of life after SET were observed. 
4
Conclusion: Women with IC benefit less during the first 3 months of SET and have 
lower absolute walking distances after twelve months of follow-up compared to men. 
More research is needed to determine whether gender-based IC treatment strategies are 
required. 
4
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INTRODUCTION
Peripheral arterial disease (PAD) affects more than 12% of the aging population1, and 
was initially thought to be more prevalent in men than in women.2 However, recent 
population-based studies demonstrated an almost equal sex distribution (men: 13.4% 
vs. women: 15.6%).3 Interestingly, women may suffer more from the consequences of 
PAD. For instance, they were found to perceive a lower physical function, experience 
greater impact on hampered daily activities and mood state, and report greater bodily 
pain compared to men with PAD.4 Moreover, a faster functional decline with greater 
mobility loss5, poorer outcomes after lower extremity revascularisation procedures6 and 
a twofold higher mortality rate with symptomatic disease were found in PAD females 
compared to their male counterparts.7 Conversely, no gender-related differences were 
observed regarding self-reported community-based walking ability.4  
Intermittent claudication (IC) is the most common manifestation of PAD. A growing 
number of reports consistently demonstrates beneficial effects of supervised exercise 
therapy (SET) on overall walking ability in patients with IC.8, 9 Most studies compared 
the efficacy of (various types of) SET to controls receiving pharmacological therapy or 
a revascularization procedure.8, 10-13 However, gender-specific outcomes following SET 
for patients with IC are seldom reported and results are conflicting.14-16 Two studies 
suggested that gender did not influence walking performance14 and that both sexes 
equally benefitted from SET.15 In contrast, a third study found that women responded less 
favourably to a program of exercise rehabilitation compared to men.16 No study addressed 
a possible gender-specific response to SET in terms of absolute walking distances or 
perceived walking (dis)ability. The paucity of data so far is likely due to a consistent female 
underrepresentation in randomized controlled trials. In a recent scientific statement, the 
American Heart Association released a ‘call to action’ for more research into gender-
based differences of patients with PAD.17 
The present study evaluated whether men and women with IC responded differently 
to SET with respect to walking distance, walking (dis)ability and quality of life. It was 
hypothesized that women have inferior outcomes after SET associated with an accelerated 
functional decline.5 
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METHODS 
This study consists of a follow-up analysis of data that were generated by the 2010 ExercIse 
Therapy in Peripheral Arterial Disease (EXITPAD) study. This multicentre randomized 
clinical trial, approved by the institutional review board of the Atrium medical center 
and at each of the participating sites, was undertaken to study the effect of either SET or 
a walking advice in IC patients. Methods and results in terms of walking distance and 
quality of life were previously published.18 The EXITPAD study included patients with 
Fontaine stage II PAD (e.g. IC), defined as having an ankle-brachial index (ABI) <0.9 
who were considered for conservative therapy. Exclusion criteria were an absolute CI 
distance (ACD) >500 meters, prior exercise therapy or vascular interventions, insufficient 
command of the Dutch language, serious cardiopulmonary limitations (NYHA 3-4), leg 
amputation, psychiatric instability, and other serious comorbidities prohibiting physical 
exercise therapy. 
In the EXITPAD study, all eligible patients standardly received cardiovascular risk 
management including cholesterol lowering medication and antiplatelet therapy. They 
were also counselled regarding management of additional atherosclerotic risk factors 
(e.g. smoking, body weight). Patients were randomized into three groups after written 
informed consent was obtained. A first group receiving a walking advice (WA, ‘go home 
and walk’), a second group underwent SET ‘with feedback’ whereas the third group 
received SET ‘without feedback’. Patients of the WA group were advised by a vascular 
surgeon to walk as often as possible. Patients of the two SET study groups were referred to 
regional physiotherapists (PT) who were previously selected and had undergone training 
to participate in the EXITPAD study. These PT’s were educated according to the guideline 
on ‘Intermittent Claudication’ of the Royal Dutch Society for Physical Therapy and were 
asked to administer SET according to this guideline.19 Main goal of SET was to increase 
maximum walking distance. Additional goals were improvement of aerobic endurance, 
pain tolerance, gait pattern and specific activities (e.g. stair climbing). Lastly, information 
on lifestyle changes was provided by these PT’s in order to stimulate healthy behaviour.20 
The training program predominately consisted of interval-based treadmill walking 
approximating (sub)maximal pain. An example of the training protocol is provided in 
table 1. Patients assigned to the SET ‘with feedback’ group received similar SET program 
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and also carried a Personal Activity Monitor (PAM) accelerometer (PAM B.V. Doorwerth, 
The Netherlands) to monitor physical activity during daily life. 
Detailed therapy evaluation and documentation sheets determining frequency, 
duration, and content of the therapy were completed by the physiotherapists after 6, 12, 
26 and 52 weeks of SET. 
Table 1. Example of the SET trainings protocol for intermittent claudication
Frequency Started at 3 times a week. Frequency is then adapted to the individual need, meaning that patients 
who perform well and comply with the exercise recommendations can phase down the therapy 
frequency sooner than other patients
Duration 20-40 minutes per training session
Intensity 40-70% of VO2max or Borg RPE score 11-15 
Content Interval training: regimen included 2-5 minutes of walking (near to ACSM Claudication Pain Rating 
Scale score 2-3) and a subsequent 2-5 minutes of passive rest. Three to five cycles per training session.
Aerobic endurance training 
Activities Primarily walking (on a treadmill, with slope of 2-8º)
Combined with cycling, rowing, stepping and sports activities in general
Progression Duration (i.e. amount of interval cycles) and intensity (i.e. duration of interval cycles) of training is in-
creased as based on individual progression. In general, first intensification takes place when a patient 
is able to exercise for 20 minutes (e.g. 5 cycles of 4 minutes) 
Home work Moderate exercising for 30 minutes (in bouts of at least 10 minutes): 5 days per week
Evaluation Continuous evaluation. Treadmill testing at least after 6 and 12 weeks
Termination Program ends when patient is satisfied and the physiotherapist expects no further progression 
VO2max = maximal oxygen consumption. Reflects the aerobic physical fitness; Borg RPE = Borg Ratings of Perceived 
Exertions. Score ranges from 6 to 20 (respectively: no exertion at all to maximal exertion); ACSM = American College of 
Sport Medicine. Claudication Pain scores range from 1 to 4 (respectively: minimal discomfort to unbearable pain).
Outcome measurements of present study
Since the EXITPAD trial found no additional improvement in patients receiving extra 
feedback18, it was allowed to combine data of both SET groups for the purpose of the 
present study. Data of patients receiving a WA were not used. Evaluation of data generated 
at baseline and after 3, 6, 9 and 12 months of SET was performed by a blinded observer 
(LG). Primary outcome was a gender difference in absolute claudication distance (ACD). 
Secondary outcomes were gender-differences regarding functional claudication distance 
(FCD) and scores obtained by the Walking Impairment Questionnaire (WIQ) and the 
Short Form (36) Health Survey (SF-36). 
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The ACD was defined as the number of meters that a patient had covered just before 
he/she was forced to stop walking because of intolerable pain. A FCD was defined as 
the number of meters that a patient had walked until it was subjectively decided to stop 
due to a certain level of pain.21 Both parameters are reliable tools to quantify walking 
distance in patients with IC.21 These distances were determined by a standardized graded 
treadmill test according to the Gardner-Skinner protocol, most reliable measure for 
walking ability.22 
The WIQ is a questionnaire that is validated for the Dutch language in patients with 
PAD.23 The self-administered revised Dutch version was used in the present study.23 A 
WIQ assesses impairment regarding three domains: walking distance, walking speed and 
stair climbing.24 WIQ scores range from 0 to 1 and lower scores correspond with more 
severe walking disability. The total WIQ score is the mean of scores of these domains.
The SF-36 is a general, often used, questionnaire determining quality-of-life (QOL).25 
It contains eight subscales evaluating physical function and role, general health, social 
function, emotional role, mental health, vitality and pain. Scores were calculated using a 
common scoring algorithm.26  
Statistical analysis 
Analysis was conducted according to the intention-to-treat principle and included 
data from patients who were randomized (for SET) and who completed the treadmill 
assessment for quantifying walking distance after 12 months of follow-up. Therefore, 
patients who terminated the SET program but who performed the treadmill assessment 
were also incorporated in the analysis. Categorical variables were presented as percentages, 
and continuous variables as means ± standard deviations if normally distributed, or as 
medians with interquartile ranges (IQR) in case of a skewed distribution. Missing values 
of walking distances at 3, 6 and 9 months were imputed based on a multivariate linear 
regression analysis. Depending on the data’s measuring level and distribution, Pearson’s 
Chi-square, one-way analysis of variance (ANOVA), Kruskal-Wallis or Wilcoxon-Signed 
Rank Test were used to determine gender differences in baseline characteristics and both 
primary and secondary outcomes. Multivariate analysis were conducted to determine 
influence of potential confounders. A significance level of P<.05 was applied. Analyses 
were performed using SPSS 20.0 (SPSS Inc, Chicago, 11). 
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RESULTS 
Study population 
Between December 2005 and May 2008, the EXITPAD study enrolled 304 patients (WA 
group, n=102 patients; SET group, n=202). Follow-up ended in May 2009. Three patients 
eventually did not participate in the SET program leading to a total number of 199 
patients receiving SET. As 26 were lost to follow up whereas four had died, 169 patients 
(men n=113, women n=56) were analysed in the present study (figure 1).
Males were not different compared to females in terms of age, BMI, ABI and comorbidities 
(table 2). A total of 30 men (26.5%) and 17 women (30.4%) discontinued the SET program 
at various time points during the 12 months follow-up period (P=.692). Insufficient 
motivation was a commonly reported reason (men: n=7, 23.2%; women: n=4, 23.5%. 
P=.525). 
PAV = peripheral arterial disease.
Figure 1. Flow chart of study population
Analyzed 
n=113
Analyzed 
n=56
Total SET group
n=199
WA
n=102
SET 
n=109
Did not got SET (n=0)
SET + feedback
n=93
Did not got SET (n=3)
Randomized
n=304
Men
n=135
Lost to follow-up (n=19)
Lack of motivation (n=5)
Progression of PAD (n=2)
Coronary heart disease (n=1)
Orthopedic disease (n=5)
Diabetic foot (n=1)
Concomitant disease (n=5)
Deceased (n=3)
Women
n=64
Lost to follow-up (n=7)
Lack of motivation (n=3)
Progression of PAD (n=0)
Coronary heart disease (n=2)
Orthopedic disease (n=1)
Diabetic foot (n=0)
Concomitant disease (n=1)
Deceased (n=1)
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Content of the SET program
Mean number of sessions per week (men: 1.8 to 0.8 vs. women: 1.7 to 0.7, P=.61) and 
total number did not differ between men and women (table 3). However, session duration 
during the first 12 weeks was significantly longer for men (men: 43 minutes vs. women: 
37 minutes, Δ 6 minutes, P=.03). The amount of training on the treadmill training and 
program compliance (>70% compliance: men: 71% vs. women: 58%, P=.17) were similar 
for both groups. 
Table 2. Baseline characteristics of study population (n=169)
Variables Men (n=113) Women (n=56) P-values
Age (years) - mean (SD) 65 (9.2) 67 (9.7) 0.21
BMI (kg/m2) - mean (SD) 28 (4.1) 27 (4.8) 0.59
ABI - mean (SD) 0.66 (0.19) 0.70 (0.14) 0.21
ACD - median (IQR) 250 (170-395) 270 (153-340) 0.45
Current smokers - % 53 60 0.35
Diabetes mellitus - % 21 23 0.79
Cardiac disease - % 27 14 0.07
CVA or TIA - % 15 14 0.88
COPD - % 20 18 0.78
LE orthopedic disease - % 13 18 0.42
BMI = body mass index, CVA = cerebrovascular accident, TIA = transient ischemic attack, COPD = chronic obstructive 
pulmonary disease, LE = lower extremities. LE orthopaedic diseases included: osteoarthritis, rheumatoid arthritis,  
a total knee or hip prosthesis and other problems related to the bone or muscular tissue. 
Walking distance before and after one year of SET
Prior to SET initiation, ACD and FCD were not different in men compared to women 
(ACD: men 250 meters vs. women 270 meters, P=.451; FCD: men 150 vs. women 140, 
P=.332). Following one year of SET, both groups demonstrated increased ACDs as well 
as FCDs (both P<.05). The largest increase in both ACD and FCD was observed during 
the first 3 months of SET (table 4). The improvement of ACD of this first interval was 
significantly greater for men (men: Δ280 meters vs. women: Δ220 meters; P=.04) (figure 
2A). Furthermore, improved walking distances maximized at 9 months of follow-up and 
no further improvement was found later on, neither for men nor for women (table 4). 
Towards the end of a year of SET, FCD in women already started to decrease (figure 2B). 
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Furthermore, men revealed larger ACD and FCD at each of the 3-month intervals 
compared to women (figure 2). However, gender differences were only significant 
regarding absolute ACD at the 12 months follow-up point (men: ACD 660 meters vs. 
women: ACD 565 meters, P=.032) (table 4, figure 2A). Compared to ACD baseline values, 
men had increased by +264%, while for women a +209% increase was found at the 12 
months follow-up point (P=.042).
Table 3. Content of and adherence to the supervised exercise program 
Men (n=113) Women (n=56)
week 1-6 
(n=97)
week 7-12 
(n=88)
week 13-26 
(n=88)
week 27-52 
(n=82)
week 1-6 
(n=52)
week 7-12 
(n=49)
week 13-26 
(n=46)
week 27-52 
(n=39)
Participantsa 
– %
86 78 78 73 93 88 82 70
Sessions 
per week  
– mean (sd)
1.8 (0.6) 1.6 (0.7) 1.1 (0.7) 0.8 (0.7) 1.7 (0.6) 1.4 (0.6) 0.9 (0.7) 0.7 (0.7)
P-valueb 0.42 0.39 0.31 0.61
Duration per 
sessionc 
– mean (sd)
41 (15) 43 (15) 40 (19) 37 (21) 35 (14) 37 16) 37 (18) 35 (19)
P-valued 0.02 0.03 0.41 0.53
Cumulative 
sessionse 
– mean (sd)
10.6 (3.7) 9.4 (4.5) 15.8 (10.4) 21.1 (18.6) 10.1 (3.4) 8.7 (3.9) 13.9 (9.7) 19.2 (17.5)
P-valuef 0.43 0.39 0.31 0.61
Training on 
treadmillg  
– mean (sd)
24 (11.5) 25 (11.4) 24 (13.5) 23 (14.6) 22 (11.4) 23 (12.5) 24 (10.9) 22 (13.4)
P-valueh 0.49 0.62 0.85 0.49
Individual 
training – %
79 75 79 82 85 80 83 77
P-valuei 0.40 0.31 0.32 0.64
Adequate 
compliancej 
– % 
74 73 72 71 72 73 64 58
P-valuek 0.48 0.96 0.40 0.17
a = number of patients who completed SET program for given duration. SET program ended on initiative of the patient: when satisfied with the 
result or on initiative of the physiotherapist: when no further progression was expected. b,d,f,h = independent-samples T-test; c,g = duration in 
minutes; e = cumulative number of training session for given duration. i,k = Pearson Chi-square test; j = adequate compliance was defined as 
>70 % adherence to the training program.
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At baseline and follow-up measures for men (n=113; dashed line) and women (n=56; solid line) separately. Error 
bars (grey for men; black for women) represent interquartile ranges. × = significant difference in change of walking 
distance from baseline to 3 months of follow-up; * = significant difference in absolute walking distance at 12 months 
of follow-up.
Figure 2. Median walking distances. A: Absolute claudication distance (ACD); B: Functional 
claudication distance (FCD). 
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Table 4. Walking distance and change in walking distance at baseline and during follow-up 
measures (meters; median and IQR)
Men (n=113) Women (n=56) P-value
Baseline
FCD 150 (100-250) 140 (83-225) 0.33
ACD 250 (170-395) 270 (153-340) 0.45
3 m follow-up
FCD 390 (267-565) 365 (203-495) 0.13
Δ FCDa 220 130 0.07
ACD 535 (395-880) 460 (333-620) 0.06
Δ ACDa 280 220 0.04
6 m follow-up
FCD 480 (283-670) 453 (253-658) 0.55
Δ FCDb 50 60 0.38
ACD 630 (398-1045) 560 (365-815) 0.32
Δ ACDb 60 70 0.76
9 m follow-up
FCD 505 (350-807) 475 (290-625) 0.13
Δ FCDc 30 0 0.17
ACD 660 (490-1320) 575 (405-818) 0.05
Δ ACDc 50 14 0.12
12 m follow-up
FCD 490 (315-770) 425 (255-638) 0.06
Δ FCDd 0 0 0.55
ACD 660 (450-1600) 565 (388-768) 0.03
Δ ACDd 0 0 0.51
m = months. a: change from baseline; b = change from 3 to 6 months; c = change from 6 to 9 months; 
d = change from 9 to 12 months. Significant differences are depicted in bold (P<.05).
Walking Impairment Questionnaire 
At baseline, group scores were not different (table 5). After 12 months of SET, men and 
women demonstrated similar increased scores (men: +0.19 ± 0.22 vs. women: +0.21 ± 
0.2, P=.592). However, 3, 6 and 12 months scores for walking speed, 3 months scores for 
stair climbing and 3 and 6 months total WIQ scores were significant lower in women 
(table 5). 
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Quality of life
Prior to SET, mental health as scored by the SF-36 was significantly lower in women 
compared to men (men: 78.3 vs. women: 71.9, P=.031). In contrast, all seven other 
domains were similar for both sexes prior to the therapy. Gender-related differences 
in change of QOL after 12 months of SET were not observed (table 5). Mental health 
at baseline did not contribute to the gender differences in ACD (multivariate analysis, 
P=.795). 
Table 5. Walking Impairment Questionnaire (WIQ) in men and women (mean and (standard 
deviation)) 
Mena Womena
Baseline 3 m 6 m 9 m 12 m Baseline 3 m 6 m 9 m 12 m 
Distance 0.36 
(0.29)
0.58 
(0.29)
0.67 
(0.29)
0.67 
(0.30)
0.69 
(0.29)
0.33 
(0.24)
0.53 
(0.34)
0.62 
(0.35)
0.69 
(0.33)
0.68 
(0.30)
Speed 0.46 
(0.24)
0.59 
(0.24)
0.61 
(0.23)
0.60 
(0.25)
0.62 
(0.25)
0.42 
(0.21)
0.44 
(0.23)
0.50 
(0.26)
0.54 
(0.23)
0.52 
(0.24)
Stairs 0.63 
(0.28)
0.76 
(0.26)
0.80 
(0.24)
0.76 
(0.25)
0.78 
(0.24)
0.57 
(0.30)
0.64 
(0.31)
0.71 
(0.27)
0.74 
(0.29)
0.72 
(0.30)
Total score 0.48 
(0.22)
0.63 
(0.22)
0.69 
(0.21)
0.66 
(0.22)
0.69 
(0.21)
0.44 
(0.20)
0.52 
(0.25)
0.60 
(0.24)
0.66 
(0.24)
0.61 
(0.25) 
Change in total score from baseline after FU Change in total score from baseline after FU
0.14 
(0.16)
0.17 
(0.23)
0.16 
(0.21)
0.19 
(0.22)
0.12 
(0.25)
0.17 
(0.23)
0.21 
(0.27)
0.21 
(0.24)
M = months, FU= follow-up. a= significant differences (P<.05), depicted in bold. The WIQ scores range from 0 to 1. 
Lower scores correspond with more severe walking disability. 
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Table 6. Short Form 36 (SF-36) Health Survey in men and women (means and (standard 
deviation))
Mena Womena
Baseline 12 m FU Change Baseline 12 m FU Change 
Physical function 53.0 (15.9) 68.4 (18.7) 13.8 (21.7) 48.8 (15.7) 63.6 (19.5) 13.8 (19.7)
Physical role 48.4 (40.4) 64.8 (38.9) 15.0 (46.9) 41.0 (38.6) 58.7 (39.9) 18.9 (44.1)
General health 51.6 (12.0) 53.4 (12.3) 1.2 (12.8) 54.4 (12.7) 52.3 (11.9) -2.0 (13.4)
Social function 78.3 (23.2) 82.5 (21.5) 4.3 (27.6) 76.1 (21.8) 83.4 (19.3) 8.3 (22.1)
Emotional role 88.4 (30.1) 87.1 (30.7) -0.9 (40.6) 78.4 (37.8) 83.6 (34.3) 3.8 (15.8)
Mental health 78.3 (18.3) 77.1 (18.4) -0.4 (17.5) 71.9 (16.5) 74.7 (19.7) 3.7 (15.8)
Vitality 63.3 (19.7) 63.0 (18.5) 0.40 (17.6) 58.8 (17.5) 59.7 (18.6) 1.7 (16.3)
Pain 53.8 (20.9) 71.6 (22.3) 17.8 (28.5) 56.4 (15.8) 67.0 (21.9) 11.0 (21.5)
a = significant differences (P<.05), depicted in bold. M = months. FU = follow-up. Follow-up at 3, 6 and 9 months not 
shown.
DISCUSSION 
The aim of this study was to investigate whether outcomes of SET in patients with IC 
were gender-related. The scarce literature reports conflicting results. The present study 
is the first to address gender-based outcomes of SET in terms of subjective walking (dis)
ability, quality of life and absolute walking distances. Our study showed that women 
benefit less from SET during the first 3 months of SET, in terms of change in absolute 
walking distance. Moreover,  women’s ACD was almost 15% less after one year compared 
to men’s ACD (660 vs. 565 meters). Our findings support the results of recent studies 
reporting a less favourable response following SET in women, although both their follow-
up included only three months.4, 16
In general, SET is known to improve walking disability.18 Interestingly, previous 
research suggested lower baseline WIQ scores in women.27 These baseline gender 
differences were not observed in the present study. Moreover, the magnitude of change in 
woman’s total WIQ score after 12 months of SET also did not differ from men. A higher 
prevalence of comorbidities and advanced female age in previous research could explain 
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these opposing results, as these factors have influence on WIQ scores.27 Furthermore, 
women had lower walking ability scores in various subdomains, most strikingly with 
regard to walking speed. Previous studies also reported that women with IC ambulate 
slower in a community setting.28 Therefore, women should possibly be encouraged to 
train at a faster pace than preferred as also suggested in one other study.28
Reduced quality of life (QOL) in an IC patient is a conflicting issue. Similar to our 
findings, Serracino-Inglot et al. also found no gender differences in QOL after SET.15 
A significantly lower mental health in women at baseline was identified in our study, 
although these differences disappeared at later time points, possibly due to small sample 
sizes. This novel finding of poorer mental health in women with IC at baseline parallels 
with recent data suggesting depression as one of the strongest risk factors for PAD in 
women.29 Poorer mental health parameters contribute to greater physical inactivity, 
which in turn induces insulin resistance and microvascular dysfunction30 rendering 
women more susceptible to develop PAD.  
There is evidence regarding microvascular gender differences in IC patients. Women 
have greater muscular ischemia during exercise than men. Due to lower hemoglobin 
oxygen saturation of the calf musculature31 and a more impaired microvascular function.32 
These phenomena might explain a differential improvement of walking distance after 
SET between men and women as found in this study. This may also explain why only 
ACD and not FCD was significantly lower in our study as FCD is more closely reflecting 
the actual functional impairment21 rather than the patients’ absolute capacity. However, 
differences between men and women regarding motivation, willingness to push through 
discomfort and pain tolerance, might play a role. In addition, lowered hemoglobin oxygen 
saturation during ambulation, next to poorer leg strength33 in women possibly contribute 
to a restricted walking pace, and may explain differences in WIQ scores regarding the 
walking speed subdomain. 
Other biochemical mechanisms might be involved in the gender issue too. Higher levels 
of oxidative stress, insulin resistance and inflammation are present in postmenopausal 
women compared to similar aged men and may contribute to lower claudication 
threshold levels.31 These findings are in line with gender-based functional differences in 
coronary artery disease.34 Oxidative stress and inflammation affect women with diabetes 
mellitus (DM) more compared to men and result in a relatively greater impairment of the 
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peripheral microcirculation. As a consequence, women with IC and DM respond worse 
to SET compared to IC women without DM.16 Unfortunately, current diagnostic ABIs 
are not suitable to determine the degree of peripheral microvascular dysfunction32, and 
alternatives are not available yet. Our post-hoc analysis in this relatively small sample 
size (n=56) also found a similar association with DM in women but not in men (women; 
P=.058 vs. men; P=.554). 
The knowledge gap and lack of research in gender-based differences in patients with 
PAD were recently highlighted by the American Heart Association.17 Women are under-
represented in cardiac rehabilitation (CR) programs whereas success rates in terms of 
mortality reduction are higher than in men.35 Reasons for diminished female participation 
in CR programs may also apply to PAD rehabilitation programs and may be related to 
women’s older age, lower socio-economic status and restricted psychosocial wellbeing.36 
Interestingly, group-based intervention programs may be more effective in women as 
sharing of emotions and experiences tends to increase intrinsic motivation for exercise.37
There is uncertainty on the optimal duration of SET resulting in maximally improved 
walking distances.38 Previous research on optimal length of SET programs has found the 
greatest improvement in walking distance during the first two months of therapy39, which 
is in accordance with our findings. Both groups of the present study received similar 
number of training sessions and were engaged in a similar amount of treadmill walking. 
However, duration in terms of minutes per sessions during the first 12 weeks was on 
average 6 minutes longer for men compared to women. The effect of duration per single 
session in couple of minutes has not been explored yet. However, it is quite unlikely that 
this small difference, though statistical significant, is the single factor explaining the 
difference in ACD after 3 or 12 months.  
Smoking behaviour, BMI, comorbidities and baseline walking distances are potential 
confounders in the relationship between gender and walking distance. However, these 
factors were the same or equally distributed among both groups, allowing for a valid 
comparison. However, the present study may suffer from shortcomings. Gender-based 
analyses were not considered at the time of data collection, observer bias is therefore 
unlikely. Selection bias was absent as only patients participating in SET programs were 
analysed. The present study was a follow-up analysis of previously accumulated clinical 
trial data precluding a power calculation based on our main outcome. However, previous 
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power calculations for the EXITPAD trial revealed a sample size of 81 patients per group 
to demonstrate a difference of 150 meters.18 By combining both groups of SET (e.g. with 
and without feedback), we were able to meet this minimal number of patients for the 
male group (n=113) but not for females (n=56). Limited numbers of women may possibly 
explain the lack of significant differences regarding short term follow-up data. Restricted 
numbers of women in our study reflect current misperception on gender differences 
in  PAD prevalence. Besides, it accents the general problem of under-representation 
of women in clinical trials,17 which is mainly due to current underdiagnoses of PAD in 
women caused by misleading clinical presentation and the contribution of alternative 
risk factors to cardiovascular diseases.40 Last, we proposed several reasons to explain 
our results. However, motivation, pain tolerance and differential use of medications (i.e. 
statins or beta-blockers) were not assessed in this study and require further investigation. 
CONCLUSION
Women with IC benefit less from SET during the first 3 months and have significant lower 
absolute walking distances after twelve months of follow-up. More research is needed to 
expand our understanding on gender-based differences in IC. This knowledge may be 
used to determine the necessity and/or requirement of gender-based exercise programs 
for patients with IC. 
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ABSTRACT
Background: To summarize literature and to address the lack of evidence on the potential 
influence of diabetes mellitus (DM) on the response to supervised exercise therapy (SET) 
in patients with intermittent claudication (IC).
Methods: Studies were obtained from MEDLINE, EMBASE, and CENTRAL. Two authors 
independently assessed randomized and nonrandomized studies investigating the effect 
of DM on walking distance outcomes after SET in patients with IC. Eligible studies 
examined SET in diabetic and nondiabetic patients with IC. Studies were evaluated for 
methodological quality using the Cochrane Collaboration’s tool for assessing risk of 
bias. Outcome measures were expressed in walking distance (meters), absolute increase 
(meters) and relative increase (percentage).
Results: The literature search identified 903 potentially relevant and unique articles. After 
screening of the titles and abstracts, and full-text evaluation, 3 articles were included. 
Methodological quality assessment revealed that all studies were having a low risk of bias. 
Of these three studies, all reported on maximal walking distance (MWD, n=845), two 
reported on pain-free walking distance (PFWD, n=87), and one reported on functional 
walking distance (FWD, n=758). Studies reported improvement in MWD, PFWD and 
FWD for both the diabetic and the nondiabetic group. One study reported a nearly 
significant effect of DM on MWD (P=.056). Another study demonstrated a difference in 
PFWD between diabetic and nondiabetic IC patients. On the contrary, the largest study 
of this review did not find any effect of DM on MWD and FWD after SET.
Conclusion: IC patients with DM demonstrate improvement on walking distance 
outcomes after SET. Conflicting results were reported when comparing diabetic and 
nondiabetic IC patients.
5
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INTRODUCTION
Peripheral arterial disease (PAD) is a major manifestation of systemic atherosclerosis, 
characterized by obstruction or occlusion of the lower extremity arteries. PAD affects 
approximately 202 million individuals worldwide.1 As the population ages, the prevalence 
of PAD is expected to increase.2, 3 Well-known risk factors for PAD include cigarette 
smoking, diabetes mellitus (DM), advanced age (≥40), hypertension, hyperlipidemia, 
and hyperhomocystenemia.4, 5 Cigarette smoking and DM in particular have a strong 
association with the development of PAD.6
The most common symptom of PAD is intermittent claudication (IC), which results 
from poor oxygenation of the muscles of the lower extremities and is typically experienced 
as pain, cramping or aching in the calves, thighs, or buttocks. Symptoms are induced 
by exercise (i.e. walking) and are relieved by rest.7 More extreme presentations of PAD 
include rest pain, tissue loss, or gangrene. These limb-threatening manifestations of PAD 
are collectively termed critical limb ischemia (CLI). It has been reported that of those 
with PAD, over one-half are asymptomatic or have atypical symptoms, about one-third 
have IC, and the remainder present with more severe symptoms.8
PAD comes with increased cardiovascular mortality rates due to the concomitant 
presence of coronary artery disease and/or cerebrovascular disease. Patients with PAD 
have a significantly higher risk of cardiovascular events (myocardial infarction, stroke).9 
The precise prevalence of DM in patients with PAD is unclear. Data from the Framingham 
Heart Study revealed that 20% of symptomatic PAD patients had DM.10 In addition, 
it has been estimated that PAD is 2 to 4 times more prevalent in individuals with 
DM.11, 12 A study aimed to assess the risk of mortality for individuals with both DM and 
PAD compared to individuals with either conditions alone, showed that the adjusted risk 
of death when having both conditions was 2.2 times higher than when having only PAD, 
further indicating that DM is a strong risk factor for PAD-associated mortality.13
DM is known to affect nearly every vascular bed. The associated proatherogenic 
changes include increased vascular inflammation, derangements of cellular components 
of the vasculature, generalized endothelial cell dysfunction, as well as alterations in blood 
cells and hemostatic factors.14 Moreover, in diabetic patients atherosclerotic lesions are 
more likely to be diffuse and more distal, accounting for an atypical IC presentation.15 
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Patients with PAD and DM also experience worse lower-extremity function than those 
with PAD alone.16 Other studies have shown faster disease progression, high rates of foot 
ulcers, and more lower-limb amputations in patients with PAD and DM.17, 18
Treatment of IC, irrespective of the presence of DM, should consist of two 
components. First, cardiovascular risk management (smoking cessation, antiplatelet 
therapy, statin therapy, glycemic control, hypertension and treatment of hyperlipidemia) 
to minimize the risk of future cardiovascular and cerebrovascular ischemic events, and 
second, symptomatic treatment of IC complaints. Recent international guidelines on the 
management of IC recommend supervised exercise therapy (SET) as the cornerstone 
therapy.19-21 It is known for more than a decade that the best results with exercise therapy 
are achieved under supervision.22, 23 In nearly all studies, unsupervised exercise regimens 
have shown lack of efficacy in improving functional capacity. Invasive revascularization 
procedures should be considered only when SET fails to achieve sufficient results.
Although the benefits of SET for IC have been documented, these findings have 
limited generalizability for patients with IC and DM. Characteristics specific to DM may 
influence the results of SET. However, in contemporary literature, information regarding 
the influence of DM on SET is limited. We conducted a review to summarize literature 
and to address the lack of evidence on the potential influence of DM on the response to 
SET in patients with IC. We hypothesized that SET may be less effective in IC patients 
with DM compared to those without DM.
METHODS 
Participants
We included studies that investigated the effect of DM on walking distance outcomes 
after SET in patients with IC (Fontaine II/Rutherford 1-3). 
Types of studies
Eligible studies examined SET in diabetic and nondiabetic patients with IC. Randomized 
and nonrandomized studies were included. Although treadmill walking is considered 
an important component of a SET program, uncertainty remains regarding the most 
113
Effect of diabetes on outcomes of supervised exercise therapy
5
effective content of such a program.24 Therefore, all types of SET programs were included. 
The search was limited to studies in humans and articles written in English or Dutch. No 
limitation to the date of publication was considered.
Search strategy
We performed a search in MEDLINE, EMBASE, and CENTRAL in July 2015, using the 
following Medical Subject Headings (MeSH), Emtree terms, and free terms: “peripheral 
arterial disease”, “peripheral occlusive artery disease”, “intermittent claudication”, 
“diabetes mellitus”,  “diabetes mellitus, type 1”, “diabetes mellitus, type 2”, “diabetes”, 
“exercise”, “exercise therapy”, “walking”, “exercise movement techniques”, “physical 
therapy modalities”, “treadmill”, “treadmill exercise”, “kinesiotherapy”, “physiotherapy”, 
“supervised exercise therapy”, “home-based exercise therapy”, “walking advice”, and 
“exercise training”. We also hand-searched bibliographies of included articles. Two 
authors (D.H. and L.G.) independently screened titles and abstracts, and selected 
articles, based on full-text evaluation. Disagreement between reviewers was discussed 
and resolved by consensus. Studies were evaluated for methodological quality using the 
Cochrane Collaboration’s tool for assessing risk of bias.
Data extraction and management
Same authors used a standardized data extraction form to extract the following data: 
details of the study population: country, study design, number of participants, gender, 
age, diabetic status, and inclusion and exclusion criteria; description of the SET protocol: 
content, frequency, duration, intensity, and amount of supervision; and outcome 
measures: walking distance, walking time, walking speed and quality of life.
Data analysis 
Data were analyzed using SPSS 19 software (IBM Corporation, Armonk, New York). 
Outcome measures were expressed in walking distance (meters), absolute increase 
(meters) and relative increase (percentage) for the different follow-up moments. If studies 
reported walking capacity in walking time (seconds), we converted the outcome to walking 
distance in meters using the information on the treadmill protocol. Also, if improvements 
in walking capacity were reported in increase in walking time (seconds), outcomes were 
converted to absolute increase in meters and relative increase in percentage.
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RESULTS 
Study selection
The literature search identified 903 potentially relevant and unique articles (figure 1). 
After screening of the titles, 841 articles were excluded. The abstracts of the remaining 62 
articles were screened, resulting in the exclusion of another 58 articles. Full-text evaluation 
of the remaining 4 articles followed, which resulted in the exclusion of 1 article.  Finally, 3 
studies with a total of 845 patients with IC were included. Among them, 268 patients were 
diabetic and 577 patients were nondiabetic. Methodological quality assessment revealed 
that all studies were having a low risk of bias.
Figure 1. Flow diagram of study inclusion
Records after duplicates removed
(n=903)
Studies included in review (n=3)
Records identified through  
database searching
(n=1260)
Additional records identified 
through other sources
(n=22)
Titles screened
(n=903)
Records excluded (n=841): 
not relevant
Full-text articles (n=1):
No SET
Records excluded (n=58):
Publication type (n=17)
Language (n=5)
No IC (n=8)
No SET (n=20)
No non-DM group (n=8)
Abstracts screened
(n=62)
Full-text articles assessed for eligibility
(n=4)
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Study characteristics 
Of the included studies, two were performed in the USA and one was performed in the 
Netherlands (table 1). Among diabetic patients, the mean age ranged from 61 to 68 years, 
whereas for nondiabetic patients, the mean age ranged from 67 to 69 years. Overall, more 
men than women participated. 
Interventions
 All studies included a SET program, predominantly treadmill walking under supervision 
(table 1). The SET programs were designed to increase the patient’s walking distance. This 
was mainly achieved by walking in intervals up to submaximal pain, followed by a short 
resting period. In one study, patients were randomized to either a home-based exercise 
therapy (HBET) program or a SET program.25 The HBET program was designed to be as 
similar to the SET program as possible. In all studies, SET was performed at least three 
times per week for at least three months. 
Outcome measures
To evaluate therapy progress, the maximum walking distance (MWD), pain-free walking 
distance (PFWD) and/or functional walking distance (FWD) were assessed at baseline 
and at least after three months of follow-up. The MWD was defined as the distance that 
a patient had covered before he/she was forced to stop walking because of intolerable 
claudication pain. The PFWD was defined as the distance that a patient had covered when 
he/she first experienced claudication pain. The FWD was defined as the distance that the 
patient had covered until he/she preferred to stop walking because of a certain level of 
claudication pain. To assess walking distances, all studies used the standardized Gardner 
maximal treadmill test protocol with a constant speed of 3.2 km/h (or 2 m/h) and an 
increasing slope of 2% every 2 minutes to a maximum slope of 10%.26, 27 The maximum 
test duration was 30 minutes.
Effect of DM on maximum walking distance (MWD) 
All three studies included outcomes on MWD after SET, and all studies reported 
improvement in MWD for both the nondiabetic and the diabetic group (n=845).25, 28, 29 
One study reported a tendency for greater improvement in the nondiabetic group 
116
Supervised exercise therapy for intermittent claudication
5
compared to the diabetic group.25 In the study by Allen et al., following the completion of 
three months of SET, the non-DM group showed a mean increase in MWD of 52% (233 
meter, P<.01), while the DM group increased by 29% (152 meter, P<.01).28 No comparison 
between groups was provided. In the study by Gardner et al. patients were classified 
according to their diabetic status and then further separated by gender, leading to the 
formation of four study groups.25 All groups demonstrated a significant improvement 
(P<.05) in MWD after three months of exercise therapy, except for diabetic women 
(P>.05). The mean MWD of the overall non-DM group increased with 57% (198 meter), 
compared to a 30% (87 meter) increase for the overall DM group. There was a trend for 
less improvement in diabetic IC patients (P=.056), as nondiabetic men and women had 
larger increases than their diabetic counterparts. Furthermore, in the study by Gardner et 
al. only 56% of diabetic women had an increase in MWD versus 78% of diabetic men. At 
baseline and at one, three and six months follow-up, Van Pul et al. found that the median 
MWD in patients with DM was significantly lower (P<.001) compared to patients without 
DM.29 However, relative and absolute  increase in median MWD were not significantly 
different between both groups. After three months, median MWD increased by 73% in 
the non-DM group (median increase of 300 meter), compared to 67% in the DM group 
(median increase of 200 meter, P=.48). At six months follow-up, median MWD increased 
with 100% in the non-DM group (median increase of 400 meter) compared to 91% in the 
DM group (median increase of 270 meter, P=.48).
Effect of DM on pain-free walking distance (PFWD)
Of the three included studies, two studies reported on PFWD outcomes (n=87).25, 28 In the 
study by Allen et al. the non-DM group demonstrated a mean increase in PFWD of 59% 
(114 meter, P<.05), whereas there was no statistically significant increase in PFWD for 
the DM group (19%, 54 meter).28 Again, no comparison between groups was provided. 
In the study by Gardner et al. all groups had significant improvement (P<.05) in mean 
and median PFWD after three months of exercise therapy, except for diabetic women 
(P>.05).25 The mean PFWD of the overall non-DM group increased with 84% (148 
meter) compared to 67% (117 meter) for the overall DM group (P=.982). In patients with 
DM, the increase in mean PFWD was 425% (196 meter) greater in men than in women 
(P<.05), whereas in those without DM, the increase in mean PFWD was only 35% (44 
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meter) greater in men (P>.05). Similar to the MWD results, the diabetic women had the 
lowest percentage of responders to exercise therapy.  Only 37% of women with DM had 
an increase in PFWD versus 100% of men with DM (P<.01).
Effect of DM on functional walking distance (FWD)
Of the three included studies, one study reported on FWD outcomes (n=758).29 
Improvement in FWD after SET was found in both the nondiabetic group and the diabetic 
group. At baseline and at one, three and six months follow-up, Van Pul et al. found that 
the median FWD in patients with DM was significantly lower (P<.001) compared to 
patients without DM.29 However, relative and absolute increase in median MWD were 
not significantly different between both groups. After three months of SET, median FWD 
increased by 100% in both groups, corresponding to a median increase of 200 meter in 
the non-DM group and a median increase of 180 meter in the DM group (P=.72). At six 
months follow-up, median FWD increased with 148% in the non-DM group (median 
increase of 332 meter), compared to 140% in the DM group (median increase of 280 
meter, P=.72).
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Table 1. Characteristics of included studies
Author Year Country Design N Diabetic group Nondiabetic group Intervention Outcomes
N Male 
(%)
Age 
(years)
N Male 
(%)
Age 
(years)
Allen28 2014 USA CCS 27 13 46 66 14 71 69 Supervised 
intermittent 
treadmill walking, 
30 to 40 min, 3 times 
per week, for 3 
months
COT, PWT: 
3 months 
follow-up
Gardner25 2014 USA RCT/
CCSa
60 25 36 61 35 54 69 HBET: intermittent 
walking, 20 to 45 
min, 3 times per 
week, for 3 months
SET: supervised 
intermittent 
treadmill walking, 
15-40 min, 3 times 
per week, for 3 
months
COT, PWT: 
3 months 
follow-up
Van Pul29 2012 NL CCS 758 230 67 68 528 61 67 Supervised 
intermittent 
treadmill walking, for 
6 months: months 
1-3, 2 to 3 times 
per week, 30 min; 
months 4-6, 0-2 
times per week, 30 
min; encouragement 
to walk on daily basis 
to submaximal pain
FCD, ACD: 
1, 3, and 
6 months 
follow-up
a = case control analysis of prospectively collected RCT data. CCS = case control study; RCT = randomized controlled trial;  
NL = the Netherlands; HBET = home-based exercise therapy; SET = supervised exercise therapy; COT = claudication onset 
time; PWT = peak walking time; FCD = functional claudication distance; ACD = absolute claudication distance.
DISCUSSION
The results of this review showed that IC patients with DM improve in maximal walking 
distance (MWD), pain-free walking distance (PFWD), and functional walking distance 
(FWD) after SET. However, conflicting results were found when comparing the effect 
of SET on walking distances between diabetic and nondiabetic IC patients. One study 
reported a nearly significant effect of DM on MWD.25 Another study demonstrated a 
difference in PFWD between diabetic and nondiabetic IC patients.28 On the contrary, the 
largest study of this review did not find any effect of DM on improvement in FWD and 
MWD after SET.29 Consequently, still some controversy exists regarding the effect of DM 
on walking distance outcomes in patients with IC.
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The results of this review are in contrast to the results of Ubels et al., who reported 
that IC patients with DM gained even more from exercise therapy than their counterparts 
without DM.30 This study was intentionally excluded from the current review since patients 
did not receive a true SET program, but just a training schedule which was adapted every 
two months. Besides, Ubels et al. used a corridor-based test to assess walking distance, 
hardly comparable to the results obtained with a treadmill test.31 In a study by Collins et 
al., who included only diabetic IC patients, no improvement in MWD and PFWD after 
a six months HBET program was found.32 These findings add to current evidence that 
HBET programs may not be as efficacious as SET programs.33
DM is associated with an impaired microvascular function in patients with IC. As a 
consequence, reduced capillary volume expansion of the calf musculature and a transient 
imbalance of muscle oxygen delivery relative to oxygen uptake during exercise have been 
found.34, 35 This suboptimal metabolic environment might contribute to a lower baseline 
walking capacity in diabetic IC patients and less improvement after SET, as found by 
some authors.28, 29
In the study by Gardner et al., patients were classified according to their diabetic status 
and then further separated by gender, leading to the formation of four study groups.25 Of 
these two factors, gender turned out to be more closely related to the exercise response than 
DM, as demonstrated by the significant gender effect for mean MWD and mean PFWD. 
However, a trend for a DM effect on the mean MWD was found. Of the four subgroups, 
only diabetic women did not significantly improve their MWD and PFWD after three 
months of exercise therapy. It has been increasingly recognized that female IC patients 
have greater baseline limitations of IC, less calf muscle hemoglobin oxygen saturation, 
and lower daily ambulatory activity.36-38 These mechanisms probably contribute to the less 
favorable response in women. However, the worse response to exercise therapy in women 
was only found in those with DM.25 Thus, an effect of DM itself cannot be excluded yet.
SET in people with IC has been shown to be highly beneficial in terms of increasing 
walking distance and improving quality of life.23, 39 According to current international 
guidelines SET is considered to be the first choice therapy for all patients with IC.19-21 
This is in contrast with a recent editorial that claimed that many IC patients may be 
unsuitable for SET, based on the presence of comorbidities and the possibly increased 
risks.40 However, based on the results of this review, no arguments can be found to retain 
diabetic IC patients from SET. 
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Besides improvement on walking distance, exercise therapy may have some other 
benefits for IC patients with DM. Exercise has been found to reduce hyperglycemia, 
insulin resistance, dyslipidemia, and hypertension.41-43 These benefits may lead to an 
improved vascular disease risk profile in these patients. Exercise may also aid in weight 
loss and may improve glycemic and lipemic control in people with DM.44 Additionally, 
exercise improves physical function and quality of life in people with DM.45, 46
This review has some limitations. First, just few studies examined the effect of DM on 
walking distance outcomes after SET in IC patients so far.  Second, the studies of Allen 
et al. and Gardner et al. included just small sample sizes (n=27 and n=60, respectively) 
and may therefore be underpowered to demonstrate true differences in walking distance 
outcomes after SET between IC patients with and without DM.25, 28 Third, the patients 
of included studies were not evenly matched for gender. Since evidence exists that 
women with IC, particularly those with DM, represent a vulnerable subgroup of IC 
patients who respond poorly to an exercise program, bias might have been introduced.25 
Fourth, the study by Gardner et al. used two different exercise interventions.25 Patients 
were randomized to either a HBET program or a SET program. Although the HBET 
program was designed to be as similar to the SET program as possible, patients did not 
receive supervision during exercise. Unfortunately, authors did not report which patients 
participated in what program, and results did not include subgroup analyses. The lack 
of supervision in the HBET group might have influenced the overall outcomes. Besides 
these limitations, studies examining the effect of DM on quality of life after SET, as well as 
reports on long term results (>6 months) of SET in diabetic patients are currently lacking.
In conclusion, IC patients with DM demonstrate improvement on walking distance 
outcomes after SET. Although conflicting results were reported when comparing diabetic 
and nondiabetic IC patients, no arguments can be found to retain diabetic IC patients 
from SET. Future studies are warranted to investigate the influence of DM on SET 
outcomes.
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ABSTRACT
Background: Disease severity and treatment outcomes in patients with intermittent 
claudication (IC) are commonly assessed using walking distance measured with 
a standardized treadmill test. It is unclear what improvement or deterioration in 
walking distance constitutes a meaningful, clinically relevant, change from the patients’ 
perspective. The purpose of our study was to estimate the minimally important difference 
(MID) for the absolute claudication distance (ACD) and functional claudication distance 
(FCD) in patients with IC.
Methods: The MIDs were estimated using an anchor-based approach with a previously 
defined clinical anchor derived from scores of the walking impairment questionnaire 
(WIQ) in a similar IC population. We used baseline and three-month follow-up data 
on WIQ scores and walking distances (ACD and FCD) from 202 patients receiving 
supervised exercise therapy from the 2010 EXITPAD randomized controlled trial. The 
external WIQ anchor was used to form three distinct categories: patients with ‘clinically 
relevant improvement’, ‘clinically relevant deterioration’ and ‘no clinically relevant change’. 
The MIDs for improvement and deterioration were defined by the upper and lower limits 
of the 95% confidence interval of the mean change in ACD and FCD, for the group of IC 
patients that remained unchanged according to the WIQ anchor.
Results: For the estimation of the MID of the ACD and FCD 102 and 101 patients were 
included, respectively. The MID for the ACD was 305m for improvement, and 147m 
for deterioration. The MID for the FCD was 250m for improvement, and 120m for 
deterioration.
Conclusion: The MIDs for the treadmill-measured ACD and FCD can be used to interpret 
the clinical relevance of changes in walking distances after supervised exercise therapy 
and may be used in both research and individual care.
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INTRODUCTION
Intermittent claudication (IC) is the most common symptom of peripheral arterial disease 
(PAD). Atherosclerosis in the major vessels supplying the lower extremities causes muscle 
discomfort provoked by exercise in IC patients. Exertional limitations of walking ability 
lead to functional disability in daily life.1 Treatment of IC aims at reducing symptoms 
and thereby improving walking capacity and health related quality of life (HRQoL).1, 2 
Disease severity and treatment outcomes are commonly assessed by walking distance 
with standardized treadmill tests, and patient-reported outcome measures reflecting 
HRQoL.1, 3
However, the clinical value of different outcome parameters in IC is currently 
under debate. Treadmill-measured walking distances have been disputed for being an 
inadequate reflection of walking capacity in daily life4, 5, and for failing to address actual 
physical activity limitations.6 Additionally, walking distances correlate moderately with 
HRQoL measures.5 Notwithstanding these concerns, changes in walking distance remain 
an important indicator of treatment effect in clinical decision-making.1, 2 Moreover, it 
functions as primary end point in most trials assessing IC.1, 3 Despite this important role, 
it is unclear what improvement or deterioration in walking performance constitutes a 
meaningful, clinically relevant, change from a patient’s perspective.
The concept of the minimally important difference (MID) represents the smallest 
change on an outcome measure which patients value as important.7 It was first 
described by Jaeschke et al.8 in an attempt to elucidate what change in an asthma QoL 
questionnaire score would be meaningful. Recently, Conijn et al.9 introduced the MID 
for an IC population. In their study, the MID was calculated for the Walking Impairment 
Questionnaire (WIQ); a patient reported assessment of walking impairment. The MID 
can be used to estimate clinically relevant improvement and deterioration, thus giving 
meaning to outcome measures such as walking distance. Hiatt et al.10 postulated an 
established MID as a requirement for an optimal functional test in PAD. Determination 
of the MID of walking distance could facilitate clinicians and researchers in their 
interpretation of this widely used outcome measure.
The purpose of the present study was to estimate the MID for the absolute claudication 
distance (ACD) and functional claudication distance (FCD) in patients with IC.
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METHODS 
Study population
We used data from the 2010 ‘Exercise Therapy in Peripheral Arterial Disease’ (EXITPAD) 
trial. The EXITPAD study was a multicenter, randomized controlled trial of supervised 
exercise therapy (SET) versus a verbal walking advice. Patients with Fontaine stage II 
peripheral arterial disease (PAD), an ankle brachial index (ABI) <0.9 and an ACD of <500 
meters were included from eleven outpatient vascular surgery clinics in the Netherlands. 
Their respective institutional review boards approved the trial and all patients gave 
written informed consent. Details on methodology were previously published11; below 
we will briefly describe aspects relevant to the current study.
In the present study, we used the baseline and three-month follow-up data on 
WIQ scores and walking distances from the 202 patients receiving SET in the former 
EXITPAD study. Patients were referred to a local physical therapist and received a SET 
programme according to recommendations in the guidelines of the Royal Dutch Society 
for Physical Therapy.12 Prior to SET, all patients received cardiovascular risk management 
including cholesterol lowering medication, antiplatelet therapy, a ‘stop smoking’ advice 
and modification of other atherosclerotic present risk factors.
Walking distances
The ACD is defined as the walking distance where intolerable claudication pain forces 
a patient to stop. An alternative term for ACD is maximal walking distance. The FCD 
is defined as the distance at which the patient preferred to stop walking due to pain.13 
Walking distances were determined by a standardized progressive treadmill test (i.e. 
Gardner-Skinner protocol) with a constant speed of 3.2 km/h starting with 0% inclination, 
increasing every 2 minutes by 2%.14 The maximum inclination was 10%, maximum 
duration of the test 30 minutes (1600 meters).11
The walking impairment questionnaire
The WIQ is a patient-reported outcome measure designed to assess the functional 
capacity of IC patients. It asks patients to rate their perceived difficulty regarding walking 
speed, distance and stair climbing. The total WIQ score constitutes a value ranging from 
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0 to 1. Lower scores represent more impairment. The validated Dutch version of the WIQ 
was used.15, 16
Determination of the MID
As per current recommendations we used an anchor-based approach, as opposed to a 
distribution-based approach, in estimating the MID, using longitudinal prospective data.17 
An anchor is an external criterion for a meaningful change, and can be based on patient 
reported outcome measures that have demonstrated MID in the target population.18 
We used a previously defined MID for the WIQ as an anchor. A study by Conijn et al.9 
reported a MID of -0.03 for deterioration and 0.11 for improvement. Meaning a decrease 
in WIQ score of ≥0.03 is clinically relevant, as is an improvement of ≥0.11. Based on 
this anchor the current study population was divided into three categories: patients 
with ‘clinically relevant improvement’, ‘clinically relevant deterioration’ and ‘no clinically 
relevant change’. Analogous to Conijn et al.9 the MID for improvement was determined 
using the upper limit of the 95% confidence interval (CI) of the mean change in walking 
distance of patients who experienced ‘no clinically relevant change’ according to the 
WIQ-anchor. The MID for deterioration was defined by the lower limit of the 95% CI in 
this ‘unchanged’ category.
Statistical analysis
It is advised that the anchor (WIQ data) and the outcome measure (treadmill-based 
walking distances) are correlated at ≥0.3 to ensure that an appropriate association between 
the two variables exists.18 So, the Pearson correlation coefficient was calculated between 
the change in walking distance (between baseline and after 3 months of SET) and the 
anchor. Categorical variables were presented as numbers with percentages. Continuous 
variables were reported as means ± standard deviations if normally distributed, or 
as medians with interquartile ranges (IQR) in case of a skewed distribution. Our 
methodology required the calculation of 95% CIs in the ‘no clinically relevant change’ 
category. Thus, when changes in ACD or FCD for the ‘unchanged’ patients demonstrated 
a distribution that was not normal, these variables were assessed for outliers. One patient, 
who deviated approximately 4 standard deviations from the mean change in ACD, was 
excluded for this reason. Baseline characteristics were compared using a Pearson’s Chi-
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square test for categorical variables and a student’s t-test for continuous variables. A 
statistical significance level of P<.05 was applied. All analyses were performed with SPSS 
version 22.0 (SPSS Inc, Chicago, Ill).
RESULTS 
Out of a total of 202 patients, data on WIQ scores as well as ACD and FCD were available 
for 103 and 102 patients, respectively. After removal of the one outlier, estimation of the 
MID for the ACD was based on 102 patients, and for the FCD on 101 patients. Baseline 
characteristics of in- and excluded patients are reported in table 1. There were no 
statistically significant differences between baseline characteristics of patients included 
and excluded from analysis, except for chronic obstructive pulmonary disease (COPD) 
prevalence, baseline FCD values and follow-up WIQ scores. Based on the WIQ-anchor, 
56.9% of the included patients had a clinically relevant improvement after 3 months of 
SET, 23.5% remained unchanged, and 19.6% of the patients deteriorated.
MID of the ACD
Three-month change in ACD was significantly correlated to the anchor (Pearson r=0.31, 
P=.001), thus complying with the criterion of Revicki.18 Table 2 presents the distribution 
of the ACD over the three categories (i.e. improved, unchanged, deteriorated) defined 
by the WIQ-anchor. The MID for the ACD was 305m for improvement, and 147m for 
deterioration. The MID for deterioration is a positive value and implicates that a small 
numerical improvement in ACD (<147m) is still perceived as clinical deterioration by 
the patient.
MID of the FCD
Three-month change in FCD was significantly correlated to the anchor as well (Pearson 
r=0.30, P=.001). Table 3 presents the distribution of the FCD over the three categories 
defined by the WIQ-anchor. The MID for the FCD was 250m for improvement, and 
120m for deterioration. Thus, a numerical improvement in FCD of <120m is considered 
as a clinical deterioration by the patient. Figure 1 shows a visual representation of the 
MIDs for both the ACD and FCD.
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Table 1. Baseline characteristics
Variablea Included patients (n=102) Excluded patients (n=99) P-valueb
Age, y 66.3 ±10 65.3 ±9.3 (n=98) .471
Body mass index, kg/m2 28.0 (5.3) (n=99) 27.0 (5.7) (n=93) .374
Ankle brachial index 0.70 (0.23) (n=100) 0.66 (0.22) (n=95) .229
Baseline WIQ score 0.46 ±0.21 0.44 ±0.22 (n=51) .427
Follow-up WIQ scorec 0.61 ±0.22 0.49 ±0.26 (n=27) .016
Baseline ACD, m 280 (210) 249 (190) (n=97) .176
Baseline FCD, m 164 (150) 130 (110) (n=97) .006
Male sex 73 (71.6) 62 (62.2) .177
Arterial hypertension 63 (61.8) 57 (57.6) (n=96) .731
Diabetes mellitus 25 (24.5) 19 (19.2) .362
Hyperlipidemia 69 (67.6) (n=101) 64 (64.6) (n=94) .972
Orthopedic disease 15 (14.7) 17 (17.2) (n=95) .544
Cerebrovascular disease 13 (12.7) 12 (12.1) (n=96) .959
Cardiac disease 26 (25.5) (n=99) 22 (22.2) (n=95) .616
COPD 27 (26.5) 9 (9.1) (n=96) .002
Smoking
Current 41 (40.2) (n=101) 40 (40.4) (n=94) .781
Former 54 (52.9) (n=101) 43 (43.3) (n=94) .501
Never 6 (5.9) (n=101) 11 (11.1) (n=94) .154
Inclusion of patients was based on presence of both WIQ data (baseline and 3 months follow-up) and walking dis-
tance measures. ACD, absolute claudication distance; COPD, chronic obstructive pulmonary disease; FCD, functional 
claudication distance; IQR, interquartile range; SD, standard deviation; WIQ, walking impairment questionnaire; 
a = Normally distributed continuous values are presented as mean ±SD, and as median (IQR) in case of a skewed distri-
bution. Categorical values are presented as number (percentages). b = By student’s t-test for parametric continuous 
variables, by Mann-Whitney U test for non-parametric continuous variables, and by Pearson’s Chi-square test for 
categorical variables. c = WIQ data after 3 months of SET. 
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Table 2. Distribution and MID of the ACD (meters) after 3 months of SET
ACD baseline (IQR) Follow up Median change Correlation with anchor
280 (210)  507 (340) 210 (253) 0.31a
Compared with anchor Patients, n Mean change ACD
Improved 58 245b IQR: 456 
Unchanged 24 226 95% CI: 147 to 305
Deteriorated 20 125 95% CI: 39 to 212
MID of the ACD
Improvement 305
Deterioration 147
ACD = absolute claudication distance; CI = confidence interval; IQR = interquartile range; MID = minimally important  
difference; SET = supervised exercise therapy; a = Pearson correlation coefficient; b = value represents a median.
Table 3. Distribution and MID of the FCD (meters) after 3 months of SET
ACD baseline (IQR) Follow up Median change Correlation with anchor
167 (145) 370 (315) 200 (240) 0.30a
Compared with anchor Patients, n Mean change ACD
Improved 58 200b IQR: 238
Unchanged 24 185 95% CI: 120 to 250
Deteriorated 19 107 95% CI: 37 to 178
MID of the ACD
Improvement 250
Deterioration 120
FCD = functional claudication distance; CI = confidence interval; IQR = interquartile range; MID = minimally important 
difference; SET = supervised exercise therapy; a = Pearson correlation coefficient; b = value represents a median.
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Threshold values at which the change in absolute claudication distance (ACD) and functional claudication distance 
(FCD) after three months of supervised exercise therapy (SET) is perceived as a clinically relevant improvement or 
deterioration by the patient. 
Figure 1. The MID of walking distance
DISCUSSION
This study was the first to estimate MIDs for the ACD and FCD in patients with IC. 
Our results can facilitate clinicians and researchers in appointing what numerical 
changes in walking distance indicate a clinically meaningful change. Recently, Hiatt et 
al. underlined the importance of estimating MIDs for treadmill walking performance in 
the PAD population, as a change in performance on a test should be related to a patient’s 
perception of his or her limitations.10 Currently, these MIDs are unknown for the IC 
population.  Based on our estimations a change in ACD of more than 305m, and FCD 
of more than 250m, is viewed as meaningful by the patient. Interestingly, the MIDs for 
deterioration were positive values (ACD: 147m; FCD: 120m) as well. This indicates that 
small improvements in walking distance are apparently not satisfactory in the patients’ 
eyes. This may not be surprising as SET demands a considerable investment of time and 
effort, therefore patients’ expectations of treatment effect are not readily met. On the 
other hand, patients might also have unrealistic expectations, in general a 50% to 200% 
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improvement of ACD has been reported.19 Besides, as overground walking requires higher 
ground reaction forces and movement power as compared to treadmill walking20, it may 
also be possible that an increase in treadmill-based walking distance of approximately 100 
meters is insufficient to reveal any effect on walking distance in daily life. These findings 
might suggest that SET should not only be focused on treadmill walking, but should 
additionally include for instance outdoor walking and strength training. 
MIDs are population specific18, and users should consider several factors before 
applying our MID values to their own patient population. There is a plethora of ways of 
measuring walking distance in IC. Notably, walking capacity can be determined using a 
treadmill test10, a corridor-based 6-minute walking test3, or by tracking outside walking 
via global positioning system (GPS) devices.21, 22 Walking distance values measured for 
the same patient with different tests generally do not correspond well.4,23 Likely, the MID 
values found in this study are only transferable to walking distances measured using a 
graded treadmill protocol. 
Treadmill training has been criticized for being an artificial form of walking that 
does not necessarily translate to improved ambulatory function in daily life.24 However, 
others found excellent agreement with values measured during outside walking, implying 
agreement with daily life impairment.23 SET treatment largely takes place on a treadmill, 
thus another argument opposing treadmill tests is that a learning effect for treadmill 
walking cannot be ruled out. This may have influenced the reported MID values. Yet it 
does not hamper their use, as such learning effect would also exist in daily practice. The 
use of a standardized treadmill protocol with a graded inclination, such as the one used in 
the present study14, is well established10 and advised in current guidelines.1 It is the most 
reliable treadmill test25 and demonstrates the best agreement to outside walking when 
compared with a non-graded treadmill protocol.26 Accordingly, it is widely used to assess 
the effect of SET.12 Thus, the MIDs found in this study are likely applicable to the majority 
of the IC patients, in both research and daily clinical practice, after three months of SET.
Limitations in walking distance are, irrespective of measuring method, not necessarily a 
true reflection of disease severity in patients with IC. Other authors reported important 
discrepancies between treadmill measurements and walking impairment as perceived 
by the patient.4, 24 Moreover, an improvement of walking distance does not necessarily 
equal increased physical activity levels in patients with IC6, and it lacks correlation with 
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IC-specific HRQoL.5 Evidently, walking distance is an imperfect outcome parameter. 
Nonetheless, it is widely used in clinical trials, as its value in assessing treatment effect 
has been well established.13,25 Indeed, assessment of walking distance provides the means 
to directly measure the primary treatment goal in IC: improvement of ambulatory (dis)
function. The MIDs found in the current study strengthen the connection between this 
widely used outcome measure and patients’ perception of treatment effect.
Our study had some important limitations. First, a single MID may be insufficient for 
all study applications as multiple approaches to estimating the MID will produce a range 
of different values. Besides, MIDs may vary by context and MID values will therefore 
differ for various treatment strategies (i.e. endovascular intervention).18 So, final selection 
of MID values for a specific outcome measure should be based on several methods. 
Second, the MID is preferably determined using an anchor that has been established 
in the target population. Preferably, the anchor provides a direct measurement of the 
patient’s perspective on the results of treatment. A ‘global rating of change’-question 
seems best-suited for this purpose in IC. Unfortunately, our data did not include such 
a question, thus we used an external anchor established in a separate study.9 Patient 
populations were similar, thereby approving the current external anchor strategy. Third, 
to ensure the greatest agreement between the external anchor’s population and our study 
subjects we used outcome data after three months of SET. Yet, most IC patients are treated 
over prolonged periods in clinical practice. Preferably, future studies should incorporate 
a longer follow-up duration to ensure optimal translation to the real world population. 
Fourth, almost half of the study population had to be excluded for failing to complete the 
WIQ at both baseline and after three months of SET. Although few differences in baseline 
characteristics between the in- and excluded population were found, MID values may 
have been influenced by unknown confounders. Notably, a similar amount of exclusions 
were found in the study by Conijn et al.9, highlighting the problem of early drop-out in 
this specific population. Finally, the correlation between the WIQ-anchor and ACD or 
FCD just barely fulfilled Revicki’s criterium (a correlation of ≥0.3).18 
Future research is needed to validate our findings by directly relating data on ACD 
and FCD to an anchor in the same population. Ideally, this anchor should incorporate 
aspects beyond walking capacity, like disease-specific quality of life (i.e. VascuQol-6 or 
-25), to include a broader perceived health status. As various methods for estimating 
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MIDs often converge, repetition is supported for the generalizability of MID estimates in 
similar applications. 
In conclusion, the MID of treadmill-measured ACD in patients with IC was 305m for 
improvement and 147m for deterioration. The MID for FCD was 250m for improvement 
and 120m for deterioration. The MIDs as found may be helpful to interpret the clinical 
relevance of changes in walking distances, which may be used in both research and the 
individual care setting.
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ABSTRACT
Introduction: Walking capacity measured by a treadmill test (TT) reflects the patient’s 
maximal capacity in a controlled setting and is part of the physical exercise capacity 
(PEC). On the other hand, daily physical activity (PA) is defined as the total of actively 
produced freely movements per day. A lower PA level has been increasingly recognized 
as a strong predictor of increased morbidity and mortality in patients with IC. Recent 
insights suggested that an increased PEC does not automatically leads to an increase in 
daily PA. However, the precise relation between PEC and PA in patients with IC is still 
unclear. 
Methods: A cross-sectional study was conducted to assess the association between 
several PEC outcomes and PA in a general IC population. PEC was determined by well-
established tests (Gardner-Skinner treadmill test (TT), a physical performance battery, 
a timed up and go test, and a six-minute walk test (6-MWT)). PA was obtained during 
seven consecutive days using a tri-axial accelerometer (Dynaport MoveMonitor). Five PA 
components (lying, sitting, standing, shuffling and locomotion) and four parameters (total 
duration, number of periods, mean duration per period and mean movement intensity 
per period) were analysed. Correlation coefficients between PEC and PA components 
were calculated. 
Results: Data of 46 patients were available for analysis. Patients were sedentary (sitting and 
lying) during 81% of the day, and physically active (standing, shuffling and locomotion) 
for the remaining 19% of the time. Overall, correlations between PEC outcomes and PA 
ranged from very weak (.025) to moderate (.663). Moderate correlations (as therefore 
assumed to be relevant) were only found for both TT and 6-MWT outcomes and 
locomotion components of PA. For instance, functional walking distance (measured 
by TT) and number of steps per day correlated reasonably well (Spearman correlation 
ρ=.663, P<.01).
Conclusion: Exercise capacity and physical activity correlate minimally in patients with 
intermittent claudication. Physical activity may be preferred as a novel outcome measure 
and future treatment target in patients with IC.
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INTRODUCTION
Intermittent claudication (IC) is the most common symptom of peripheral artery disease 
(PAD) and results from atherosclerosis in large peripheral arteries.1 Among conservative 
therapies, supervised exercise therapy (SET) was found the most effective tool in 
decreasing IC symptoms and increasing physical exercise capacity (PEC).2 The term 
PEC actually reflects what a person is maximally capable of in a controlled laboratory 
setting.3 In patients with IC, PEC is usually determined by a standardized treadmill test 
(TT).4 With this test, a physician is able to evaluate a patient’s individual walking capacity 
(i.e. maximum walking distance), which is especially useful to determine the effect of 
SET.4 Moreover, TT-based walking capacity is frequently used to assess the effect of novel 
treatment strategies in clinical trials.
A recent study demonstrated that an improvement in PEC does not automatically lead 
to an increase in daily physical activity (PA).5 These insights are in line with a recent study 
that also found no increase in daily PA levels after SET in patients with IC.6 These results 
may have important implications as daily PA level is a strong predictor of morbidity and 
mortality,  in patients with IC.7 Several studies have now demonstrated that patients with 
IC exhibit lower daily PA levels than healthy controls,8, 9 and the majority does not meet 
the internationally recommended standard for PA.8 The World Health Organisation 
defines PA as ‘any bodily movement produced by skeletal muscles that requires energy 
expenditure’.10 The different aspects of PA include mode, frequency, duration, intensity 
and context in which the activities occur. Hence, daily PA reflects the total of actively 
produced movements a person actually performs on a daily basis.
In current practice, PA levels are most commonly determined by interviews or 
questionnaires. These self-report tools proved to be poorly reproducible11 and seem 
insensitive for assessing IC symptoms.12 Despite the current possibility to objectively 
measure PA with the use of activity monitors (i.e. pedometers and accelerometers), this 
approach is rarely applied in daily clinical practice. Although, such devices are small, 
easily wearable, and found to provide reliable information on PA.13 Patients only need 
to wear the device for multiple days in order to obtain an accurate measure of daily PA 
levels, since PA can fluctuate over days.14
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For both research and clinical purposes, it might be important to focus more on 
daily PA as an outcome parameter.7, 15 Whether PEC outcomes however could serve as a 
surrogate marker for PA is currently unknown in patients with IC, as the relation between 
PEC and daily PA is still unclear. For chronic obstructive pulmonary disease (COPD), 
research already showed that PEC and daily PA are two completely different entities.16 
These results underscored the importance of measuring daily PA in order to optimize 
treatment for COPD, which might be the same for IC patients. The current study therefore 
aims to evaluate how different PEC measures relate to daily PA in a general IC population. 
In line with previously results obtained from a COPD population, we hypothesized that 
PEC outcomes are poorly associated with daily PA behaviour.
METHODS 
Participants
Between February and May 2015, patients with symptoms of IC were recruited at the 
vascular surgery outpatient clinic of the Catharina Hospital, Eindhoven, the Netherlands, 
and from two physical therapy centres in respectively Eindhoven and Veenendaal (the 
Netherlands). Inclusion criteria were PAD Rutherford stage 1-3 and an ankle-brachial 
index (ABI) <0.90 at rest and/or a drop of >0.15 after a graded TT, or a duplex or 
magnetic resonance angiography (MRA) demonstrating a significant arterial stenosis 
(>50%). Exclusion criteria were serious cardiopulmonary comorbidities (NYHA 
3-4), PAD Rutherford stage 4-6, previous lower-limb amputation, use of walking aids, 
high probability of non-adherence to protocol (e.g. for instance due to dementia), 
other comorbidities that might limit the patient’s walking ability (e.g. severe arthritis, 
Parkinson’s disease, recent trauma to the lower extremities), and wearing the PA device 
for less than five days, as that is the minimum number of days for obtaining accurate data 
on locomotion bouts.17 
Patients who were willing to participate were counselled regarding the study protocol 
prior to providing written informed consent. All procedures were approved by the 
Medical Ethical Committee of the Catharina Hospital, Eindhoven, the Netherlands.
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Study protocol
A cross-sectional design was used to investigate the relation between PEC outcomes and 
components of daily PA. All participants were extensively instructed how to wear the 
PA device properly. Patients returned to our hospital once for the PEC measurements. 
Assessment of PEC and PA was scheduled in random order. Three researchers (LG, IJ, 
RG) were responsible for the data collection. 
Measurements 
Ankle-brachial index
According to standardized institutional protocols, ABIs were measured by experienced 
nurses at the vascular laboratory of the Catharina Hospital. Using a hand-held 8 MHz 
Doppler probe, systolic pressures were measured at the brachial artery of both arms, 
followed by the posterior tibial artery and dorsal pedal artery at the level of both ankles. 
A baseline measurement was performed at rest. Subsequently, a post-exercise ABI was 
obtained (i.e. treadmill test at 3.2 km/h, and a 6-degree slope for a maximum of six 
minutes). The ABI was calculated by dividing the highest obtained ankle pressure by the 
highest obtained arm pressure.
Physical exercise capacity
PEC was determined through a sequence of tests. Patients performed a TT, a short 
physical performance battery (SPPB), a timed up and go (TUG) test and a six-minute 
walk test (6-MWT).
• A standard TT was based on the graded Gardner-Skinner protocol.18 Patients 
started walking on a flat treadmill with a constant speed of 3.2 km/h. The incline 
was increased by 2% every two minutes until a maximum of 10% was reached. The 
test ends at a maximum of thirty minutes (1600 meters). The functional claudication 
distance (FCD) and absolute claudication distance (ACD) were recorded. FCD was 
defined as the distance at which a patient prefers to stop because of claudication 
symptoms.19 ACD was defined as the maximal walking distance limited by 
intolerable pain.
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• The SPPB, developed by Guralnik et al.20, is a battery that consists of three tests 
and aims to assess general lower extremity function. In a 3-meter walking velocity 
test, patients were asked to walk three meters at their usual speed. Participants 
performed the test twice, whereupon the fastest result was selected. In a repeated 
chair rise test, patients were instructed to stand up and sit down five times as fast as 
possible, with arms folded across the chest. The time for completing was recorded 
and results generally reflect leg strength and balance.20 In the standing balance 
test, patients were asked to maintain balance for ten seconds in the following three 
positions; feet together (side-by-side position), heel of one foot next to the big toe 
of the other foot (semi-tandem position) and the heel of one foot in front of the toe 
of the other foot (tandem position). A maximum of 4 points can be scored in each 
of these three tests, leading to a 12 points maximum score. 
• During a TUG test, patients were instructed to rise from a chair, walk three meters, 
turn around, walk back to sit again, all at their fastest pace. The total time was 
recorded as a result. 
• A 6-MWT was based on the standardized Montgomery and Gardner protocol.21 
Patients were asked to walk up and down a twenty meter distance for six minutes, 
covering as much distance as possible. Total walking distance was registered as well 
as the number of stops due to IC symptoms. 
Daily physical activity
PA was measured using the Dynaport MoveMonitor®, a tri-axial seismic accelerometer 
(McRoberts BV, The Hague, the Netherlands). This device has been validated to objectively 
measure physical activity in patients with IC.13 It consists of a rechargeable battery, USB 
connection and raw data storage capability on a micro secure digital card. Participants 
wore the device with a belt around the waist for seven consecutive days, except when 
showering or bathing. The MoveMonitor (MM) includes three orthogonal accelerometers 
that measure acceleration in three axes: x (longitudinal), y (mediolateral) and z (anterior-
posterior), at a sample rate of 100 samples per second. Raw data were processed using 
pattern recognition algorithms (Movemonitor analysis software, version 1.0.7.21), and 
expressed in terms of body posture (i.e. lying and sitting), locomotion, and movement 
parameters (i.e. movement duration, intensity and frequency). Following PA categories 
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were retrieved: lying, sitting, standing, shuffling and locomotion. Shuffling separation 
divides the active (not walking) parts into two categories: shuffling and transitions. So 
shuffling is defined as all movement from A to B that is not walking. Thus, if the number 
of steps is fewer than three, or the intensity and direction of the motion do not comply 
with the characteristics of walking, the movements are classified as shuffling.13 Four 
subsequent parameters were reported for each activity category: total duration, number 
of periods, mean duration per period and the weighted mean movement intensity (MI) 
per period. 
Data analysis 
Continuous variables were expressed as means (± standard deviation) when normally 
distributed, and as medians with interquartile ranges (IQR) in the case of a skewed 
distribution. For categorical variables, percentages were presented. Normality checks were 
performed visually using histograms and with a Kolmogorov-Smirnov test. The relation 
between daily PA (variables being lying, sitting, standing, shuffling and locomotion) and 
PEC (variables being the outcomes measures of a TT, SPPB, TUG and 6-MWT) was 
determined by calculating Spearman correlation coefficients (rho, ρ) as PEC data revealed 
a skewed distribution. According to Zou et al. correlations of ≥0.50 and ≥0.80 were 
considered as respectively, moderate and strong associations.22 Multivariate regression 
analysis was conducted to study the potential influence of gender and age on the relation 
between PEC and PA. All data was analysed using SPSS Statistics for Windows, version 
21.0 (IBM, Armonk, NY, USA). A P-value <.05 was regarded as being statistically 
significant. Sample size calculation (with alfa=0.05 and beta=0.80) revealed a sample size 
of 46 subjects to realize statistical significant correlations of ≥0.4 between PEC and PA.
RESULTS 
Recruitment and response
A total of 55 patients met eligibility criteria and were willing to participate. Inclusion of 
nine patients was based on duplex or MRA images. A total of nine patients (~17%) were 
excluded (MM worn <5 days (n=2), technical failure (n=1), withdrawal due to personal 
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reasons (n=4), and unanticipated operative interventions during the MM measurement 
period (n=2)). Therefore, complete data sets of 46 patients were available for analysis.
Sample characteristics
Baseline characteristics are depicted in table 1. Mean age was 66 years (± 9 years), and the 
majority were men (n=35, 76%). About half demonstrated bilateral complaints (n=21, 
46%). The lowest mean ABI in rest was 0.63 (± 0.17), dropping to 0.38 (± 0.19) after 
exercising. Cardiovascular risk factors (smoking, diabetes mellitus) were commonly 
observed (table 1). 
Table 1. Baseline characteristics of the study population (n=46)
Gender, male (n, %) 35 (76)
Age, years (mean ± SD) 66 ± 9
BMI, kg/m2 (mean ± SD) 25.1 ± 4.9
Affected side (n, %)
Left 16 (35)
Right 9 (20)
Both 21 (45)
Lowest ABI (mean ± SD)a
Rest 0.63 ± 0.17
Post-exercising 0.38 ± 0.19
Comorbidity (n, %)
Pulmonary 7 (15)
Cardiac 10 (22)
TIA/stroke 5 (11)
Diabetes mellitus 10 (22)
Hypertension (n, %) 32 (70)
Current smokers (n,%) 14 (30)
a=based on ABI values of 37 IC patients, ABI=ankle-brachial index, TIA=transient 
ischemic accident
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Physical exercise capacity
The median functional and absolute claudication distances on the TT were 360 meters 
(IQR: 160.00-536.50) and 438 meters (IQR: 298.25-714.50), respectively. Six patients 
(13%) achieved the maximum walking distance of 1600 meters. The median walking 
distance assessed by a 6-MWT was 400 meters (IQR: 320.50-468.50). For the TUG test 
a median of 7.58 seconds for completion was found. A total of 87% patients attained a 
SPPB total score of 10 (out of 12, range 8-12). The SPPB subtests revealed that 76% had a 
maximum score for balance, 98% had a maximum score for walking speed, but just 18% 
scored maximal points on the repeated chair rise test (table 2). 
Physical activity in IC patients
Patients were physically active for 4.46 hours per day (standing, shuffling, locomotion), 
equivalent to 19% of a 24-hour day. On the other hand, mean number of hours that 
patients spent in a sedentary mode (lying or sitting) was 18.98, corresponding with the 
remaining 81% of a day. Note that this also includes sleeping overnight. Patients initiated 
a median number of 408 (IQR: 264-611) locomotion periods per day, with a mean 
movement intensity of 0.187 m/s2 (SD: ± .022) and a median time of 9.88 seconds (IQR: 
8.81-12.02) per period. The median number of transitions from sitting to standing was 
52 (IQR: 40-69). A detailed overview of the median daily PA levels is shown in table 3.
Table 2. Physical exercise capacity of the study population 
median (IQR)
Treadmill test 
FCD (m) 360 (160-537)
ACD (m) 438 (298-715)
6-MWT walking distance (m) 400 (321-469)
TUG (s) 7.58 (6.66-9.86)
SPPB
Balance (1-4) 4 (3-4)
Velocity (1-4) 4 (4-4)
Chair rise test (1-4) 3 (2-3)
Total score (1-12) 11 (10-12)
IQR=interquartile range; m=meters; s=seconds, FCD=functional claudication distance, ACD=absolute 
claudication distance, TUG=timed up and go test, SPPB=short physical performance battery
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Table 3. Physical activity outcomes of the study population
Mean duration per 
day (h) 
± SD
Median number of 
periods per day 
+ IQR
Median time per 
period (s or m) 
+ IQR
Mean movement 
intensity (m/s2) 
± SD
Lying 10.1 (+/- 1.92) 9 (6-15) 60.8 (41.6-91.6)a 0.005 (+/- 0.002)
Sitting 8.52 (+/- 1.87) 109 (90-141) 4.38 (3.0-6.1)a 0.023 (+/- 0.013)
Standing 2.67 (+/- 1.19) 756 (528-1202) 11.02 (9.4-15.9)b 0.052 (+/- 0.012)
Shuffling 0.40 (+/- 0.26) 409 (277-686) 2.77 (2.6-3.0)b 0.139 (+/- 0.028)
Locomotion 1.30 (+/- 0.72) 408 (264-611) 9.88 (8.8-12.0)b 0.187 (+/- 0.022)
Mean activity time per day (h)c 4.46 (+/- 2.0)
Mean sedentary time per day (h)c,d 18.98 (+/- 1.9)
Median number of sit-to-stand 52 (40-69)
Median number of steps per day 6,315 (3,364-9,207)
Mean MM not worn per day (m)c 36,9 (+/- 62,1)
h=hours; m=minutes; s=seconds; IQR=interquartile range; SD=standard deviation; a=minutes; b=seconds; c=add up 
to 100%; d=note that the sedentary time also includes sleeping overnight.
Correlation between PEC and daily PA
No significant or relevant correlations (ρ≥.4) were present between SPPB/TUG test 
outcomes and any of the PA components (data not shown), except for a weak inverse 
correlation (ρ=-.492, P<.01) between locomotion movement intensity and the results of 
the TUG test. 
ACD (using a TT) and duration of locomotion per day were moderately correlated 
(ρ=.561, P<.01). In contrast, corridor-based walking distance (using a 6-MWT) and 
duration of locomotion per day showed just a weak correlation (ρ=.375, P<.01). Stronger 
correlations were present between total number of steps per day and TT outcomes (FCD: 
ρ=.663; ACD: ρ=.621, both P<.01). In addition, outcome of 6-MWT was moderately 
associated with locomotion movement intensity (ρ=.599, P<.01). The sedentary activity 
modes did not show any relevant correlations with either TT or 6-MWT outcomes (table 
4). 
Multivariate regression analysis did not reveal any significant contribution of gender 
or age to the PEC and PA correlations.
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Table 4. Spearman correlation coefficients between PEC and PA 
  Treadmill test
FCD ACD 6-MWT
Lying Duration -.173 -.138 -.234
No of periods -.297* -.245 -.137
Time/period .306* .257 .114
Intensity -.230 -.190 .029
Sitting Duration -.163 -.196 -.060
No of periods .305 .153 .303*
Time/period -.116 -.183 -.204
Intensity -.103 .025 .157
Standing Duration .253 .281 .228
No of periods .439** .422** .343*
Time/period -.459** -.387** -.245
Intensity .251 .286 .359*
Shuffling Duration .449** .438** .406**
No of periods .431** .417** .356*
Time/period .088 .093 .256
Intensity .094 .168 .237
Locomotion Duration .617** .561** .375*
No of periods .463** .422** .245
Time/period .596** .549* .499*
Intensity .277 .323* .599**
Steps per day Total number .663** .621** .425**
No=number; * indicates a significance P<.05; ** indicates a significance of P<.01, FCD=functional claudication 
distance, ACD=absolute claudication distance.
DISCUSSION
In this study we investigated the relation between PEC outcomes and daily PA in patients 
with IC. Overall, only weak to moderate correlations between these parameters were 
found. A substantial portion of the correlations was therefore considered of minor 
relevance (ρ≤0.5), despite their statistical significance.22 Among relevant correlations, 
results of a treadmill test (TT, i.e. FCD and ACD) showed strongest association with 
locomotion (i.e. total amount of locomotion and duration of locomotion per period). 
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These findings possibly imply that ‘the better a TT performance, the more a patient walks 
in daily life’. Similar conclusions may be drawn from the correlations between TT-based 
FCD and ACD and number of steps per day. A moderate correlation was also found 
between a 6-MWT walking distance and locomotion movement intensity (MI). MI 
as determined by the acceleration and declaration signals indicates movement power. 
A comparison between corridor-based walking and treadmill walking demonstrated 
reduced anterior-posterior ground reaction forces during the latter protocol.23 Therefore, 
it may be expected that results of MI and 6-MWT demonstrate stronger correlations when 
compared to MI and TT outcomes. Besides, other authors also reported that 6-MWT 
results correlated well with PA levels as expressed in general ‘activity units’.24 In general, 
correlations of FCD and PA were stronger then the correlations between ACD and PA. 
It may therefore be proposed that a measurement of FCD is currently the most optimal 
predictor of daily walking activity. 
Understanding of the underlying motives of physical activity behaviour is an aid 
for optimizing intervention strategies.25 This assumption may particularly be true in 
sedentary populations including IC patients8, as health benefits of increased PA are 
likely substantial. However, PA is a complex endpoint that is influenced by a range of 
factors (e.g. personal, exercise-related, environment and policy).25 Moreover, there is still 
uncertainty about the exact factors defining someone’s behaviour to be physically active. 
A poor relation between PEC and PA as shown in this study may be not surprising, as 
it was also demonstrated in other populations including healthy elderly14 and COPD.16 
The concepts of PEC and PA may therefore be different.26, 27 Our results indicate that 
the parameter PEC is able to predict 44% of the variance in PA (FCD versus numbers of 
steps per day) at best. Leaving more than half for others factors to explain PA behaviour. 
Considering these results and knowing that a low PA level is a strong risk factor for 
developing comorbidities7, assessment of PA as an additional outcome measure may have 
important implications for IC care. 
Correct assessment of PA in patients with IC seems to be a challenge. Questionnaires 
may help to identify a severely inactive patient, but these tools largely fail to provide 
a correct reflection of an entire patient population. Moreover, self-reported responses 
on daily PA are subject to social desirability bias.28 In contrast, activity monitors were 
found to be reliable tools for PA assessment and are currently widely available.13 These 
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devices are easy to wear, whereas the number of problems that were encountered in the 
present study was minimal. A unique aspect of our methodology was the quantification 
of a range of different activity components (e.g. sitting and standing) rather than 
more general measures of PA (e.g. activity units or metabolic equivalents of a task; 
MET).24, 29 A precise measurement of PA is important as recent insights revealed that 
prolonged sitting (i.e. sedentary behaviour) predicts all-cause mortality, independent 
of these overall physical activity levels in METs.30 Prolonged sitting is found to disrupt 
metabolic functions, resulting in increased plasma triglyceride levels, decreased levels 
of high-density lipoprotein cholesterol, and decreased insulin sensitivity.30 Based on 
the results from molecular biology and medical chemistry studies, physical activity and 
sedentary behavior are thought to have different influences on the body, supporting their 
independent effects on health.31 Consequently, the positive effect of (vigorous) physical 
activity for a couple of times per week (for instance during SET) does not seem to 
compensate for the independent negative effect when one is predominantly sedentary for 
the remaining time. Thus, incorporating different activity components of PA in patients 
with IC, in particular time spent in sedentary modes, may be more predictive compared 
to measurements of just energy consumption. 
Previous studies failed to demonstrate beneficial effects of SET on daily PA in patients 
with IC. Both Fokkenrood et al. and Crowther et al. concluded that PA levels did not 
increase following three and twelve months of SET, respectively.6, 32 The finding that an 
exercise program primarily focussing on stimulating physical capacity does not improve 
daily PA is explainable. When PAD gradually progresses over the years, the patient likely 
develops a sedentary lifestyle requiring more than just an increase in exercise capacity 
to change. This explanation is in line with a previous conclusion from a COPD study.5 
Exercise interventions require targeting to exercise capacity as well as to behavior change 
with regard to daily physical activity, in order to achieve improvement in PA.5 Behavioural 
changing techniques such as motivational interviewing might be helpful in achieving and 
maintaining improved PA levels. A brief psychological intervention of just two 1-hour 
sessions significantly increased daily walking in patients with IC33, an effect that was 
sustained for over two years.34 SET provides an ideal opportunity for incorporation of 
such psychological interventions (i.e. health behaviour changing techniques), thereby 
probably optimizing SET programs and improving patient outcome. However, high-
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quality trials examining the effectiveness of these health behaviour changing techniques 
in patients with IC are urgently needed.35 The additional value of health technology 
applications (e.g. incorporated in smart phones) for enhancing PA also require detailed 
studies. 
Based on present results on may argue that measurement of PEC does not have an 
additional role in an improved understanding of daily PA in patients with IC. However, 
such a functional assessment was found to reflect the IC patients’ abilities and limitations36, 
and may therefore provide valuable information. Evidently, walking distance as measured 
using a TT has limitations, as discrepancies between treadmill measures and perceived 
walking impairment are reported.37 It must also be appreciated that treadmill based walking 
distance is the most widely used outcome parameter to evaluate treatment effects of SET 
in both clinical trials and daily practice.36 Both the TUG and SPPB measures may be of 
less relevance and/or suitable for this patient population. The high number of maximum 
scores (‘ceiling effect’) imply that patients were not really challenged during these tests, 
both protocols require just a very short period of activity (usually <15 seconds), whereas 
most IC patients experience pain at a later time point. PEC is considered to determine 
someone’s maximal capacity and may therefore be inadequately estimated by these 
tests. As also indicated by the lack of correlations with PA. Consequently, we propose to 
incorporate PA as a novel outcome measure and treatment goal for IC alongside current 
walking (TT or 6-MWT) PEC measurements.   
The present study must be interpreted in view of the fact that PEC results may be 
overestimated as persons are generally thought to push to their limits when challenged 
during a test setting, as compared to a normal day-to-day situation. It may therefore be 
possible that this has influenced correlation strength. Moreover, several factors apart from 
age and gender might influence potential correlations between PEC and PA. Variance in 
the use of sort and type of medication, presence of comorbidities and BMI for instance 
have a possible effect on PA and correlations with PEC might be different for certain 
subgroups of patients with IC. Unfortunately, the study’s cross-sectional design does 
not allow for studying causality. Future research should preferably explore determinants 
which possible contribute to PA. Such an analysis may allow for a more selective use of 
monitoring equipment.  
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In conclusion, walking distance as determined with a 6-MWT or graded TT protocol 
revealed weak to moderate correlations with locomotion components of PA. Whereas, 
no to weak correlations were found with sedentary PA components. On the basis of the 
present study results, the sedentary nature of IC patients, and the increased mortality 
risks accompanied with these low PA levels, we suggest including of objectively measured 
PA as an additional outcome measure and treatment target in patients with IC.  
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ABSTRACT
Background: Patients with intermittent claudication (IC) tend to walk slower and 
consume about 40% more oxygen during walking compared to healthy individuals. 
An unfavourable locomotion pattern has been suggested to explain this metabolic 
inefficiency. However, knowledge on gait patterns in IC is limited.  
Methods: In a cross-sectional study, the gait pattern of newly diagnosed IC patients 
was compared with similar healthy controls. Spatio-temporal gait parameters such as 
step length and duration of the stance phase were obtained by a photoelectric system 
(Optogait®). This system has shown a strong concurrent validity and test-re-test reliability 
in various study populations. Parameters were determined during pain-free and painful 
(in IC only) treadmill walking at comfortable self-determined walking pace. A total of 80 
steps was selected for each participant to calculate averaged parameter values.
Results: A total of 28 patients and 28 controls were examined. IC patients walked 1.2 km/h 
(-27%) slower than controls (P<.001), coinciding with a significantly shorter step length 
(-20%) and lower cadence (-11%). IC patients demonstrated a longer stance and double 
support phase, even before the onset of ischemic pain. Differences were also observed in 
the segments of the stance phase, as a 14% shorter propulsion (P<.001) and 17% longer 
flat foot phase (P<.001) during painful walking was found. With respect to the absolute 
time however, differences were only present for the time for flat foot (Δ0.10 seconds, 
P<.001).
Conclusion: Patients with intermittent claudication demonstrate an altered gait pattern. 
Most striking differences include the prolonged relative and absolute duration of the flat 
foot position during the stance phase. This adaptation may be intuitive as arterial blood 
inflow to skeletal muscles takes place during the relaxation phase. Therefore, not only 
the lack of propulsion but also gain of relaxation may explain these gait disturbances to 
a certain part.
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INTRODUCTION
The most common symptom of peripheral arterial disease (PAD) is intermittent 
claudication (IC), characterized by limb pain that is elicited by exercise and resolves 
after rest. Patients with IC demonstrate limited walking distance, lower physical activity 
levels,1, 2 less isokinetic distal muscles strength3 and reduced quality of life.4 Besides, 
patients with IC were found to consume more oxygen during walking compared to healthy 
controls.5-7 Researchers have suggested various mechanisms that may be responsible 
for this increased oxygen requirement. For instance, an unfavorable gait pattern and 
a reduced recovery of potential energy through the pendulum-like mechanism were 
implicated.8 Interestingly, a reduced metabolic efficiency was ruled out.5
Previous studies already found that IC patients walk slower, have lower cadence 
rates and smaller stride lengths, mainly caused by an increased double limb support and 
stride time.1, 9 However, only basic spatio-temporal parameters have been studied in IC 
so far. Distinct sub phases during the stance phase may also be interesting,10 particularly 
foot contact and toe off (propulsion).5 The calf muscles are known to contribute most 
to propulsion and constitute the main determinants of walking speed.11 Precisely these 
muscles are considered the ‘functional end organs’ in the lower extremity ischemia of 
IC patients.12  So, additional differences at this level may be plausible. Moreover, further 
insight in these sub phases might substitute to the development of rehabilitation strategies 
to restore the gait pattern and eventually walking distances, quality of life and possibly 
even survival. Since reduced exercise capacity is the most powerful harbinger of long-
term mortality in PAD.13 
One study on the potential effect of SET on altered gait pattern failed to demonstrate 
any improvement.14 However, consensus on which type of exercise is leading to optimally 
improved walking ability is lacking.15 Hence, current exercise protocols may be not 
tailored to elicit significant improvements in walking patterns, or gait pattern outcomes 
are not adequately specified. Moreover, previous research was mainly based on limited 
number of steps.1, 16 Fortunately, suitable gait analysis systems for continuous data 
capturing during treadmill walking have become available. These novel tools allow for 
optimizing accuracy and generalizability of collected data on the gait pattern. 
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The primary aim of this study was to explore spatio-temporal gait parameters in IC 
patients during continues treadmill walking and compare these parameters with healthy 
controls. We hypothesized that patients with IC demonstrate changes of in particular the 
sub phases of the stance phase. 
METHODS 
Participants
Patients were recruited from a population presenting between October 2014 and March 
2015 with new onset manifestations of IC at the Vascular Surgery outpatient departments 
of three regional Dutch hospitals (Catharina Hospital Eindhoven, Maxima Medical Center 
Veldhoven and St. Anna Hospital Geldrop). According to standardized institutional 
protocols, potential patients underwent an ankle-brachial index (ABI) measurement in 
rest and following exercise. Individuals demonstrating a resting ABI <0.90 or an ABI 
drop >0.15 after treadmill testing17 and typical symptoms of claudication in at least one 
leg, were eligible for study. Additional inclusion criteria were symptoms >4 weeks and 
the ability to walk on a treadmill for ≥1 minute. Patients were excluded if they suffered 
from a comorbid condition possibly influencing gait pattern such as lower extremity 
amputation, severe osteoarthritis (based on the American College of Rheumatology 
Osteoarthritis criteria),18, 19 previous knee or hip prosthesis, severe cardiopulmonary 
problems (i.e. chronic obstructive pulmonary disease ≥Gold III and/or New York Heart 
Association ≥III), neurological diseases including peripheral polyneuropathy (e.g. due 
to diabetes mellitus), Parkinson’s disease, stroke, previous surgery of lower extremities, 
use of walking aids or orthopedic shoes or medication influencing walking pattern (e.g. 
psychotropic medication). Patients who experienced rest pain, suffered from chronic 
wounds or received more than five sessions of SET during the preceding three years were 
also excluded. 
Control subjects of similar age, gender, height, and weight were recruited from family, 
friends and hospital personnel. They were exhibiting an ABI in rest >0.90 and did not 
experience pain or limitations during walking. Other exclusion criteria were similar as 
for the patients with IC. Participants that were willing to undergo the study protocol were 
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counseled prior to providing written informed consent. All procedures were approved by 
the Medical Ethical Committee of the Catharina Hospital, Eindhoven, the Netherlands.  
Study protocol 
Two researchers (LG and AS) were responsible for the data collection and performed all 
measurements. Height and weight allowed calculation of the Body Mass Index (BMI). 
Leg length was determined with a tape measure in standing position and defined as 
the distance from the trochanter major of the hip to the inferior aspect of the lateral 
malleolus.20 
After anthropometric measurements, participants walked for ten minutes (for IC 
patients, with intervals of rest, if necessary due to IC pain) on a treadmill to get accustomed 
to its specifics.21 The preferred walking pace was determined next, defined as ‘walk at a 
pace that is comfortable and comparable to your outside walking’.21 The treadmill was 
started at 2.4 km/h. Speed was increased in 0.1 km/h increments until self-selected 
comfortable walking speed was achieved. Speed was then further increased until fastest 
pace was attained, and again decreased until the comfortable speed was reached once 
more. Gait pattern measurements were obtained at this final, self-selected comfortable 
walking pace. After 20 minutes of rest, IC patients were specifically questioned whether 
IC pain was completely resolved, participants again started walking on the treadmill. 
During one minute of painless walking, gait parameters were obtained. Once IC patients 
experienced claudication pain as determined using a 4-point Claudication Pain Scale,22 
gait parameters were again captured for one minute. 
Control subjects underwent same measurements just once (i.e. pain-free trial). All 
participants walked bare feet on a flat treadmill to exclude differences based on variable 
footwear. Additionally, both patients and controls were interviewed regarding general 
health, cardiovascular risk factors (smoking) and comorbid conditions. 
Gait pattern
Spatial and temporal gait parameters were collected using an OptoGait photoelectric 
cells system (Microgate S.r.l., Bolzano, Italy). The instrument consists of two bars of one 
meter each, a transmitting and receiving unit respectively. Both bars contain 96 LED 
diodes, one cm apart and 3 mm above floor level, and are positioned onto the side bars 
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of the treadmill (figure 1). Parameters are determined when LED diodes are interrupted 
by (one of) the feet during walking. Data were sampled at a frequency of 1000 Hz and 
saved on a laptop using OptoGait version 1.9.9.0 software (Mircogate S.r.l., Bolzano, 
Italy). The system is validated for spatio-temporal gait parameters on a treadmill and has 
shown strong concurrent validity and test-re-test reliability in various other populations 
including healthy adults, stroke patients and patients after knee arthroplasty.23, 24 Besides, 
reported minimum detectable changes are several times smaller than previously described 
differences in gait parameters of IC patients.
Following parameters were obtained: walking speed, cadence, gait cycle duration, step 
length, step time, duration of single and double limb support, swing and stance phase 
duration and contact, flat foot and propulsive phase (figure 2). Step length was defined 
as the distance from heel contact of the first foot to the heel contact of the subsequent 
contralateral foot. 
Statistical analysis
Sample size calculation (with alfa=0.01 and beta=0.80) was based on both a spatial (stride 
length difference of 15 cm) and temporal (percentage stance phase difference of 2%) 
outcome variable9 and revealed a sample size of respectively 25 and 14 subjects per group, 
to realize a statistically significant difference between both groups.
Analyses and calculations of the data generated by the OptoGait software were 
performed in a customized program that was created in Matlab R2012a (Mathworks 
Inc, Natick, Massachusetts, USA). Eighty representative steps were obtained from each 
participant. Mean values and standard deviations were calculated for individual parameters 
per leg. In IC patients, the most symptomatic leg as based on the patients’ history was 
considered the index leg. In healthy controls, the index leg was randomly selected. 
SPSS 20.0 (IBM, Armonk, NY, USA) was used for statistical analysis. Demographic 
characteristics were expressed as percentages or group means and standard deviations. 
Differences between patients and controls were studied. In addition, evaluation within 
the patient group was performed. The symptomatic (e.g. index leg) was compared to the 
asymptomatic leg (e.g. asymmetry), and the index leg was compared during the pain-
free and painful one minute measuring period. Pearson’s chi-square tests were used for 
analysis of categorical variables, whereas an independent-samples and paired t-tests 
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analyzed continuous variables. Variables that lacked normal distribution were expressed 
as median and corresponding interquartile ranges. Mann Whitney U-tests were used 
to compare these variables. Pearson correlation coefficients (Rho: ρ) were calculated to 
explore relations between spatio-temporal parameters and clinical determinants (walking 
speed, ABI values). Statistical significance was applied at P<.01 to control for multiple 
testing (type I error rate). 
The transmitting (A) and receiving (B) bars are positioned on the side bars of the treadmill. Spatio-temporal parame-
ters are obtained via interruptions in the LED signal between the bars, when a subject passes between the bars.
Figure 1. Study set-up including the OptoGait System
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The gait cycle is divided in the stance phase and swing phase. The stance phase, which is defined as the heel to toe 
contact of the foot, accounts for around 60% of the gait cycle and the swing phase for the remaining 40%. The stance 
phase can be divided in heel strike: first contact of the heel with the floor; foot flat phase: period where the complete 
foot is in contact with the ground and the propulsion phase: termination of stance phase, starts when the heel leaves 
the ground and ends with complete set off of tip of the foot. (adapted from: R.C. Schafer, Clinical Biomechanics, 1987. 
Chap 4: Body alignment, Posture, and Gait – used with permission)
Figure 2. Phases of the normal gait cycle
 
RESULTS 
Study population  
The study population consisted of 28 IC patients and 28 controls of similar age (mean 
age: 68 years), gender distribution, height, weight and leg length (table 1). Hypertension 
rate however, was higher in the IC group. ABIs of patients during rest and after treadmill 
walking were 0.64 and 0.35, respectively. Almost half (n=13, 46%) of the IC patients had 
unilateral complaints. 
IC patients versus control subjects
The IC patients walked at a 1.2 km/h slower pace (IC: 3.3 km/h vs. controls: 4.5 km/h, 
P=<.001, table 2), coinciding with a significantly 24% shorter step length (IC: 49.2 cm vs. 
controls: 61.3 cm, P=<.001), a 11% lower cadence (IC: 111 steps/min vs. controls: 122 
steps/min, P=<.001) and a 14% longer contact time (IC: 0.74 sec vs. controls: 0.65 sec, 
P=<.001). 
The relative duration of the single support phase was significantly shorter in IC 
patients compared to controls (Δ2.3% and Δ3% for respectively pain-free and painful 
ambulation), and the relative duration of the double support phase significantly longer 
(Δ4.3% and Δ5% for respectively pain-free and painful ambulation). Moreover, IC 
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patients had an evidently longer lasting foot flat phase (pain-free: Δ4.9%; P=.007 and 
painful: Δ7.4%; P<.001) and shorter propulsive phase than controls (pain-free: Δ4.1%; 
P=.016 and painful: Δ6.5%; P<.001). Reported differences between IC patients and 
controls increased during painful walking (table 2). Despite the difference in the relative 
duration of the propulsive phase, no difference was found in absolute propulsion time 
between IC patients and controls. 
Table 1. Demographics  of study groups undergoing gait analysis
Characteristics IC patients (n=28) Controls (n=28) P-value
Gender (male) – n (%) 20 (71) 16 (57) .27
Age (years) – mean (SD) 68 (6.8) 68 (6.7) .75
Height (m) – mean (SD) 1.70 (0.08) 1.69 (0.08) .64
Weight (kg) – mean (SD) 80 (13) 75 (11) .10
Leg length (cm) – mean (SD) 80.6 (5.2) 80.5 (4.5) .92
Index leg (left) – n (%)a 13 (46) 14 (50) .79
ABI index leg – mean (SD)
Rest 0.64 (0.19) 1.08 (0.16) .00
After treadmill walking 0.35 (0.16) -
Duration of symptoms (months) – mean (SD) 17 (16) -
Uni- or bilateral complaints (unilateral) – n (%) 13 (46) -
BMI (kg/m2) – mean (SD) 28.6 (4.9) 26.4 (4.7) .10
Smoking
Current smoker –  n (%) 14 (50) 3 (11) .02
Former smoker – n (%) 11 (39) 14 (50)
Never smoker – n (%) 3 (11) 11 (39)
Hypertension – n (%) 19 (68) 6 (21) .00
Diabetes Mellitus – n (%) 7 (25) 1 (4) .05
Cardiac disease – n (%)b 8 (29) 2 (7) .08
Transient ischemic attack – n (%) 2 (7) 1 (4) 1.00
COPD – n (%) 4 (14) 3 (11) 1.00
Osteoarthritis – n (%) 4 (14) 1 (4) .35
a: index leg = most symptomatic leg in IC patients and randomly selected for controls. b: cardiac. ABI = ankle-brachial 
index; BMI = body mass index; cardiac disease included coronary artery disease, arrhythmia, pacemaker; COPD = 
chronic obstructive pulmonary disease.
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Pain-free versus painful walking in patients with IC
For the comparison between pain-free and painful walking in IC patients, differences 
were only found in the sub phases of the stance phase. The relative duration of flat foot 
increased significantly from 54.4% to 56.8% (P=.002), while the relative contribution of 
propulsion decreased from 34.0% to 31.6% (P<.001) when claudication pain presented. 
In addition, mean flat foot time increased by 0.02 seconds (P<.001) whereas mean 
propulsion time decreased by 0.02 seconds (P<.001) during painful walking. 
No asymmetry in gait parameters was found when comparing the index leg (i.e. most 
symptomatic IC leg) and the contralateral leg, for both the pain-free and painful session 
(data not shown). A subanalysis of the unilateral IC patients (n=13) also revealed no 
significant differences between both legs of IC patients. 
Table 2. Gait characteristics of IC patients compared to age-matched controls
Variables IC patients (n=28) P-value1 Controls (n=28) P-value2 P-value3
Pain-free Painful
Speed, km/h 3.3 (0.6) 4.5 (0.8) <.001
Step length, cm 49.2 (8.4) 50.0 (8.7) .028 61.3 (9.8) <.001 <.001
Stride length, cm 99.6 (3.0) 99.9 (3.0) .615 123.6 (19.5) <.001 <.001
Cadence, steps/min 111 (7.9) 110 (8.0) .729 122 (9.6) <.001 <.001
Contact time, sec 0.74 (0.06) 0.74 (0.07) .748 0.65 (0.1) <.001 <.001
Single support, % 32.4 (2.5) 31.7 (2.9) .008 34.7 (2.2) .001 <.001
Double support, % 35.3 (4.3) 36.0 (4.7) .026 31.0 (4.4) .001 <.001
Stance phase, % 67.7 (2.3) 67.6 (2.3) .879 65.7 (2.5) .003 .004
Swing phase, % 32.3 (2.3) 32.4 (2.3) .966 34.3 (2.5) .003 .003
Contact phase, % 11.6 (2.6) 11.6 (3.7) .884 12.4 (2.5) .217 .356
Contact phase, s 0.08 (0.02) 0.09 (0.03) .777 0.08 (0.02) .389 .422
Foot flat phase, % 54.4 (7.1) 56.8 (7.0) .002 49.5 (6.1) .007 <.001
Foot flat phase, s 0.40 (0.07) 0.42 (0.07) .001 0.32 (0.06) <.001 <.001
Propulsion, % 34.0 (6.5) 31.6 (5.9) <.001 38.1 (5.9) .016 <.001
Propulsion, % 0.25 (0.05) 0.23 (0.04) .001 0.25 (0.04) .810 .164
Step length = distance between heels of two subsequent feet. Contact time = time when the foot is in contact with 
the ground. Single support = time when only one foot touches the ground. Double support = sum of two partial 
double supports of one gait cycle. Stance phase = similar to the contact time but expressed as percentage of one gait 
cycle. Contact phase = moment between first contact of the heel (e.g. heel strike) to foot flat. Foot flat = moment that 
foot completely touches the ground. Propulsion = moment from lifting the heel to complete set off of the tip of the 
foot (figure 1). 1 = paired t-test: pain-free versus painful within IC patients group; 2 = independent-samples t-test: pain-
free versus control; 3 = independent-samples t-test: painful versus control.
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Correlations 
No clinically relevant or significant correlations were found between ABI values and 
any gait parameters. In healthy controls walking speed was moderately correlated with 
relative duration of the propulsion phase (ρ=.541, P=.005). Whereas, no correlation was 
found for these variables in IC patients (ρ=.187, P=.341). Foot flat time on the other hand 
was significantly correlated to walking speed in both IC patients and controls (figure 3). 
IC patients: r -.565, P=.002; controls: r -.784, P<.001.
Figure 3. Scatterplot of the time for flat foot and walking speed
DISCUSSION
The purpose of this study was to explore spatio-temporal gait parameters in patients 
with IC during continuous treadmill walking. This is the first study that also investigated 
individual phases of the stance phase in this patient population using this approach. 
Patients with IC walked 27% slower and spent a larger percentage in stance phase than 
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healthy controls. In addition, distinct differences were present for the separate segments 
of the stance phase. A 14% decrease in propulsion duration and a 17% increase in foot 
flat duration were observed in IC patients. Interestingly, these alterations were already 
present before claudication pain started.
Previous research reported contrasting findings regarding altered gait pattern in 
patients with IC. Most studies observed differences in percentage of stance phase and 
double support,9 walking speed and cadence25, 26 that are in line with our results. While 
some described no effect of claudication on several temporal and spatial gait measures.27, 
28 However, the relatively small samples sizes28 and the use of papered walkways with 
stopwatch recording27 might explain the lack of differences in these latter studies, as study 
populations were comparable with our IC patients in terms of age and ABIs. 
A unique aspect of the present study is the assessment of gait parameters during 
continuous treadmill walking. We based our results on 80 steps, while others obtained 
data from just a couple of steps during a short 4 to 7 meter walkway.1, 9 In the study of 
McCully et al., patients walked on a treadmill until a sufficient pain level was obtained 
followed by gait measurements during overground walking.29 Our treadmill based 
methodology also allowed for data capturing immediately after the pain threshold was 
reached, thereby excluding confounding due to possible recovery processes. Based on 
this optimized and standardized methodology, we are confident that the results of the 
present study truly reflect the alterations in gait pattern that occur in patients with IC.  
Differences in gait patterns between IC patients and controls are deemed important 
for several reasons. Walking is one of the most important activities of daily human life. 
From the very first step that is made, individual gait patterns are optimized as walking is 
the most economical means of locomotion. Gait speed is known to be an independent 
predictor of all-cause mortality30 and gait speed differences between 0.36 km/h to 0.72 
km/h are termed ‘clinically relevant’.31 The difference as found in the present study was 
(at least) twice as large (1.2 km/h) and biomechanical gait alterations might contribute to 
the slower walking speed of IC. Insight and subsequent improvement of the gait pattern 
might therefore contribute to the prognosis of IC patients. The difference in propulsion 
(14%) between painful walking in IC and controls revealed a Cohen’s d effect size of 
0.48, which may be interpreted as a medium effect. So, even small differences may have 
a substantial impact. 
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The precise explanation for the gait changes in IC is still unknown. There may be a 
pathophysiological mechanism, related to the lower blood flow of IC patients,32 which 
partly explains the gait changes as observed in patients with IC. The present study showed 
that IC patients spend a significantly shorter percentage of the gait cycle in propulsion 
and a significantly longer percentage in flat foot position. Expressed in absolute time 
however, only a significantly longer flat foot position was found. Hence, the additional 
time per gait cycle as a consequence of the slower walking pace in IC, is completely used 
for the flat foot phase. This phenomenon may reflect an intuitive adaptation since skeletal 
muscles blood flow mainly occurs during the relaxation phase of dynamic exercising. The 
relaxation period in part determines the magnitude of arterial inflow.33 It may therefore 
seem that, analogous to the definite walking stops when claudication pain maximizes, 
IC patients have already ‘discontinued’ walking for a longer period during every step, as 
a means to allow for sufficient blood inflow and supply of oxygen. This hypothesis may 
also explain why IC patients take fewer rather than shorter steps when claudication pain 
develops.25 
Calf muscle weakness has previously been described as a potential mechanism 
underlying IC gait adaptions.34 The calf muscles are known to constitute most to the 
propulsion11 and a recent study demonstrated a reduced dynamic capability of these 
muscles in IC.35 These findings are in accordance with both the results of another study 
which reported a shorter time until maximum plantar flexion occurred36 and our findings 
of reduced propulsion. Subsequently, propulsion is the main determinant of walking 
speed.11 Reduced walking speed in IC might therefore be a consequence of decreased calf 
muscle strength and propulsion, as well as a compensatory strategy to allow for a longer 
relaxation phase. 
Strategies to improve walking speed might be a valuable starting point for the clinical 
management of these patients. Walking at a higher speed during SET might increase 
training efficiency, as patients are thought to reach the claudication threshold earlier by 
superseding the compensatory mechanism. On the other hand, a higher walking speed 
might also be advantageous in terms of walking economy, since IC patients are known 
walking at a velocity below the optimal point of energy costs.37 Future studies may focus 
on the value of treadmill training on a higher pace. Besides, effort to increase calf muscle 
strength could also be vital to improve propulsion and eventually the gait pattern of IC. 
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Last, the value of rollover footwear (i.e. MBT footwear) might be of particular interest 
for IC patients. Previous research described reduced peak internal plantarflexion ankle 
moments during propulsion, without change in metabolic costs or walking speed.38 
Some study limitations need to be addressed. First, we included only participants 
without additional comorbidities (e.g. osteoarthritis or previous lower limb surgery) 
potentially affecting the gait pattern. Therefore, the present findings were obtained in IC 
patients who were in a relatively good condition. As a consequence, the present results 
might be overestimated in favor of a relatively normal gait pattern. Besides, results may 
be not generalized to IC patients with numerous comorbid conditions. Second, we 
captured data during treadmill walking which is not necessarily similar to overground 
walking. However, Riley et al. reported identical kinematic and kinetic parameters during 
treadmill and overground gait.39 It is thus felt that movement analysis during treadmill 
walking reveals valid results, all the more so when taking other advantages of treadmill-
based protocols into account. One might question the influence of a treadmill protocol on 
the lack of asymmetry in spatio-temporal parameters, especially in unilateral IC patients, 
as found in this study. However, Gardner also found no asymmetry in IC patients during 
an overground walking protocol.9 Third, the present research included spatio-temporal 
analysis only. As data on kinematics, kinetics and surface electromyography were lacking, 
we were not able to provide additional views from alternative perspectives. However, 
our findings might serve as a starting point for further research to elucidate underlying 
mechanisms of impaired walking function in patients with IC. Future research should 
focus on muscle contraction patterns to address the exact relation between distal muscles 
relaxation during flat foot, and the subsequent contraction during propulsion.  
In conclusion, patients with intermittent claudication demonstrate altered spatio-
temporal gait parameters during treadmill walking that happen before the actual onset of 
claudication pain. The gait pattern is characterized by a slower walking pace and longer 
double support phase and stance phase. The prolonged flat foot phase might be a possibly 
compensatory mechanism contributing in a reduced walking speed. Future research 
should focus on strategies to improve walking speed.  
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ABSTRACT
Background: Patients with intermittent claudication (IC) tend to walk at a slower pace, 
have less lower leg muscle strength and consume about 40% more oxygen during walking 
compared to healthy individuals. An unfavorable locomotion pattern has been suggested 
to explain this metabolic inefficiency. However, knowledge on gait patterns in IC is limited. 
Muscle activity patterns during walking as measured by surface electromyography (EMG) 
were never investigated in this patient population.
Methods: In this cross-sectional study, gait pattern of newly diagnosed IC patients and age-
matched controls were evaluated using kinematic parameters and medial gastrocnemius 
(MG) and tibialis anterior (TA) muscles activity patterns. The protocol included pain-free 
and painful (only IC patients) treadmill walking sessions.
Results: A total of 22 IC patients and 22 healthy controls were included. Patients walked 
1.4 km/h slower (3.2 km/h vs. 4.6 km/h, P<.001) than controls, coinciding with a 10% 
slower cadence (110 steps/min vs. 122 steps/min, P<.001). The kinematic analysis resulted 
in a patient’s ankle plantar flexion reduction of 45% during the propulsion phase, and 
ankle dorsal flexion reduction of 41% at initial contact. No additional kinematic changes 
were observed once claudication pain presented. Interestingly, kinematic differences did 
not influence the muscle activity duration during walking, as equal duration of muscle 
activity was found in IC patients and healthy controls. However, amount of muscle 
activity in microvolts did significantly increase in IC patients when claudication pain 
presented (TA: Δ23%, P<.001; MG: Δ54%, P=.007).
Conclusion: Patients with IC demonstrate significant kinematic changes during walking. 
These alterations did not affect EMG activity duration of MG and TA muscles. However, 
EMG amplitude of both muscles did significantly increase during painful walking in IC 
patients.
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INTRODUCTION
Peripheral arterial disease (PAD) is a chronic disease of the lower extremities caused 
by systemic atherosclerosis, affecting more than 12% of the population >65 years.1 
Intermittent claudication (IC) is the most common manifestation of PAD and is 
characterized by limb pain during exercise that resolves after a short period of rest. Patients 
with IC demonstrated reduced walking performance2 and revealed higher prevalence of 
falls3 compared to non-IC patients. Studies have demonstrated several mechanisms for 
these impairments,4, 5 as patients were found to have less peak propulsion force, and a 
reduced ability to swing their legs forward.6 
Other studies have suggested that the energy cost of locomotion is almost 40% greater 
in IC.7 Various mechanisms may be responsible for this higher cost of locomotion. For 
instance a maladapted and unfavorable gait pattern based on IC induced neuromuscular 
dysfunction. Patients with IC may use the same muscles, but with a different sequence 
of fibre recruitment7, as a result of chronic fibre changes following exercise induced 
ischemia.8 Previous studies already found that lower extremity ischemia has a direct, 
negative effect on calf muscle diameter, density and muscle fibre types.8, 9 
Surface electromyography (EMG) is a non-invasive technique that measures muscle 
action potentials that occur during muscle contraction while performing motor tasks, 
such as walking.10 The electrical activity is recorded by means of surface electrodes 
that are placed on the skin overlying a muscle or group of muscles.11 It is a widely 
used method to determine activation patterns of different muscles (i.e. timing, ‘on-off 
pattern’) and it allows to study normal and pathological motor strategies.12 Surface EMG 
has been demonstrated to be a feasible and valid method to record muscle activity.13 A 
recent study in patients after total hip arthoplasty also included EMG as an adjunctive 
tool that complements gait analysis.14 To our knowledge, surface EMG analyses during 
walking was not previously performed in patients with IC. This method may yield 
valuable information in IC patients as a means to investigate the previously suggested 
neuromuscular dysfunction. Chronic ischemia as present in IC, may lead to alterations 
in motor unit recruitment (EMG amplitudes) and/or muscle coordination patterns. EMG 
evaluation examined together with kinematics (joint angles) provides a thorough insight 
into muscle performance and their role in accomplishing motor tasks.10
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The primary aim of the current study was to determine lower extremity joint angles 
and EMG patterns in patients with IC and in healthy controls during continuous treadmill 
walking. Besides, the effect of claudication pain on these gait parameters was studied. We 
hypothesized that patient with IC demonstrate less range of ankle and knee motion and 
generate a different pattern of muscle activity compared to healthy controls. 
METHODS 
Participants
Patients were recruited from a population presenting between October 2014 and March 
2015 with new onset manifestations of IC at the Vascular Surgery outpatient departments 
of three regional Dutch hospitals (Catharina Hospital Eindhoven, Maxima Medical Center 
Veldhoven and St. Anna Hospital Geldrop). According to standardized institutional 
protocols, potential patients underwent an ankle-brachial index (ABI) measurement 
in rest and following exercise. Individuals demonstrating a resting ABI <0.90 and/or 
an ABI drop >0.15 after treadmill exercise15 and typical symptoms of claudication in 
at least one leg, were eligible for this study. Additional inclusion criteria were presence 
of symptoms >4 weeks and the ability to walk on a treadmill for ≥1 minute. Patients 
were excluded if they suffered from a comorbid condition possibly influencing the gait 
pattern, such as lower extremity amputation, severe osteoarthritis, knee or hip prosthesis, 
severe cardiopulmonary problems (i.e. chronic obstructive pulmonary disease ≥Gold 
III and/or New York Heart Association ≥III), neurological diseases such as peripheral 
polyneuropathy (based on history and eventual physical examination), Parkinson’s 
disease, or stroke, previous lower extremities surgery (e.g. bypass, percutaneous vascular 
intervention), use of walking aids, orthopedic shoes or medication influencing walking 
pattern (e.g. psychotropic medication). Patients who experienced rest pain, suffered from 
chronic wounds or had received more than five sessions of supervised exercise therapy 
(SET) during the preceding three years were also excluded. 
Age-matched control subjects were recruited from family, friends and hospital 
personnel. They were exhibiting an ABI in rest >0.90 and did not experience any pain 
or limitations during walking. Other exclusion criteria were similar as for the group of 
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patients. Participants that were willing to participate were counseled prior to providing 
written informed consent. All procedures were approved by the Medical Ethical 
Committee of the Catharina Hospital Eindhoven, the Netherlands.  
Study protocol 
Two researchers (LG and AS) were responsible for data collection. Height and weight 
measurements allowed calculation of the body mass index (BMI). Leg length was 
determined with a tape measure in standing position and defined as the distance from 
the major trochanter of the hip to the inferior aspect of the lateral malleolus. 
After anthropometric measurements, participants walked for ten minutes (for IC 
patients, with intervals of rest if necessary) on a treadmill system to get familiarized with 
the system16 and to determine a ‘preferred’ walking pace, defined as ‘walk at a pace that is 
comfortable and comparable to your outside walking’.16 The treadmill was started at 2.4 
km/h and speed was increased in 0.1 km/h increments until this comfortable walking 
speed was achieved. Speed was then further increased until a rapid pace was attained, and 
decreased until the comfortable speed was reached once again. Gait measurements were 
obtained at this final, self-selected comfortable walking pace.  
Following a short period of rest, participants received reflective markers that were 
placed at specific anatomical locations of each participants’ lower limb (figure 1). The 
two-dimensional (2D) marker trajectories were captured with a high-speed real-time 
camera (Basler, 1394a/b, GigE) and its software system (Simi Aktysis version 1.4.1.2, Simi 
Reality Motion Systems GmbH, Unterschleissheim, Germany) sampling at 100 samples/
seconds (hertz). Before placement of surface EMG probes, skin sites were cleaned with 
70% isopropyl alcohol and hair was removed if necessary. The wireless EMG probes (BTS 
FreeEMG, BTS Bioengineering Corp., Brooklyn, USA) were attached to the skin via pre-
gelled disposable Ag-electrodes (Kendall ECG electrodes H124SG) and positioned over 
the medial gastrocnemius (MG) muscle and tibialis anterior (TA) muscle following the 
SENIAM recommendations.11 MG and TA were assessed as these muscles are considered 
main actuators of the ankle.17 Besides, the MG muscle is the most common site of 
ischemic pain that limits exercise tolerance in IC.18 Recording muscle electrical activity 
using surface EMG during gait has been found to demonstrate a sufficient repeatability, 
reliability and consistency.19 Data were captured at 1000 hertz and synchronized with the 
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kinematic data using a triggerbox. Data were real time stored and converted into digital 
signals by the EMG-Analyzer software program (BTS Bioengineering Corp., Brooklyn, 
USA).
After 20 minutes of rest following marker and electrode application, IC patients again 
started walking on the treadmill. During one minute of painless walking, gait parameters 
were obtained. Once IC patients experienced claudication pain as determined using a 
4-point Claudication Pain Scale, gait parameters were again captured for one minute. 
Control subjects underwent similar measurements just once (i.e. pain-free trial). All 
participants walked bare feet on a flat treadmill. 
Kinematic data analysis 
The position of the reflective markers provided a proper 2D lower extremity segment 
orientation and knee and ankle joint angles during walking. The maximal forward 
trajectory of the lateral malleolus reflective marker in the sagittal plane was used as 
an indication of heel strike. All kinematic parameters were normalized to 100% of the 
gait cycle (e.g. 100 points representing heel strike to the following heel strike) using a 
cubic spline interpolation technique. Forty representative cycles were selected for each 
participant to determine following (averaged) parameters: range of motion (ROM), 
maximum and minimum joints’ flexion and extension angles, and joints’ angles at the 
moment of heel strike. All signal processing and calculations were performed using 
a customized program that was created in Matlab R2012a (Mathworks Inc, Natick, 
Massachusetts, USA).
EMG data analysis
After digitalization of the raw EMG signals, further processing and analysis were 
performed in a customized Matlab program. The EMG signal was high-pass filtered (cut-
off frequency of 20 hertz) to suppress potential movement artifacts, full-wave rectified by 
subtracting the mean off-set value from the absolute signal values, and then low-passed 
filtered (cut-off frequency of 6 hertz) to create linear envelope EMG signals. A power 
spectrum analysis confirmed that chosen cut-off settings were appropriate. EMG data 
were normalized to a 100% gait cycle using the kinematic data of the lateral malleolus 
marker. Similarly, forty gait cycles were used to calculate the ensemble average percentage 
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of muscle activity and peak performance (in microvolts) for the MG and TA muscles per 
gait cycle. The threshold for muscle onset was based on a 25% of the mean peak value of 
the EMG signal during walking.20 
Left picture: LED lights are positioned on the bony landmarks of the lower limb, to determine the knee and ankle joint 
angles, respectively. A=knee joint angle; C=ankle joint angle. Current positions are set at zero degrees. B=EMG device 
on the tibialis anterior muscle. Middle picture: position of the EMG device on the tibialis anterior muscle, dashed circle 
indicated the muscle belly (D). Right picture: position of the EMG device on the medial gastrocnemius muscle, dashed 
circle indicated the muscle belly(E). 
Figure 1. Measurement set up
Statistical analysis
Differences in kinematic and EMG parameters of the index leg in IC patients and controls 
were studied. In IC patients, the most symptomatic leg was considered the index leg. 
In controls, the index leg was randomly selected. Evaluation within the patient group 
was performed by comparing the values of the pain-free and painful trial, respectively. 
A Pearson’s chi-square test was used for analysis of differences between categorical 
variables, whereas an independent samples t-test and paired t-test analyzed continuous 
190
Supervised exercise therapy for intermittent claudication
9
variables. Variables that lacked normal distribution were expressed as median and 
interquartile range. A Mann Whitney U-test and a Wilcoxon signed-rank test were 
used to study these variables. Pearson’s correlation coefficients (Rho: ρ) were calculated 
to study associations between kinematic data and EMG data. Multivariate regression 
analyses were performed to study the effect of walking speed on kinematic and EMG 
outcomes. Statistical significance was applied at P<.05. SPSS software version 20.0 (IBM 
Corporation, Armonk, New York, USA) was used for the statistical analysis. 
Sample size calculation was based on duration of muscle activity per gait cycle, which 
was considered the primary outcome. As data of IC patients are not available, data from 
patients after total hip arthroplasty instead were used.14 Calculation (using alfa=0.05 
and beta=0.80) revealed that 16 subjects per group were required to attain a statistical 
significant difference of 5% gastrocnemius activity.
RESULTS 
Study population
The study population consisted of 22 IC patients and 22 age-matched controls. Baseline 
characteristics were similar, except for current smoking and hypertension, which were 
more prevalent among IC patients (table 1). ABIs of patients during rest and after 
treadmill walking were 0.64 and 0.35, respectively (table 1). A total of 9 patients (41%) had 
unilateral IC complaints. IC patients walked at a 1.4 km/h slower pace and demonstrated 
a significantly lower cadence and shorter step length compared to the controls (table 2).
Kinematic parameters in IC 
Except for a significant difference in total knee ROM (Δ1.3°, P<.019), no differences 
were found when comparing pain-free and painful walking in patients with IC (table 
2). However, evident differences were present between IC patients and controls. Patients 
with IC demonstrated approximately 7° less knee flexion after heel strike (IC: 10.9° vs. 
controls: 18.4°, P<.001, figure 2). There was also a significant difference in total ankle 
ROM (Δ7°, IC: 18.3° vs. controls: 25.3°, P<.001), predominantly due to a decreased peak 
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plantar flexion (Δ8.3°, IC: -10.2° vs. controls: -18.5°, P<.001, figure 3). Moreover, IC 
patients were found to exhibit less ankle ROM from initial heel contact to the flat foot 
position (Δ2.3°, IC: 3.3° vs. controls: 5.6°, P=.001). No differences in variability of total 
ROM for respectively the knee and ankle joints between IC patients and controls were 
found (table 2).
In healthy controls, a significant correlation was found between walking speed and 
peak plantar flexion (ρ=-.709; P<.001). In contrast, this correlation was not found in 
IC patients (ρ=-.388, P=.074). Multivariate regression analyses revealed a significant 
contribution of walking speed to the difference in maximal ankle plantar flexion between 
IC and controls (P<.001), accounting for 64% of the explained variance.  
Surface electromyography in IC 
Analysis of the EMG signals included 19 controls (86%) and 18 IC patients (82%) as 
EMG data of 3 controls and 4 IC patients were corrupted and therefore not used. Figure 4 
presents the EMG activity of the MG and TA muscles in a typical IC patient, as generated 
by the present study. In IC patients, no differences were found in MG muscle activity 
when comparing pain-free and painful walking. The TA muscle activity on the other 
hand, decreased significantly once claudication pain occurred (pain-free: 58% activity 
of the gait cycle, painful: 49% activity of the gait cycle; P=.005). In addition, a significant 
increase of peak muscle activity was found for both muscles during painful ambulation 
(MG: +54%, P=.007; TA: +23%, P<.001). For the comparison between patients and 
controls no differences were found for the MG muscle. Both groups used the MG muscle 
for approximately 43% of the gait cycle. Differences for the TA muscle tended to be more 
distinct, but were not significantly different (table 3). 
For healthy controls, walking speed was significantly correlated to the position of 
peak MG muscle activity, as percentage of the gait cycle (ρ=.543, P=.020), whereas this 
correlation was not found in IC patients (ρ=.068, P=.789). In addition, no correlations 
were found between either EMG parameters and ABI indices or EMG parameters and 
kinematic outcomes. 
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Table 1. Demographics of study groups undergoing gait analysis
Characteristics IC patients (n=22) Controls (n=22) P-value
Gender (male) – n (%) 17 (77) 16 (73) .73
Age (years) – mean (SD) 69 (6.6) 69 (6.6) .80
Height (m) – mean (SD) 1.70 (0.08) 1.70 (0.08) .84
Weight (kg) – mean (SD) 80 (12) 76 (12) .33
Leg length (cm) – mean (SD) 81 (4.3) 81 (5.8) 1.00
Index leg (left) – n (%)a 11 (50) 10 (46) .76
ABI index leg – mean (SD)
Rest 0.64 (0.2) 1.1 (0.2) <.001
After treadmill walking 0.32 (0.13) -
Duration of symptoms (months) – mean (SD) 19 (17) -
Uni- or bilateral complaints (unilateral) – n (%) 9 (41) -
BMI (kg/m2) – mean (SD) 27.3 (3.4) 26.3 (3.5) .30
Smoking
Current smoker –  n (%) 12 (55) 2 (9) .03b
Former smoker – n (%) 8 (36) 11 (50)
Never smoker – n (%) 2 (9) 9 (41)
Hypertension – n (%) 15 (68) 6 (27) .01
Diabetes Mellitus – n (%) 6 (27) 1 (5) .10c
Cardiac disease – n (%)d 6 (27) 2 (9) .24c
Transient ischemic attack – n (%) 2 (9) 1 (4.5) 1.00c
COPD – n (%) 3 (14) 2 (9) 1.00c
Osteoarthritis – n (%) 3 (14) 1 (5) .61c
ABI=ankle-brachial index; BMI=body mass index; COPD=chronic obstructive pulmonary disease; a=index leg, most 
symptomatic leg in IC patients, randomly selected for controls; b=Fisher’s Exact test, calculation was based on never 
smoker and former smoker versus current smoker; c=Fisher’s Exact test; d=cardiac diseases included coronary artery 
disease, arrhythmia, pacemaker.
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Table 2. Gait parameters in IC patients (n=22) and healthy controls (n=22)
Variables IC patients P-valuea Controls P-valueb P-valuec
Mean (±SD) Pain-free Painful
Walking speed, km/h 3.2 (0.6) 4.6 (0.8) <.001
Cadance, steps/min 110 (7.1) 122 (9.2) <.001
Step length, cm 48.2 (8.7) 48.8 (9.0) .758 62.4 (10.6) <.001
Knee heel striked 12.0 (6.9) 11.2 (7.5) .213 7.3 (5.2) .014 .054
Knee heel strike to weight support 
ROMe
10.5 (5.7) 10.9 (6.0) .238 18.4 (4.6) <.001 <.001
Knee total ROM 56.2 (6.0) 57.5 (6.7) .019 59.5 (5.2) .056 .269
Knee sd total ROM 1.6 (0.2) 1.7 (0.3) .138 1.6 (0.4) .606 .231
Ankle plantar flexion -10.6 (4.5) -10.2 (3.8) .372 -18.5 (6.5) <.001 <.001
Ankle dorsiflexion 7.7 (4.2) 8.1 (3.9) .156 6.7 (4.0) .462 .265
Ankle heel strike ROMf 3.4 (2.0) 3.3 (2.2) .643 5.6 (1.9) .001 .001
Ankle total ROM 18.3 (3.5) 18.3 (3.6) .961 25.3 (5.6) <.001 <.001
Ankle sd ROM 1.2 (0.2) 1.2 (0.3) .995 1.2 (0.3) .446 .484
sd= standard deviation; a=paired t-test between pain-free and painful trial; b=independent samples t-test: pain-free 
versus control; c=independent samples t-test: painful versus control; d= knee angle during heel strike (initial contact); 
e=ROM between heel strike and complete weight support; f= ROM of the ankle between heel strike and flat foot 
position. 
Table 3. Electromyographic analysis in IC patients (n=18) and healthy controls (n=19)
Variables IC patients P-valuea Controls P-valueb P-valuec
Mean (±SD) Pain-free Painful
MG activityd, % 43.7 (7.0) 42.6 (9.6) .497 43.1 (7.0) .829 .773
TA activityd, % 58.0 (12.1) 49.0 (7.9) .005 53.5 (11.6) .268 .127
MG peak activitye, µV 67 (46-97) 103 (83-134) .007 f 91 (57-156) - -
TA peak activitye, µV 105 (50-127) 129 (101-185) <.001f 135 (98-169) - -
MG peak positiong ,% 45.9 (11.4) 44.6 (14.1) .604 45.3 (11.8) .870 .866
IC=intermittent claudication; SD=standard deviation; a=paired t-test between pain-free and painful trial, except for 
f (see below); b=independent samples t-test: pain-free versus control; c=independent samples t-test: painful versus 
control; d= duration of muscle activation as percentage of the complete gait cycle, e=peak muscle activity in micro-
volts, represented in median and interquartile range, f=Wilcoxon signed-rank test, g=position of the peak muscular 
activity in percentage of the complete gait cycle. 
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Knee joint angles in the sagittal plane during the complete gait cycle (i.e. heel strike to heel strike) for IC patients 
during pain-free walking (x), painful walking (-), and healthy controls (*). Dashed vertical line separates the stance 
phase (~60%) and swing phase (~40%) of the gait cycle. 
Figure 2. Knee joint angles in the sagittal plane during the complete gait cycle 
Ankle joint angles in the sagittal plane during the complete gait cycle (i.e. heel strike to heel strike) for IC patients 
during pain-free walking (x), painful walking (-), and healthy controls (*). Dashed vertical line separates the stance 
phase (~60%) and swing phase (~40%) of the gait cycle. Plantar flexion angels were expressed as negative values, and 
dorsal flexion angles as positive values. 
Figure 3. Ankle joint angles in the sagittal plane during the complete gait cycle  
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Graphs showing the level of muscle activity (microvolts) of a typical IC patient of the present study. Data of both the 
medial gastrocnemius (MG, black solid and dashed line) and tibialis anterior (TA, grey solid and dashed line) muscles, 
during the complete gait cycle for respectively pain-free and painful ambulation, is presented. The dashed vertical line 
separates the stance phase (~60%) and the swing phase (~40%) of the gait cycle.
Figure 4. Graphs showing the level of muscle activity (microvolts) of a typical IC patient 
DISCUSSION
The purpose of this study was to evaluate kinematic gait parameters and muscle activity 
as assessed via EMG in patients with IC and age-matched controls. To our knowledge, 
this is the first study investigating both EMG and kinematic parameters using this type 
of methodology in this patient population. Patients with IC demonstrated a substantially 
reduced ankle joint displacement during initial contact (-41% dorsal flexion) and the 
propulsion phase (-45% plantar flexion), resulting in a significantly decreased total ankle 
ROM compared to healthy controls. Interestingly, no additional differences were found in 
the ankle joint angles once claudication pain presented itself. The surface EMG analysis 
revealed no significant differences between IC patients and controls regarding muscular 
activity duration of the MG and TA muscles. However, painful walking did result in 
an increased amount of muscle activity (i.e. EMG amplitude) within the group of IC 
patients. These findings suggest that IC pain due to ischemia coincides with an increased 
recruitment of motor units and muscle fatigue.   
Limb movements are induced by muscles acting over a joint. The lesser ankle ROM 
as found in the present study might be considered as a compensatory mechanism to 
minimize the requested duration of muscle contraction (i.e. reduced work load). This 
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adaptation might be beneficial during painful walking in particular, as limited blood flow 
and oxygen (i.e. ischemia) are thought to hinder muscle contraction. Our data however 
indicated that IC patients use their lower limb muscles to a similar percentage of the gait 
cycle as controls do. Therefore, evidence for our assumption that such data are strongly 
coupled is not provided yet. These findings however support previous studies which also 
found no changes in calf muscle activity despite evident changes in ankle movements.21
A small number of studies analysing gait patterns in patients with IC reported conflicting 
results so far. For instance, one group described reduced plantar flexion and total ankle 
ROM, in line with our results.22 Whereas a second group found an increased ankle ROM23, 
although they did not include peak plantar flexion during the start of the swing phase, 
a moment when the largest ankle plantar flexion is generally found (figure 3). It must be 
appreciated that the present study is unique in its assessment of gait parameters during 
continuous treadmill walking. Previous research groups based their conclusions on just a 
limited number of steps22, 23 while larger number has been recommended.24  Based on this 
optimized and standardized methodology, we are confident that the results of the present 
study reflect true alterations in the gait pattern of IC patients.   
Walking in IC patients is known to occur at a much greater cost of transport (i.e. 
walking economy). As a consequence, IC patients consume more oxygen/energy per unit 
walking distance then matched controls.7, 25 This phenomenon was judged by some as a 
consequence of an altered mechanical gait pattern.7 As slower walking speeds are known 
to decrease metabolic efficiency.26 We observed evident kinematic differences in the ankle 
joint that can in part be explained by the difference in walking velocity between IC and 
controls. Causality cannot be tested by the cross-sectional nature of the present study, but 
results imply that both variables are related. Correction of the observed gait abnormalities 
may therefore contribute to an improved metabolic efficiency and will possibly allow IC 
patients to continue walking, whereas ischemic pain will likely be postponed. The present 
study found that gait abnormalities became evident before the onset of claudication pain. 
Therefore, mechanisms other than restricted blood flow and IC pain may be responsible 
for the observed ambulatory dysfunction. Reduced calf muscle strength for instance.27 
As oxidative damage due to exercise induced ischemia may contribute to metabolic 
myopathy in the lower extremity muscles.28, 29 Alternatively, increased fatigability and 
predominance of type II muscle fibres (i.e. anaerobic and fatigue-prone) of the medial 
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gastrocnemius were also found in IC patients.30 Muscle weakness and fatigue lead to 
an increased recruitment of motor units and a rise in EMG amplitude when similar 
work load (i.e. constant walking speed) is applied. These alterations may be reflected by 
significantly higher EMG amplitudes during painful ambulation, as found in this study. 
As fatigue is generally considered an important control parameter for muscular training, 
current results provide evidence for the beneficial effect of supervised exercise training 
(SET) recommended to performed at an intensity intensity near maximal pain level.31 
The current research may fuel the search for novel training modalities of SET aimed 
to improve gait pattern. As plantar flexion is strongly associated with walking speed,32 one 
might first focus on improvement of plantar flexion during the pre-swing phase. It has 
been suggested that a reduced plantar flexion and subsequent inability to propel the body 
forward also contribute to the increased risk of falling in elderly.33 Therefore, restoration 
of gait patterns may be beneficial from this perspective as well. Moreover, the effect of 
strength training on gait parameters in this patient population may be promising as 
well. A recent meta-analysis in IC already concluded that progressive resistance training 
with high intensities is a most effective exercise modality for improving gait speed.34 
Furthermore, lower limb strength training was shown to improve gait kinematics in 
elderly women.35 
Some limitations of the present study need to be addressed. First, only participants 
without additional comorbidities (e.g. osteoarthritis or previous lower limb surgery) 
were included thereby excluding factors potentially influencing the gait pattern. The 
present findings were obtained in patients who were in a relatively good condition, and 
results might be overestimated in favour of a relatively normal gait pattern. However, 
participants with diabetes mellitus (DM) were not excluded. One study reported lower 
ankle generative mechanical work in patients with DM, even in the absence of diabetic 
neuropathy.36 As DM was more prevalent among IC, reduced joint ankle ROM is possibly 
overestimated in the IC group. Second, data as captured during treadmill walking may 
not necessarily be similar to data that is obtained during over ground walking. However, 
very equal characteristics of gait were reported37, despite slight differences in stance 
duration and muscle activation.38 It is thus reasoned that movement analysis during 
treadmill walking reveals outdoor day-to-day situations, all the more so when taking 
other advantages of treadmill-based protocols into account. However, caution should 
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be taken when comparing the present EMG data with results as acquired from over 
ground walking protocols. The same may be true regarding bare foot walking compared 
to walking using common footwear, as footwear is found to influence kinematic during 
walking. To exclude differences in gait pattern due to variable footwear, we decided to 
have all participants walk without shoes.39 Third, we just studied two lower limb muscles. 
Although these muscles are considered main actuators of the ankle17 and being the 
‘functional end organs’ in the lower extremity ischemia40, it would be of interest to include 
additional muscles in future research. It must also be appreciated that surface EMG 
registration inherently has certain restrictions. EMG refers to the collective electric signal 
from muscles produced during contraction and the amplitude of an EMG signal is known 
to be dependent of several factors, such as the properties of the overlying tissue (e.g. 
thickness of overlying skin and adipose tissue). It is therefore not possible to compare raw 
EMG amplitudes across subjects. So, surface EMG should be used for studying muscle 
activation patterns and activity duration only. In contrast, muscle force is not reflected by 
this method. Last, we did not examine passive range of joint motion. Therefore, kinematic 
differences may possibly be attributed in part to a difference in passive range of motion. 
However, participants with a history of orthopaedic complaints, functional loss in range 
of motion, or observational abnormities during walking were excluded. 
CONCLUSION
Patients with IC demonstrate significant changes in kinematic parameters during walking, 
even before the onset of claudication pain. However, these changes did not influence 
EMG activity duration of the medial gastrocnemius and anterior tibialis muscles. 
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SUMMARY & GENERAL DISCUSSION 
Intermittent claudication
Intermittent claudication (IC) is the most common manifestation of peripheral 
arterial disease (PAD) and may be considered as a locoregional expression of systemic 
atherosclerosis. IC is defined as muscle discomfort in a lower limb that is predictably 
evoked by exercise and relieved after a short period of rest. Most patients with IC develop 
a serious walking impairment during daily life. 
Barriers and misconceptions regarding supervised exercise therapy
Supervised exercise therapy (SET) is the first-line symptomatic treatment for IC as 
stated in several contemporary international guidelines.1, 2 In clinical practice however, 
SET is largely underused3 and most IC patients do not receive SET at all.4 There are 
three categories of reasons why this cost-effective treatment is not widely adopted yet 
(chapter 1).5, 6 First, SET places a considerable burden on patients in terms of effort and 
responsibility rather than offering a ‘quick fix’ for their discomfort, so patient reluctance is 
understandable. A second category of reasons for SET resistance involves clinicians. Self-
interest of doctors performing interventions that involve fee-for-service is most likely 
a contributor. Moreover, there is also misinterpretation of potential SET indications, 
for instance with regard to the efficacy of SET for IC due to aortoiliac stenosis.7 A third 
and possibly most important factor precluding a wider implementation of SET is lack 
of access and inadequate reimbursement.8 Therefore, even clinicians who fully endorse 
SET as the initial treatment for IC may end up performing invasive interventions as their 
patients cannot find a nearby qualified SET practitioner. This is even more bitter when the 
absence of budgetary restrictions regarding invasive procedures is considered. 
It is IC patients who lose out 
These three different types of resistance severely frustrate a universal implementation of 
SET as the standard care for patients with IC. Based on a 2009 invoice data analysis of 
a large Dutch health insurer (3.4 million members) it was demonstrated that only 14% 
of the IC patients actually did receive SET.4 An unknown portion of the remaining IC 
patients likely underwent a primary invasive revascularization, while most others may 
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have possibly been provided with a single ‘go home and walk’ advice. Consequently, IC 
patients are either unnecessarily exposed to the risks of an invasive intervention or received 
a truly inferior IC treatment, since general and unstructured exercise recommendations 
as prescribed by a physician do not lead to sufficient clinical benefit.9-11 Moreover, most 
physicians do not even recommend home-based walking exercise to patients with IC.12  
In the Netherlands, the tide may slowly be turning now as increased numbers of IC 
patients were referred for SET in 2011 (to be published, based on similar invoice data 
analysis). Great effort has been put into the implementation of a nation-wide network 
of physiotherapists (PT) providing SET in a community-based setting.13 ClaudicatioNet, 
founded in 2010, is a so-called open network which means that membership is attainable 
for every PT who fulfills a standard set of participation criteria. ClaudicatioNet strives 
to provide a stepped-care approach where all IC patients are initially referred to a SET 
program whereas invasive revascularization is exclusively considered for individuals 
not responding sufficiently to SET.2 This approach may be advantageous over a primary 
invasive intervention strategy as recent evidence indicated that a PTA is likely to be more 
cost-effective when combined with SET. These findings once again underscore the general 
benefits of any form of regular exercise.14 
Blueprint for implementation of SET
To date, ClaudicatioNet includes 1,552 fully trained PTs. These health care professionals 
provide information in a personalized portfolio on the network’s national website 
and attend mandatory educational courses. A web-based referral system is available 
to help patients find the ClaudicatioNet PT nearest in their community. This referral 
system guarantees that SET is initiated within 5 working days after diagnosis as PTs are 
instructed to contact a patient within 3 days. If a first PT fails to do so, a second other PT 
is automatically invited to contact this patient. 
While the scale of this Dutch network is comparatively small, this concept could 
provide a blueprint for the implementation of structured SET programs throughout 
Europe and the US. As for the health care budget as a whole, the financial benefits of SET 
are considerable. A recent calculation of this stepped care approach (assuming a 80% 
referral rate) showed savings of up to 32M euro a year in the Netherlands alone.4 Efforts 
to expand SET implementation outside the Netherlands is of importance for IC patients 
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in general, but also to anticipate to the current trend as observed in clinical trials which 
are mostly focusing on alternative IC exercising protocols (e.g., the value of home-based 
exercise programs). Unfortunately but not completely unexpected, large randomized 
controlled trials yielded mixed results on the efficacy of home-based protocols.15, 16 
Moreover, the evidence that a conservative therapy is as effective as invasive alternatives 
is easily ignored.
Comparison of SET to alternative conservative exercise protocols 
Further evidence for the efficacy of SET and its role as an alternative treatment tool 
was provided in a meta-analysis presented in chapter 2. The efficacy of four available 
conservative treatment options for IC (i.e. medical treatment, walking advice, home-
based exercise, SET) was compared in the largest analysis to date (n=1,406 patients). A 
beneficial outcome of SET with significant effect sizes >0.8 was demonstrated at the 6 
weeks, 3 and 6 months follow-up. SET resulted in superior walking distances compared 
to all other treatment options. A dose-response trend appeared present suggesting that 
grade of supervision was directly related to walking distances. Hence, supervision is 
necessary to optimally profit from the benefits of exercise in IC. 
After 6 months of follow-up however, results following SET were not significantly 
different from a home-based protocol (HB). It therefore seems that the intensive 
supervision has its particular value during the first months of training. On the other hand, 
it may also be possible that ongoing improvement in maximal walking distance is not to 
be expected beyond the reported 50% to 200% increase.10 In addition, studies on the 
additional value of life-style interventions during SET have not been performed. These 
modifications probably make SET even more effective, both as reflected by an increased 
walking distance as in terms of altered morbidity and mortality as discussed later. 
At the present time, a 3 months SET program is preferable, possibly followed by a 
combined ‘SET-HB’ program. Such a combined follow-up program may be more cost-
effective due to the limited amount of supervision and use of training facilities. Moreover, 
these programs may be further optimized by future monitoring via novel eHealth and 
mHealth applications.8, 17 
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Additional benefits of supervision
Intensive supervision at the start of an exercise program for IC may also have benefits when 
viewed from other perspectives. SET offers an opportunity for simultaneous motivational 
interviewing supporting IC patients in changing unhealthy habits including smoking, too 
high calorie of fat food intake and sedentary lifestyle. Evidence regarding the benefits of 
life style modification programs is growing.18 A lifelong habit of sedentary behavior due 
to reluctance to exercise aggravated by leg pain during walking or co-existing (multi-)
morbidity can only be changed by simultaneous and prolonged efforts under professional 
supervision.19-21 A series of SET sessions evidently provide better opportunities for 
stimulating health-related behavioral changes than a single invasive intervention.20 
Unfortunately, large studies on the effect of these interventions during SET are currently 
lacking, as previously stated. The potential positive influence on lifestyle adjustments 
however is just another argument for advocating SET.  Another plea would be the positive 
influence of SET on the entire vascular system rather than on a portion thereof. The 
contralateral leg, which may not appear to be affected by symptomatic PAD yet, may also 
be trained. SET trains the entire cardiorespiratory system and improves overall fitness 
levels22 and by the same token significantly reduces long-term cardiovascular morbidity 
and mortality.23 Moreover, SET also allows to differentiate between (and further explore 
the influence of) comorbidities (e.g. osteoarthritis, chronic obstructive pulmonary 
disease). Last but not least, SET can be employed in a group setting, providing patients 
with a chance to share emotions and experiences. Such a group-based intervention also 
tends to increase the intrinsic motivation for exercise programs.24
Concerns about safety of SET are unjust 
Despite a nationwide coverage of community-based SET in the Netherlands and successful 
removal of some barriers (poor availability and limited access), there are still obstacles on 
the road to success. There is an ongoing uncertainty whether SET is sufficiently safe in IC 
populations as concomitant coronary artery disease is prevalent.25 For example, a cross-
sectional survey among Dutch vascular surgeons and fellows found that respondents were 
reluctant to refer for SET in the presence of significant cardiopulmonary comorbidity.7 
This concern is also found among physiotherapists as reflected in their 2003 guideline 
of the Royal Dutch Society for Physical Therapy (KNGF) recommending screening by 
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a cardiologist or exercise-physiologist prior to the start of SET.26 This guideline was only 
recently updated (2014).27 Although the onset of a cardiovascular event during exercise 
is not inconceivable, cardio-pulmonary screening prior to the initiation of SET may 
raise an additional unnecessary barrier. The prediction of a future severe cardiac event 
during exercise is difficult, if not impossible.28 Consequently, the use of cardiopulmonary 
exercise testing (CPET) as a screening tool for myocardial ischemia in people without 
known coronary artery disease is no longer recommended in the National Institute for 
Health and Care Excellence (NICE) guideline.29 Surprisingly, the 2015 guideline of the 
Society for Vascular Surgery still advocates screening for cardiopulmonary reserves to 
allow safe participation.1 
In chapter 3 of this thesis, evidence was provided regarding the safety of SET in 
patients with IC. SET related complications were systematically studied on the basis of 
74 articles, representing 82,725 hours of SET in 2,876 IC patients. Six adverse events of 
cardiac and two of non-cardiac origin were identified resulting in a very low 1 to 10,340 
patient-hours all-cause complication rate. SET can therefore safely be prescribed to 
patients with IC. In line with current evidence but contrary to the SVS 2015 guideline, 
routine cardiac screening prior to initiation of SET is therefore not advised. 
Caution is only required if one wants to generalize these safety findings, as our 
systematic review excluded IC patients with known major exercise-limiting comorbidities 
(e.g. poorly controlled hypertension, severe congestive heart failure). However, other 
studies too demonstrated the safety and benefits of exercise in these subpopulations.30 The 
risk of acute cardiovascular events was also low in patients with known coronary artery 
disease participating in a high-intensity exercise rehabilitation program.31 Moreover, 
exercise was superior compared to coronary angioplasty in improving exercise capacity 
and event-free survival in patients with coronary artery disease.32 
In conclusion, patients with (cardiac) comorbidity should not routinely be excluded 
from SET in daily practice. These patients obviously require careful monitoring whereas 
exercise intensity should always be tailored to the patient’s condition by a well-educated 
PT. Unfortunately, the benefits of such personalized exercise programs are difficult to 
scientifically evaluate as some form of standardization is needed. Based on our study, 
the previous recommendation on a mandatory cardiac screening was removed from the 
recently updated KNGF guideline for PTs in the Netherlands.27 
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Do women and men equally benefit from SET?
Gender-specific research on diagnostics and treatment in cardiology is very common but 
not in the field of peripheral arterial disease (PAD). This difference was also emphasized 
in a scientific statement of the American Heart Association.33 From a cardiovascular 
pathophysiological perspective however, true gender differences likely exist.34 For instance, 
smaller vessel size and dissimilar atherosclerotic plaque composition were demonstrated 
in females.35 Women were also found to suffer more from the consequences of PAD as 
they perceive a lower physical function and greater impact on daily activities.36 Moreover, 
women are less likely to receive antiplatelet and lipid-lowering therapy in the presence 
of cardiovascular diseases.37 One study also reported inferior patency rates following 
surgical lower-extremity revascularization in women.33 
Data on gender-specific SET outcomes are limited and conflicting.38-40 In chapter 4, a 
follow-up analysis on gender-specific response following SET was reported. A population 
of 113 men and 56 women who initially participated in a 2010 multicenter randomized 
controlled trial named ExercIse Therapy in Peripheral Arterial Disease (EXITPAD) study 
were again studied. The SET program was supervised by PT’s and included interval-based 
treadmill walking approximating maximal pain, combined with activities such as cycling 
and rowing. Patients usually started with three 30 minutes sessions a week, and training 
frequency was adapted during the following year on the basis of individual needs. At 
baseline, similar demographic characteristics (e.g. age, comorbidities, cardiovascular 
risk factors), maximal walking distances (men: 250 meters, women: 270 meters) and 
subjective walking impairment (expressed in terms of scored on a walking impairment 
questionnaire) were found. After 12 months of follow-up, both men and women 
demonstrated a significant increase in walking distance. However, men’s maximal walking 
distances were significantly larger after 3 and 12 months of SET. A gender-difference of 95 
meter (difference in median) after 12 months was found. Surprisingly, improvement in 
subjective walking impairment (as measured by the walking impairment questionnaire) 
was found to be similar in men and women.
It may be concluded that female IC patients certainly benefit from SET but 
demonstrate less improvement in walking distance after 12 months. The reasons for this 
difference may be related to pathophysiological dissimilarities (atherosclerotic plaques, 
vessel diameter), more common presence of atypical symptoms, different perception 
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of IC symptoms, more impaired lower extremity function and less leg strength in 
women.41, 42 However, if, how and to what extent these factors contribute to the gender-
related difference in walking distance after SET is still unknown. Current results do 
not provide arguments for immediate initiation of gender-based exercise programs for 
IC. However, research on female aspects of cardiovascular care must be expanded as a 
previous study reported that IC women are more likely to present with further advanced 
disease, which is in line with the disparity in time-to-diagnosis and access-to-care 
between men and women with PAD.42
Does diabetic status influence the efficacy of SET?
Diabetes mellitus (DM) is one of the strongest risk factors for the development of 
PAD43, and a high prevalence of DM in IC is acknowledged.44 IC patients with DM tend 
to experience worse lower-extremity function than patients with IC alone45, and it has 
been suggested that patients with DM have a reduced exercise tolerance.46 Others also 
advocated that IC patients with comorbidities might be less suitable for SET.47 The exact 
influence of diabetes on the effect of SET in IC is under debate, and this lack of knowledge 
may raise unjust barriers against commencing SET. 
In chapter 5, current evidence regarding the effect of DM on the response to SET 
in IC patients was summarized. A total of three studies representing a total of 845 IC 
patients met inclusion criteria. All reported maximal walking distance outcomes, one 
study also included functional walking distance whereas the two other studies described 
pain-free walking distance. In general, IC patients with DM did improve in walking 
distance following a SET program. Nevertheless, conflicting results were found when 
diabetic and non-diabetic IC patients were compared. The largest study found no 
differences44, whereas significant and nearly significant differences on maximal and pain-
free walking distance were demonstrated by the other two studies.40, 48 In a subanalysis on 
gender, female diabetic IC patients responded poorest to SET and were a most vulnerable 
group.40 Similar results were found in a follow-up analysis as described in chapter 4 of 
this thesis. Although future studies are warranted to precisely elucidate the role of DM on 
SET outcomes, no arguments have been found to deny diabetic IC patients a form of SET. 
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How to adequately interpret effects of SET?
Outcome of SET is often evaluated in terms of (changes in) walking distance. Whether 
to measure walking distance on a treadmill or in a corridor by means of a 6-minute 
walking test was recently discussed.49, 50 Both methodologies have limitations considering 
that the optimal test should directly correlate with patient-reported physical limitations. 
An outdoor measurement by a community-based global positioning system (GPS) was 
recently found to be a promising alternative compared to both indoor walking tests.51 
Outdoor measurements are expected to reflect a real life situation, and it must be 
appreciated that GPS assessment has been found to correlate better with patient-reported 
measures of walking limitation.52 On the other hand, GPS revealed larger short-term 
walking capacity variability thereby limiting its test-retest reliability.53 Future studies are 
needed to determine the optimal functional outcome measure in IC. 
Apart from the quest of the ideal method of measurement, adequate interpretation 
of currently applied outcome measures is important. To aid clinicians and researchers in 
determining what numerical change indicates a clinically meaningful change, the concept 
of a minimally important difference (MID) value was introduced as a means to define 
certain outcomes. In chapter 6, MID values were determined for treadmill-based walking 
distances in patients with IC. An anchor-based approach using longitudinal data of 103 
IC patients who participated in a SET program was followed. Regarding the maximal 
walking distance after 3 months of SET, MIDs of 305 meters and 147 meters were found 
for improvement and deterioration, respectively. A positive value for deterioration implies 
that such a small increase in walking distance is apparently not satisfactory to the patient. 
This may not be surprising as SET demands a considerable patient’s investment of time 
and effort (chapter 1). Although the largest effects of SET were reported after 3 months 
of SET (chapter 2)54, it would be of interest to also determine MIDs for longer follow-
up periods (i.e. 12 months). Inclusion of patient-reported outcome measures (PROMS, 
e.g. walking impairment questionnaire, vascular quality of life questionnaire) when 
evaluating treatment effects and patient satisfaction has been recommended.55 However, 
the current quality of disease specific PROMs for IC is alarmingly low.56  
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Physical activity in IC, a novel outcome measure?
There is an ongoing debate regarding the value of physical activity (PA) and its essential 
role in ensuring health and well-being.57 A recent analysis found that acquiring the 
recommended minimum level of physical activity (from a level of ‘no activity’), led to an 
all-cause 19 percent mortality reduction.58 A dose-response relationship between degree 
of PA and early death was reported59 which is in line with the American Heart Association 
website’s statement saying that ‘Something is always better than nothing’. Moreover, an 
increase in daily activity was just as strongly associated with reduced mortality as quitting 
smoking.60 
Unsurprisingly, equal trends regarding the benefits of PA have also been reported 
in PAD patients. For instance, higher levels of PA were associated with less functional 
decline61 and a lower all-cause mortality risk.62, 63 Patients with IC exhibit lower daily PA 
levels compared to healthy controls64, 65 and several barriers (e.g. personal, environmental) 
to refrain from being physically active were described.66 Therefore, benefits of increased 
PA are likely more substantial in IC. However, PA levels in IC populations are rarely 
questioned or objectively monitored in current clinical practice, in contrast to standardly 
used walking capacity tests. To explore whether commonly used physical exercise capacity 
(PEC) outcomes could serve as probably a surrogate marker for PA, a cross-sectional 
study was conducted in chapter 7. A total of 46 patients completed a set of PEC tests and 
wore a tri-axial accelerometer for seven consecutive days to determine actual PA levels. 
Overall, (very) weak to moderate correlations between PA and PEC indicate that the 
concepts PEC and PA, although overlapping, are distinct. 
Achieving a higher level of PEC does therefore not necessarily mean that higher 
PA will follow. Notwithstanding, a higher exercise capacity that is often attained after 
prolonged training is permissive of greater physical activity (intensity and duration) in 
home and community environments. Previous assumptions are in line with a recent 
study which did not find an effect of SET on PA in patients with IC.67 These results, 
and the established correlation between PA and all-cause mortality, provide compelling 
arguments for focusing on PA as a distinct novel outcome measure for PAD patients (and 
possibly other populations as well). As it has recently been recognized that prolonged 
sitting (i.e. sedentarism), independent of overall physical activity levels, may be even 
more important to the all-cause mortality risk68, it seems most appropriate to measure 
both active and sedentary PA components. 
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Classification of IC patients 
The currently proposed PA measurement is only clinically relevant when it has a concei-
vable effect on the patient’s decisions and behavior. PA however is a complex endpoint 
that is influenced by a range of factors (e.g. personal; motivation, exercise-related, en-
vironment and policy). Current SET programs may be not specified (enough) for im-
proving PA, as indicated by the lack of improvement in PA after SET.67 Nevertheless, 
promising results were reported regarding the effect of a brief psychological intervention 
on walking behavior. Two 1-hour sessions, 1 week apart at the patients’ homes, signifi-
cantly improved the mean number of daily steps (Δ1,567 steps per day), as compared 
with a control group receiving standard care.20 Interestingly, this effect was maintained 
for 2 years.21 Such a psychological intervention could perfectly be incorporated into SET 
as provided by specialized PT’s trained in motivational interviewing, thereby probably 
extending the effectiveness and subsequent benefits of SET in regard to its effect on PA.
In the present thesis, measurements of both PEC and PA parameters are suggested, 
as this information allows for a novel classification of IC patients (figure 1). It is expected 
that a number of factors contribute to the category in which a patient actually belongs. 
For instance, an IC patient with a very good response to SET (high PEC) who leads 
a very sedentary life (low PA) fits into category C. A detailed characterization (e.g. 
demographics, motivation, health status, environment, etc.) of the patients in these four 
categories may facilitate an improved understanding of the underlying determinants 
for a certain type of PA behaviour. This may eventually aid in optimizing intervention 
strategies and employment of personalized medicine. Thus, the purpose is not to move 
patients from one category to the other, but to gain insight in the patients’ characteristics 
in order to provide ‘tailor-made’ therapy. 
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Figure 1. Model to classify IC patients according to their physical exercise capacity (PEC) 
and daily physical activity (PA) status
Altered gait patterns in IC 
Spatio-temporal changes of gait pattern were previously described in IC patients. IC 
patients were found to walk slower, have a lower cadence (i.e. steps per minute), and 
have a shorter step length.69, 70 Moreover, oxygen uptake during pain-free ambulation 
was higher when compared to age-matched controls indicating that IC patients exhibit 
a poorer walking economy.71, 72 Walking economy (i.e. cost of transport) progressively 
decreased following the onset of claudication pain. In addition, poorer walking economy 
correlated with diabetic status73, probably explaining the poorer response to SET of 
diabetic IC patients (chapter 5). However, since oxygen uptake is already higher in pain-
free ambulation, factors other than IC pain have to be responsible, and adaptations of the 
gait pattern might therefore be a contributor.72
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Previous research revealed that SET conferred no effect on altered gait pattern in 
patients with IC.74 Lack of improvement in gait after SET may be due to insufficiently 
tailored SET programs to elicit significant improvement. Additional research into detailed 
muscle and biomechanical adaptations may provide new insights to improve the effects of 
SET.74 Besides, previous research based their conclusions on just a couple of steps, while 
it has been recommended to include at least 20 to 30 strides.  
In chapter 8 and 9 of this thesis, different aspects of gait pattern of IC patients were 
studied using a treadmill-based protocol. Continuing analysis during treadmill walking 
allows for assessment of a large number of steps. In addition, this novel methodology 
permitted for data capturing immediately after the pain threshold was reached, thereby 
excluding confounding factors potentially due to recovery processes. 
A first analysis of spatio-temporal parameters in 28 IC patients and 28 healthy age-
matched controls was conducted (chapter 8). IC patients walked at a self-selected 3.3 km/h 
pace, whereas controls walked a significantly 1.2 km/h faster. Most evident differences 
between IC patients and controls were found in the foot contact phase and toe off (i.e. 
propulsion) phase. A 14% shorter propulsion and a 17% longer foot contact phase were 
demonstrated in IC patients. Moreover, the ankle-brachial index (a measure for disease 
severity and atherosclerotic occlusion) was correlated with both walking speed and 
decrease in propulsion during ischemic pain. IC patients seem to ‘discontinue’ walking 
for a longer period during every step. These adaptions might be intuitive as arterial blood 
inflow and supply of oxygen to the skeletal muscles takes place during this relaxation 
phase.75, 76 This may explain why IC patients take fewer rather than shorter steps when 
claudication pain develop as also suggested by a previous study.77
Based on these spatio-temporal results (chapter 8) it was hypothesized that IC 
patients use a longer contact phase to enable muscle relaxation to occur for a prolonged 
period of time, as the relaxation phase is known to be the largest moment of arterial blood 
inflow. Chapter 9 described the subsequent analyses to test this hypothesis. Lower limb 
joint kinematics and muscle activity by means of surface electromyography (EMG) were 
determined during similar self-selected comfortable walking speed. The study population 
consisted of 22 IC patients and 22 healthy age-matched controls. The kinematic analysis 
showed a significantly smaller ankle displacement (-28%) in IC patients, most evidently 
in the propulsion phase. Therefore, joint angle data supported the hypothesis. The 
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EMG data however demonstrated no differences in muscle activity duration of tibialis 
anterior and medial gastrocnemius muscles suggesting that IC patients use these muscles, 
considered main actuators of the ankle, for a similar amount of time during the gait cycle. 
Duration of muscle activity was expressed in percentages of the gait cycle in order to 
correct for the differences in walking speed between both groups. 
In conclusion, IC patients demonstrate predictable spatio-temporal and kinematic 
changes during walking, even before the onset of claudication pain. This strategy however 
did not result into longer muscle relaxation periods, as duration of lower-limb muscle 
activity was similar in both groups. There are several ways to explain these results. Surface 
EMG solely measures muscle activity but not muscle force. It has been described that a 
minimal level of intensity (i.e. above 50% of the maximum voluntary contraction force) 
is needed to cause a reduction in calf muscle blood flow.75 As a consequence, it might 
be the amount of muscle force rather than the duration of contraction which really 
determines arterial blood inflow. This idea is substantiated by previous research which 
demonstrated a reduced propulsion force and a decreased ability of the ankle plantar 
flexors in IC patients.78, 79 On the other hand, spatio-temporal and kinematic changes 
can also be due to a reduced muscle force, instead of an intended strategy to cope with 
the disease related arterial obstruction. This could also explain the unfavourable reduced 
metabolic efficiency in IC patients, which in fact adds to a reduced walking speed and 
walking capacity.    
Implications for clinical practice and suggestions for future research 
Serious effort should be put into effective measures overcoming the problem of a limited 
access of SET allowing its routine implementation in clinical practice. The success of the 
community-based ClaudicatioNet network proves that significant financial investments 
are not required.13 However, the mere availability of a nation-wide network of SET 
facilities is not enough, since it essentially only provides a sound infrastructure. After 
establishing a network, structural funding should be secured by incorporating SET in 
standard health care budgets. In addition, continuous education on IC related issues is 
required to motivate doctors, PT’s as well as patients.  
Further research should focus on identifying the optimal contents of a modular 
package of SET that is tailored to subgroups of IC patients. The possibility of incorporating 
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lifestyle-changing techniques into standard SET sessions requires exploring. Lifestyle-
changing interventions fit perfectly into the suggested addition of PA measurement in 
daily clinical routines and its subsequent aim to improve PA in patients with IC. As it is 
very hard to change deep-rooted behavior of an IC patient, a second focus should be on 
gaining more insight into the type of factors determining this behavior. A classification 
as proposed in figure 1 may aid in categorizing IC patients and may allow for the 
identification of specific categories sharing certain characteristics.
Third, the effect of specific lower-limb muscle strength training on walking distance 
and gait patterns should be investigated. Limb muscle strength is an important contributor 
to both walking speed and balance (i.e. risk of falling)80, 81 and it seems therefore logical to 
add strength training to a SET program. This is in line with the current trend of providing 
a variety of exercises during SET. Longitudinal EMG registration (baseline measurement 
followed by an intervention and follow-up measurement) may be suggested to study 
the effect of muscle strength training on the gait pattern, as for paired EMG measures, 
amplitudes can be interpreted as muscle force. 
The data in this thesis provide evidence for specific changes regarding contact time 
and propulsion phase during walking in IC. As these changes were related to walking 
speed, the fourth focus of future research should be on the effect of improving gait speed 
during SET. 
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Conclusions of this thesis
1. Supervised exercise therapy (SET) is a safe treatment in patients with intermittent 
claudication (IC).
2. SET leads to a longer walking distance when compared to other conservative 
treatment options. 
3. Women with IC tend to benefit less from SET in terms of absolute walking distance. 
4. Patients with IC and diabetes mellitus do profit from SET. 
5. The ‘minimally  importance differences’ (MID) of treadmill-based maximal walking 
distance for improvement and deterioration are 305 and 147 meters, respectively. 
The positive MID value for deterioration indicates that a minor improvement in 
walking distance apparently is not satisfactory in the patients’ eyes.
6. Correlations between physical exercise capacity (PEC) and daily physical activity 
(PA) of patients with IC are weak to moderate indicating that the concepts PEC and 
PA, although overlapping, are distinct.  
7. Patients with IC walk slower and present with less propulsion and ankle range 
of motion during walking compared to healthy controls. No difference in 
electromyographic muscle activity duration is present between IC patients 
and controls. However, painful walking in IC did result in significantly higher 
electromyographic muscle activity.  
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SAMENVATTING & ALGEMENE DISCUSSIE
Perifeer arterieel vaatlijden 
Perifeer arterieel vaatlijden, afgekort als PAV, is een uiting van atherosclerose 
(slagaderverkalking). Door afzetting van vetten en kalk verliezen de slagaderlijke 
bloedvaten van het been hun elasticiteit, kan de binnenkant van het bloedvat beschadigd 
raken, wordt de diameter kleiner en ontstaat een vernauwing.1 Uiteindelijk leidt dit tot een 
belemmering van de bloeddoorstroming. PAV kenmerkt zich door een in ernst oplopend 
spectrum van klachten, beginnend bij ziekte zonder klachten (asymptomatisch PAV) 
tot weefselversterf (gangreen) aan het einde van dit spectrum. Claudicatio intermittens 
(CI) is het meest voorkomende symptoom van PAV en betekent letterlijk ‘intermitterend 
hinken’.2 Doordat de toevoer van bloed en daarmee zuurstof naar de spieren tekort schiet, 
ervaren patiënten met CI pijn en kramp in de benen tijdens inspanning, welke spontaan 
verdwijnt na een korte periode van rust. De loopafstand is veelal beperkt en bijkomend kan 
sprake zijn van een verminderd uithoudingsvermogen (conditie), beperkte spierkracht 
en angst voor pijn en/of inspanning.3-5 
Nog vaak wordt vergeten dat atherosclerose een systeemziekte is. Dus ook de 
kransslagaders rond het hart en de slagaders naar en van de hersenen zijn per definitie 
aangedaan. Daardoor hebben patiënten met PAV (dus ook personen zonder merkbare 
symptomen) een aanzienlijk verhoogd risico op het krijgen van een hart- en/of 
herseninfarct en is de levensverwachting met ongeveer 10 jaar verkort.2
In een Nederlands populatieonderzoek onder 55-plussers werd de prevalentie van 
PAV geschat op 19,1%. Voor de Nederlandse situatie wordt uitgegaan van 800.000 tot 
één miljoen individuen.6 Per jaar krijgen ruim 25.000 nieuwe patiënten de diagnose CI te 
horen. Wereldwijd wordt het aantal patiënten met CI geschat op meer dan 200 miljoen.7 
De verwachting is dat het aantal patiënten met deze ‘welvaartsziekte’ de komende jaren 
alleen maar verder zal toenemen. PAV wordt daarom terecht een pandemie genoemd 
welke met enorme kosten voor de gezondheidszorg gepaard gaat.
Behandeling van CI bestaat uit twee pijlers, het cardiovasculaire risicomanagement 
(CVRM) en de symptomatische behandeling. Het CVRM beoogt het voorkómen van 
toekomstige cardiovasculaire events (hart- en/of herseninfarct) en vroegtijdig overlijden 
en bestaat uit medicatie (plaatjesremmer en cholesterolverlager) en adequate regulering 
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van de eventueel aanwezige diabetes mellitus of hypertensie. Daarnaast wordt aangestuurd 
op leefstijlaanpassingen als stoppen met roken, gezonde(re) voeding en meer bewegen. 
De symptomatische behandeling is gericht op het verminderen van klachten, bij CI 
veelal de beperkte loopafstand. Als eerste keus behandeling wordt in (inter)nationale 
richtlijnen gesuperviseerde looptherapie (GLT) aanbevolen. GLT bestaat uit training 
onder begeleiding van een fysiotherapeut.2, 8 Meerdere malen per week wordt, veelal 
op de loopband, intervalsgewijs door de pijn heen gelopen. Daarnaast wordt een breed 
scala aan functionele en cardiopulmonale oefeningen aangeboden en worden patiënten 
gestimuleerd om ook in de thuisomgeving (meer) te gaan lopen en bewegen en een 
gezondere leefstijl na te streven.9
Idealiter wordt pas op het moment dat GLT tot onvoldoende resultaat leidt een 
invasieve behandeling (bijvoorbeeld een dotterbehandeling) overwogen.8 Helaas wordt 
nog te vaak primair voor een invasieve behandeling gekozen. Ondanks het feit dat uit 
onderzoek is gebleken dat een invasieve behandeling na meer dan een jaar tot vergelijkbare 
loopafstanden leidt als een traject GLT.10 Echter, invasieve behandelingen gaan gepaard 
met risico’s voor de patiënt (kans op een hart- en/of herseninfarct peri-procedureel, 
(na-)bloedingen, infecties, trombo-embolische complicaties, valse aneurysmata, lokaal 
zenuwletsel) en substantieel hogere kosten.11, 12 
Barrières en misconcepties ten aanzien van GLT
Ondanks dat GLT de eerste keus behandeling is, ontvangt slechts een minderheid van de 
patiënten deze veilige en aangetoond doelmatige behandeling in de dagelijkse praktijk. 
Uit een analyse op basis van verzekeringsgegevens (2009; 3,4 miljoen verzekerden), bleek 
dat slechts 14% van de patiënten in Nederland daadwerkelijk werd doorverwezen voor 
GLT.6 
Drie categorieën van oorzaken kunnen worden onderscheiden waarom deze 
behandeling voor CI nog geen landelijke (en zeker geen wereldwijde) implementatie 
heeft gevonden (hoofdstuk 1).13, 14 Ten eerste de weerstand van patiënten. GLT vraagt 
de nodige inzet, inspanning en tijd van een patiënt, terwijl een invasieve behandeling als 
een ‘quick-fix’ uitkomst voor het ongemak biedt. De tweede categorie betreft weerstand 
bij de behandelde (of verwijzende) artsen die zijn opgeleid om, al dan niet invasief, 
in te grijpen. Gebrek aan kennis over de mogelijkheden van GLT of de wijze waarop 
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patiënten verwezen kunnen worden voor GLT liggen hier aan ten grondslag.15 Daarnaast 
bestaan vermeende categorieën van patiënten die primair voor een invasieve behandeling 
in aanmerking zouden moeten komen. Patiënten met CI veroorzaakt door een aorto-
iliacale stenose of occlusie bijvoorbeeld.16 Wetenschappelijk bewijs ontbreekt echter. Tot 
slot dragen ook financiële prikkels, onderhouden door de invloedrijke industrie, hieraan 
bij. De belangrijkste categorie die verdere implementatie van GLT belemmert, is het 
ontbreken van een gedegen financiële vergoeding (GLT in Nederland moet voor de eerste 
20 behandelingen worden vergoed uit een aanvullend verzekeringspakket). Hierdoor 
raken zelfs huisartsen en vaatchirurgen die GLT volledig onderschrijven ontmoedigd en 
zijn daardoor te vaak genoodzaakt om naar de tweede lijn te verwijzen respectievelijk 
invasief te behandelen. Dit staat in schril contrast met de vergoeding voor invasieve 
behandelingen die wel worden vergoed vanuit de basiszorg. 
ClaudicatioNet
In de rest van de wereld wordt het beperkte aanbod van geschoolde therapeuten als 
een ernstig belemmerende factor gezien voor het niet slagen van GLT.16, 17 Het landelijk 
netwerk voor gesuperviseerde looptherapie; ClaudicatioNet (CNet), heeft dit probleem 
in Nederland reeds opgelost.18 ClaudicatioNet werd in 2010 opgericht als netwerk van 
gespecialiseerde fysiotherapeuten. Iedere fysiotherapeut die aan de vooraf gestelde set 
van eisen voldoet (d.w.z. scholing, praktijkeisen), kan lid worden van dit open netwerk. 
CNet streeft naar een ‘stepped-care’ aanpak waarbij iedere patiënt met CI als eerste 
wordt verwezen voor GLT. Deelnemende fysiotherapeuten zijn zichtbaar op de website 
(www.claudicationet.nl) met een persoonlijk portfolio en het hieraan gekoppeld digitaal 
verwijssysteem staat garant voor een snelle verwijzing van patiënten naar desbetreffende 
fysiotherapeut in de nabije omgeving. Sinds 2014 bestaat in Nederland een landelijk 
dekkend netwerk van ruim 1.400 aangesloten fysiotherapeuten. 
Uit een nog te publiceren analyse met verzekeringsgegevens uit 2011 blijkt dat 
het aantal patiënten doorverwezen voor GLT ten opzichte van 2009 is toegenomen. 
Het tij lijkt zich dus (heel) langzaam te keren. CNet heeft laten zien dat met minimale 
investeringen het aanbod van GLT in de nabije omgeving van de patiënt geoptimaliseerd 
kan worden. Hoewel Nederland relatief klein is en daarmee een hoge populatiedichtheid 
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kent, kan CNet prima dienen als blauwdruk voor de implementatie van gestructureerde 
GLT programma’s binnen Europa, de Verenigde Staten en elders in de wereld.  
Vergelijking van GLT met andere conservatieve behandelingen 
Aanvullend bewijs dat GLT superieur is ten opzichte van andere conservatieve 
behandelingen (d.w.z. medicamenteus, eenmalig loopadvies, ‘home-based’ oefentherapie) 
werd geleverd in hoofdstuk 2 van dit proefschrift.19 In de grootste meta-analyse (1,406 
patiënten met CI) tot op heden werden deze vier verschillende behandelvormen met 
elkaar vergeleken. GLT bleek het meest effectief na respectievelijk 6 weken, 3 maanden 
en 6 maanden in vergelijking met de alternatieve conservatieve behandelingen. Tevens 
werd een dosis-respons trend gezien waarbij meer supervisie leidde tot een grotere 
loopafstand. Opvallende bevinding was dat de ‘home-based’ en GLT groep na 6 maanden 
niet significant van elkaar verschilden. Het zou kunnen dat de meest intensieve supervisie 
vooral zijn vruchten afwerpt in de eerste maanden van behandeling. Overigens hebben 
eerdere studies laten zien dat patiënten maximaal 50% tot 200% in loopafstand vooruit 
gaan.20 Een andere verklaring voor het uiteindelijke vergelijkbare resultaat tussen home-
based oefentherapie en GLT is dat de GLT groep dit plafond mogelijk in kortere tijd reeds 
heeft bereikt. 
Wat wij ons daarnaast moeten realiseren is dat de mogelijkheden van GLT en 
leefstijlinterventies nog in de kinderschoenen staan. De mogelijke (meer)waarde van 
leefstijlinterventies tijdens de GLT sessies is tot nu toe nauwelijks onderzocht. Toevoeging 
van dergelijke interventies kan GLT mogelijk nog effectiever maken. Niet door een 
vergrote loopafstand, maar ook door mogelijke reductie in mortaliteit en morbiditeit 
wanneer patiënten een gezondere leefstijl aannemen.
Op basis van het huidige bewijs en in overeenstemming met eerdere onderzoeken 
lijkt GLT voor ten minste 3 maanden het meest effectief.21 Mogelijk zou GLT vervolgens 
gecontinueerd kunnen worden binnen een gecombineerd ‘GLT/home-based’ programma. 
Met de mogelijkheden van innovatieve M-health en E-health applicaties, die op dit 
moment binnen CNet worden onderzocht, kan een dergelijk programma in de toekomst 
gerealiseerd worden.22
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Vermeende onzekerheid over veiligheid van GLT blijkt ongegrond
Ondanks een landelijk dekkend netwerk van GLT programma’s zijn er in Nederland nog 
tal van barrières te beslechten. Zo blijkt een voortdurende onzekerheid over de veiligheid 
van GLT te bestaan onder zowel artsen als fysiotherapeuten.15 In de richtlijn van het 
Koninklijk Nederlands Genootschap voor Fysiotherapie (KNGF, 2003) werd bijvoorbeeld 
voor aanvang van GLT cardiale screening door een cardioloog of inspanningsfysioloog 
geadviseerd.23 Hoewel bewijs voor dit advies ontbrak, bleek dit een diepgewortelde 
angst bij veel fysiotherapeuten die (sub)maximale belasting tijdens trainingen in de weg 
stond. Gezien de kwetsbare patiëntengroep met een verhoogd risico op cardiovasculaire 
incidenten en de reële kans dat tijdens training een incident plaatsvindt, is de angst wel 
begrijpelijk. Echter, voorspellen van toekomstige cardiale incidenten is lastig, zo niet 
onmogelijk.24 Mede daardoor wordt screening van patiënten met onbekend coronair 
lijden door vigerende internationale richtlijnen en in de herziende KNGF richtlijn (2014), 
niet meer geadviseerd.9, 25 Het is dan ook opvallend dat de zeer recente richtlijn van de 
Society for Vascular Surgery (2015) cardio-pulmonale screening nog steeds aanbeveeld.2 
In hoofdstuk 3 van dit proefschrift werd de veiligheid van GLT bij patiënten met CI 
bestudeerd. GLT-gerelateerde incidenten werden systematisch beoordeeld op basis van 
een review van 74 studies, met 2.876 claudicanten. Zes cardiale en twee niet-cardiale 
incidenten werden gerapporteerd hetgeen op een ratio van 1 complicatie per 10.340 
patiënt-trainingsuren neer komt. GLT blijkt dus een veilige behandeling, en cardiale 
screening voorafgaand aan GLT wordt, mede gezien het feit dat het dit eigenlijk niet goed 
mogelijk is, niet geadviseerd. 
Enige voorzichtigheid is natuurlijk geboden bij patiënten met een uitgebreide 
cardiopulmonale comorbiditeit (bijv. ernstig hartfalen), omdat de helft van de studies 
zoals opgenomen in deze review patiënten met deze problematiek uitsloot van studie 
deelname. Echter, andere studies met deze patiëntencategorieën hebben eerder 
aangetoond dat zelfs tijdens een hoog-intensief programma zich niet tot nauwelijks 
(cardiale) incidenten voordoen.26 Bovendien bleek een oefenprogramma bij patiënten 
met coronair lijden een beter effect te hebben op de mortaliteit en morbiditeit dan een 
dotterbehandeling.27 Daarmee zijn de gunstige effecten van inspanning op het gehele 
hart- en vaatstelsel nogmaals bevestigd. 
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Kortom, ook CI patiënten met cardiopulmonale comorbiditeit dienen een traject 
GLT aangeboden te krijgen en hoeven in de dagelijkse praktijk zeker niet routinematige 
geëxcludeerd te worden. Vanzelfsprekend dient zorgvuldige begeleiding en een 
individueel programma te worden aangeboden door goedgeschoolde fysiotherapeuten 
die alarmsymptomen tijdig herkennen, basic life support volledig beheersen en bij 
voorkeur een AED (automatische externe defibrillator) in de praktijk hebben. 
Profiteren mannen en vrouwen met CI in dezelfde mate van GLT?
In de cardiologie is al geruime tijd aandacht voor geslachts-specifiek wetenschappelijk 
onderzoek.28 Bij PAV daarentegen is nog nauwelijks iets bekend over eventuele man-vrouw 
verschillen met betrekking tot diagnostiek en therapie. Dit verschil werd ook benadrukt 
in een recente oproep van de American Heart Association waarin werd gepleit voor meer 
geslachts-specifiek onderzoek bij patiënten met PAV.29 Vanuit pathofysiologisch vasculair 
oogpunt zijn namelijk duidelijke verschillen tussen mannen en vrouwen beschreven. Zo 
zijn bij vrouwen de bloedvaten kleiner en de atherosclerotische plaques vaak diffuser van 
aard.30 Bovendien is bekend dat vrouwen meer fysieke beperkingen ervaren en heeft PAV 
een grotere impact op de dagelijkse activiteiten.31 Daarnaast lijken vrouwen minder vaak 
adequate medicatie te krijgen in de aanwezigheid van cardiovasculaire aandoeningen.32 
Een studie beschreef ook dat chirurgische revascularisatie bij vrouwen vaker minder 
succesvol is. Met betrekking tot geslachts-specifieke uitkomsten van GLT bij patiënten 
met CI is weinig bekend en van beschikbaar onderzoek zijn de resultaten tegenstrijdig.33,34 
Hoofdstuk 4 beschrijft een analyse waarin gekeken is naar de geslachts-specifieke 
uitkomsten van GLT bij patiënten met CI. De gegevens van 113 mannen en 56 vrouwen 
die eerder deelnamen aan de ExercIse Therapy in Peripheral Arterial Disease (EXITPAD) 
studie, een multicenter gerandomiseerde klinische studie, zijn opnieuw onderzocht. 
Alle patiënten ontvingen een standaard GLT programma, zoals beschreven in de 
KNGF richtlijn.23 Het programma startte met een frequentie van 3 trainingen van 30 
minuten per week, waarna op individuele behoefte het aantal door een fysiotherapeut 
begeleidde trainingen werd gereduceerd. Aan het begin van de studie waren de twee 
onderzoeksgroepen (d.w.z. mannen en vrouwen) vergelijkbaar wat betreft demografische 
kenmerken, maximale loopafstand (mannen: 250 meter, vrouwen: 270 meter) en subjectief 
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ervaren loopbeperking (zoals gerapporteerd op de ‘walking impairment vragenlijst’). 
Zowel mannen als vrouwen lieten een significante verbetering zien in loopafstand na 12 
maanden. Echter, zowel na 3 als 12 maanden was de maximale loopafstand bij mannen 
significant groter dan bij vrouwen. Er bestond een mediaan geslacht-specifiek verschil 
van 95 meter na 12 maanden. Opmerkelijk genoeg werden geen verschillen gevonden in 
subjectieve wandelbeperking tussen de beide groepen. 
Hoewel vrouwen dus minder progressie lieten zien, mag geconcludeerd worden 
dat zowel mannen als vrouwen met CI baat hebben bij GLT. De eerder genoemde 
pathofysiologische verschillen kunnen een rol spelen bij het gevonden man-vrouw 
verschil in loopafstand na GLT, maar ook de vaak atypische symptoompresentatie van 
vrouwen, het verschil in klachtenperceptie en de vaak meer beperkte functie van de 
onderste extremiteiten en spierkracht dragen hier mogelijk aan bij.35 Het is echter nog 
onbekend in welke mate de individuele factoren een rol spelen. 
Hoe dan ook geeft het huidige onderzoek niet direct aanleiding tot het ontwikkelen 
van geslachts-specifieke GLT programma’s, maar aanvullend onderzoek om de kennis 
naar man-vrouw verschillen binnen de cardiovasculaire zorg verder uit te breiden is 
noodzakelijk. Zeker gezien het feit dat er nog steeds ongelijkheid bestaat tussen mannen 
en vrouwen met PAV voor wat betreft de tijd tot diagnose en de toegang tot zorg.36 
Heeft diabetes mellitus invloed op de effectiviteit van GLT?
Diabetes mellitus (DM) is een van de sterkste risicofactoren voor het ontwikkelen 
van PAV.37 De hoge prevalentie van DM onder patiënten met CI is welbekend.38 CI 
patiënten met DM lijken een slechtere functie van de onderste extremiteiten te hebben in 
vergelijking met CI patiënten zonder DM.39 Bovendien heeft DM een negatieve invloed 
op de inspanningstolerantie.40 Anderen suggereren dat IC patiënten met comorbiditeiten 
ongeschikt zouden zijn voor GLT.41 De exacte invloed van DM op het effect van GLT bij 
patiënten met IC is echter nog onbekend. Het gebrek aan kennis lijkt daardoor met name 
een barrière te vormen voor het starten van GLT.
In hoofdstuk 5 is het beschikbare bewijs ten aanzien van de rol van DM op het effect 
van GLT onderzocht. Een drietal studies waarin 845 patiënten met CI voldeed aan de 
inclusiecriteria van deze review.34, 38, 42 Alle studies rapporteerden maximale loopafstand 
na GLT, twee rapporteerden daarnaast ook de pijnvrije loopafstand, terwijl één studie 
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tevens de functionele loopafstand heeft gemeten. In zijn algemeenheid lieten patiënten 
met zowel CI als DM duidelijke vooruitgang in loopafstand zien. De vergelijking tussen 
CI patiënten met en zonder DM liet echter tegenstrijdige resultaten zien. Terwijl de 
grootste studie geen verschillen in verbeterde loopafstand liet zien38, vonden de andere 
twee studies een trend richting significantie in maximale en pijnvrije loopafstand na 
GLT.34, 42 In een subanalyse betreffende de rol van het geslacht kwam bovendien naar 
voren dat met name vrouwen met CI en DM een slechte respons hebben op GLT. Dit 
komt overeen met het verschil tussen mannen en vrouwen zoals gevonden in hoofdstuk 
4 van dit proefschrift. Hoewel nieuwe studies ter verder verduidelijking nodig zijn, heeft 
het huidige review geen argumenten gevonden om patiënten met CI en DM een traject 
GLT te onthouden. 
Hoe kunnen we de effecten van GLT juist interpreteren? 
Uitkomsten van GLT worden vaak geëvalueerd in termen van (veranderingen in) 
loopafstand. Of het beter is om deze loopafstand te meten op een loopband of door middel 
van een 6-minuten wandeltest werd onlangs bediscussieerd.43, 44 De meest optimale 
test moet direct te correleren zijn aan de zogenaamde patiënt-gerapporteerde fysieke 
beperkingen. Vanuit dit perspectief kennen beide methoden hun beperkingen. Een meting 
in de dagelijkse omgeving door middel van een global positioning system (GPS) met een 
mobiele applicatie werd onlangs beschreven en lijkt een veelbelovend alternatief voor de 
eerder genoemde methode die worden afgenomen in een gecontroleerde situatie.45 Op 
basis van eerder onderzoek wordt aangenomen dat een meting in de dagelijkse omgeving 
meer overeenkomt met de werkelijke praktijk. Anderzijds lijken deze metingen wel een 
grotere variabiliteit in de wandelcapaciteit op te leveren, ten nadelen van de test-hertest 
betrouwbaarheid.46 Aanvullende studies zijn nodig om de meest optimale uitkomstmaat 
voor het bestuderen van het effect van GLT te bepalen bij patiënten met CI.
Naast deze aanvullende studies is correcte interpretatie van de huidige 
meetinstrumenten van even groot belang. Om clinici en onderzoekers te helpen bij het 
bepalen welke numerieke verandering overeenkomt met een aanzienlijke verandering 
vanuit het perspectief van de patiënt, is het begrip ‘minimaal relevant verschil’ (Engels: 
minimally important difference, MID) geïntroduceerd.47 Met andere woorden: bij welke 
verandering is sprake van een verandering die er in de ogen van de patiënt toe doet. In 
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hoofdstuk 6 zijn de MIDs voor de loopafstand zoals gemeten op een loopbandtest geschat 
voor patiënten met CI. Met behulp van een ankermethode en longitudinale gegevens 
van 103 CI patiënten die eerder hebben deelgenomen aan een GLT programma in het 
kader van de EXITPAD studie, werden de MIDs bepaald. Voor de maximale loopafstand 
na 3 maanden GLT werden MIDs van +305 meter en +147 meter gevonden voor 
respectievelijk een verbetering en verslechtering van de loopafstand. De positieve waarde 
voor verslechtering is hierbij met name een interessante bevinding. Blijkbaar wordt een 
kleine vooruitgang in loopafstand door de patiënt niet als een relevante vooruitgang 
gevoeld. Dit is misschien niet geheel onverwacht want GLT vraagt om een aanzienlijke 
inzet, inspanning en tijdsinvestering van de patiënt (hoofdstuk 1). Hoewel de grootste 
effecten van GLT zijn beschreven na 3 maanden (hoofdstuk 2), zou het interessant 
zijn om ook MIDs te bepalen na een langere follow-up periode (d.w.z. na 12 maanden 
GLT). Daarnaast is het zinvol om ook zogenaamde patient-reported outcome measures 
(PROMS) te analyseren in de evaluatie van GLT. Echter, de kwaliteit van de huidige 
ziekte-specifieke PROMS (walking impairment questionnaire (WIQ), vascular quality of 
life questionnaire (VasQol)) laat nog te wensen over, zo blijkt uit recent onderzoek.48  
Fysieke activiteit van patiënten met CI als nieuwe uitkomstmaat?
Er is momenteel discussie over de waarde van de fysieke activiteit (FA) en de essentiële 
rol in het behouden van een goede gezondheid en algemeen welzijn.49, 50 Uit een recente 
analyse bleek dat het voldoen aan de aanbevolen minimale hoeveelheid lichaamsbeweging 
per dag (vergeleken met het niveau van ‘geen enkele lichamelijke activiteit’), leidt tot een 
vermindering in ‘sterfte door alle oorzaken’ van 19 procent.50 Een dosis-respons relatie 
tussen de mate van FA en vroegtijdig overlijden werd beschreven.51 Deze resultaten 
zijn in overeenstemming met een verklaring op de website van de ‘American Heart 
Association’ die zegt dat ‘Something is always better than nothing’.52 Opmerkelijk genoeg 
is een toename in dagelijkse fysieke activiteit net zo sterk gerelateerd aan een reductie in 
sterfte als het stoppen met roken.52 
Zoals te verwachten gelden de gunstige effecten van FA ook voor patiënten met 
PAV. Een hogere FA is geassocieerd met een kleinere functionele achteruitgang53 en 
een lagere mortaliteit.54 Het is bekend dat patiënten met CI minder frequent fysiek 
actief zijn in vergelijking met gezonde controles.55 Er zijn diverse barrières (zoals 
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persoonsgebonden en omgevingsfactoren) beschreven die patiënten met CI weerhouden 
om te gaan bewegen.56 Tot op heden wordt FA echter nauwelijks uitgevraagd, laat staan 
objectief gemeten tijdens een bezoek aan een arts (vaatchirurg) in tegenstelling tot de 
wandelcapaciteit die standaard wordt bepaald met behulp van een loopbandtest. De 
maximale wandelcapaciteit maakt onderdeel uit van de fysieke inspanningscapaciteit 
(FIC). Om te onderzoeken of de FIC als surrogaatmarker kan dienen voor FA werd een 
cross-sectionele studie verricht in hoofdstuk 7. Een totaal van 46 patiënten onderging 
een reeks van testen om de FIC te bepalen en droeg daarnaast gedurende zeven dagen een 
versnellingsmeter om de FA vast te stellen. Over het algemeen werden (zeer) zwakke tot 
matige correlaties gevonden tussen FIC en FA. Dit betekent dat deze deels overlappende 
uitkomstmaten als twee afzonderlijke entiteiten beschouwd kunnen worden. 
Het bereiken van een betere FIC leidt dus niet per definitie tot een toename van 
de dagelijkse FA. Desalniettemin, een zekere toename in FIC, veelal bereikt door 
training, blijft noodzakelijk voor een toename van FA in de thuisomgeving. De eerder 
geformuleerde conclusies komen overeen met studies die geen effect van GLT beschreven 
op de dagelijkse fysieke activiteit bij patiënten met CI.57 De huidige resultaten en de 
aangetoonde associaties tussen fysieke activiteit en mortaliteit vormen duidelijke 
argumenten om FA te introduceren als nieuwe uitkomstmaat voor patiënten met PAV (en 
mogelijk ook andere groepen van chronische patiënten). Recente studies lieten daarnaast 
zien dat ook langdurige inactiviteit (d.w.z. zitten en liggen), onafhankelijk van de mate 
van activiteit, een belangrijke risicofactor is voor vroegtijdig overlijden.58 Het lijkt daarom 
zinvol om zowel activiteit als sedentaire gedrag te meten. 
Classificatie van CI patiënten
De voorgestelde meting van het fysieke activiteitenniveau is alleen zinvol (klinisch 
relevant) wanneer dit een aanmerkelijk effect heeft op beslissingen en gedrag van een 
patiënt. FA is echter een complex eindpunt dat beïnvloedt wordt door tal van factoren 
als motivatie, training en omgeving maar ook politieke beslissingen in het kader van 
vergoedingen bijvoorbeeld. Daarnaast zijn de huidige GLT programma’s mogelijk niet 
specifiek (genoeg) om daadwerkelijk effect te hebben op FA, zoals werd aangetoond door 
uitblijven van verbetering op de FA na 3 maanden GLT.57 Daarentegen zijn er wel gunstige 
resultaten beschreven van een kortdurende psychologische interventie op het loopgedrag 
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van patiënten met CI.59 De interventiegroep die twee behandelingen van één uur ontvingen 
liet een significante verschil in het dagelijks aantal stappen (Δ1.567 stappen per dag) zien 
in vergelijking met de controlegroep die standaardzorg ontving. Dit effect hield tot 2 
jaar na de interventie aan.60 Dergelijke psychologische interventies (gespreksvoering) 
zouden uitstekend ingebouwd kunnen worden in een GLT programma, zoals uitgevoerd 
door fysiotherapeuten die getraind zijn in ‘motivational interviewing’ technieken. Op die 
manier wordt de effectiviteit van GLT op de verbetering van FA mogelijk extra verbeterd. 
In het huidige proefschrift worden metingen van zowel FIC als FA geadviseerd, 
want informatie over beide uitkomstmaten is behulpzaam bij het classificeren van IC 
patiënten (figuur 1). Naar verwachting draagt een aantal (nog onbekende) factoren 
bij aan de categorie waartoe een patiënt behoort. Bijvoorbeeld, een CI patiënt met 
een goede reactie op GLT (hoge FIC) die een sedentair leven leidt (lage FA) behoort 
tot categorie C. Een gedetailleerde karakterisatie (bijv. demografische kenmerken, 
motivatie, gezondheidstoestand, omgeving, etc.) van patiënten uit deze vier categorieën 
kan bijdragen tot het begrip van de onderliggende determinanten die het beweeggedrag 
van patiënten bepalen. Dit zou uiteindelijk kunnen leiden tot geoptimaliseerde en 
meer geïndividualiseerde zorg. Dus het doel is niet om patiënten van een ‘ongezonde’ 
categorie te verplaatsen naar een meer gezonde categorie, maar juist inzicht te verwerven 
waarom patiënten in een bepaalde categorie terechtkomen om zodoende een passende 
behandeling te kunnen geven. 
243
Samenvatting & algemene discussie
11
Figuur 1. Schematische weergave om patiënten in te delen op basis van het fysieke 
activiteitenniveau en de inspanningscapaciteit
Aanpassingen van het looppatroon door claudicatio intermittens
Spatio-temporele veranderingen van looppatroon werden eerder beschreven in patiënten 
met CI.61, 62 Ze lopen langzamer, hebben een lagere cadans (d.w.z. minder stappen per 
minuut) en een kortere staplengte. Bovendien is de zuurstofopname tijdens pijnvrij lopen 
hoger in vergelijking met controles van dezelfde leeftijd.63, 64 CI patiënten nemen blijkbaar 
een slechtere loopefficiëntie (‘cost of transport’) aan, welke nog verder afneemt op het 
moment dat de claudicatio klachten ontstaan. Cost of transport lijkt verder onder andere 
beïnvloedt te worden door het hebben van diabetes.65 Deze bevinding kan in ieder geval 
ten dele verklaren waarom CI patiënten met diabetes slechter reageren op GLT dan CI 
patiënten zonder diabetes (hoofdstuk 5). Aangezien de zuurstofopname reeds verhoogd 
is tijdens pijnvrij lopen, moeten er andere factoren zijn die ook en rol spelen hierin. 
Aanpassingen van het looppatroon dragen hier mogelijk ook aan bij.
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Uit eerder onderzoek bleek dat GLT geen effect had op het veranderde looppatroon 
bij patiënten met CI.66 Het uitblijven van verbetering kan samenhangen met onvoldoende 
afstemming van de GLT oefeningen om daadwerkelijk evidente verbeteringen te kunnen 
bewerkstelligen. Aanvullend onderzoek naar aanpassingen op bijvoorbeeld spierniveau 
zouden mogelijk nieuwe inzichten kunnen opleveren die GLT programma’s kunnen 
optimaliseren. Opmerkelijk genoeg zijn bevindingen uit voorgaand onderzoek gebaseerd 
op analyses van slechts enkele stappen terwijl het natuurlijk veel logischer is om minstens 
30 of 40 stappen te bestuderen. 
In hoofdstuk 8 en 9 van dit proefschrift werden de verschillende aspecten van het 
looppatroon van CI patiënten onderzocht met behulp van een loopbandprotocol. 
Gecontinueerde analyse tijdens het lopen op een loopband maakt beoordeling van een 
oneindig aantal stappen mogelijk. Daarnaast kan deze methodologie het looppatroon op 
het moment dat de pijndrempel bereikt is nauwkeurig analyseren. 
Allereerst werd een analyse van spatio-temporale parameters in 28 CI patiënten en 28 
gezonde voor leeftijd gematchte controles (hoofdstuk 8) verricht. CI patiënten liepen met 
een zelf gekozen snelheid van 3,3 km/uur, terwijl controles 1,2 km/uur harder liepen. Het 
duidelijkste verschil werden gevonden in contact- en afzetfase (zie figuur 2, pagina 170). CI 
patiënten lieten een 14% kortere afzetfase en een 17% langere contactfase zien. Daarnaast 
bleek de enkel-arm index (een maat voor de ernst van de ziekte en atherosclerotische 
occlusie) gecorreleerd te zijn aan zowel de loopsnelheid als de afname in afzet tijdens 
het optreden van claudicatio pijn. CI patiënten blijken dus tijdens iedere stap net iets 
langer stil te staan. Deze aanpassingen kunnen intuïtief verklaard worden wanneer men 
bedenkt dat de arteriële bloedinstroom en daarmee zuurstoftoevoer naar de skeletspieren 
plaatsvindt tijdens deze relaxatiefase.67, 68 Dit kan ook verklaren waarom CI patiënten niet 
kleinere stappen gaan zetten als de pijn optreedt, maar juist minder, zoals ook in eerder 
onderzoek beschreven werd.69  
Op basis van deze spatio-temporele resultaten (hoofdstuk 8) werd gedacht dat CI 
patiënten misschien wel gebruik maken van een langere contactfase om zodoende een 
maximale spierontspanning te bewerkstellingen. Immers, hoe langer de ontspanning des 
te meer tijd voor instroom van bloed. Hoofdstuk 9 beschrijft de verschillende analyses 
met behulp van kinematica en oppervlakte elektromyografie (EMG) om deze hypothese 
te toetsen. De onderzoekspopulatie bestond uit 22 CI patiënten en 22 gezonde gematchte 
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controles. De kinematische (d.w.z. knie- en enkelgewrichtshoeken) analyse toonde een 
significant kleinere enkelbeweging (-28%) bij CI patiënten en ondersteunt daarmee de 
eerder geformuleerde hypothese. Echter, de EMG data toonden geen verschillen aan 
in duur van spieractiviteit van de tibialis anterior en de mediale gastrocnemius (m.a.w. 
kuitspier) spieren. Patiënten met CI gebruiken de belangrijkste onderbeenspieren voor 
het lopen dus voor een vergelijkbare duur als gezonden. De duur van de spieractiviteit 
werd uitgedrukt als percentage van de complete gangcyclus om te corrigeren voor de 
verschillen in loopsnelheid tussen beide groepen en kunnen dus onderling met elkaar 
vergeleken worden ondanks het verschil in loopsnelheid. 
Concluderend, CI patiënten vertonen duidelijke spatio-temporele en kinematische 
veranderingen van het looppatroon, zelfs al voordat de claudicatiopijn optreedt. Het is 
echter niet aangetoond dat deze strategie ook leidt tot een kortere aanspanning van de 
kuitspier aangezien de duur van spieractiviteit gelijk was in gezonde controlepersonen. 
Er zijn verschillende manieren om deze resultaten te verklaren. Oppervlakte EMG meet 
uitsluitend spieractiviteit en geen spierkracht. Het is eerder beschreven dat een minimale 
intensiteit (d.w.z. boven 50% van de maximale vrijwillige contractiekracht) vereist is 
om een verlaging van de arteriële bloeddoorstroming van de kuitspier te veroorzaken. 
Het is dus mogelijk dat niet de duur, maar de mate van aanspanning verschillend is 
tussen CI patiënten en gezonde controles. Dit idee wordt ondersteund door onderzoek 
waarin een verminderde afzetkracht en een afgenomen vermogen van de kuitspieren 
bij claudicanten werden beschreven.70, 71 Anderzijds zijn de gevonden spatio-temporele 
en kinematische veranderingen mogelijk niet een (on)bewuste strategie om met de aan 
CI gerelateerde arteriële obstructie te gaan, maar juist het gevolg van een, deels door 
ischemie veroorzaakte, vermindering van spierkracht. Dit zou namelijk ook de ongunstige 
metabole efficiëntie (cost of transport) van CI patiënten kunnen verklaren, aangezien een 
verminderde spierkracht bijdraagt aan een verminderde loopsnelheid en een beperkte 
wandelcapaciteit. 
Implicaties voor de praktijk en suggesties voor nieuw onderzoek
Beleidsmatig dienen serieuze inspanningen geleverd te worden om de beperkte 
beschikbaarheid en toegang tot GLT te slechten zodat deze voorkeursbehandeling 
routinematig en wereldwijd in de klinische praktijk kan worden toegepast. Het succes 
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van het ClaudicatioNet netwerk bewijst dat aanzienlijke financiële investeringen niet 
per se nodig zijn. Maar louter beschikbaarheid van een landelijk netwerk van GLT is 
niet genoeg, omdat dit systeem feitelijk alleen een goede infrastructuur biedt. Na de 
oprichting van een netwerk, is structurele financiering noodzakelijk voor waarborging 
van de faciliteiten. Dit zou in de Nederlandse situatie bijvoorbeeld bewerkstelligd kunnen 
worden door opname van GLT in het basispakket van de zorgverzekering. Daarnaast 
is permanente scholing van CI gerelateerde onderwerpen noodzakelijk om artsen, 
fysiotherapeuten alsmede patiënten te motiveren.
Toekomstig wetenschappelijk onderzoek zou zich idealiter dienen te richten op 
inhoudelijke verbetering van GLT. Het meest optimale en effectieve GLT programma 
alsook de ontwikkeling van aangepaste programma’s voor subgroepen van CI patiënten 
moet worden vastgesteld. Daarnaast lijkt met name het verwerken van voorstellen tot 
leefstijlverandering in het GLT programma veelbelovend. Advies en interventies rondom 
de (ongezonde) leefstijl passen uitstekend bij de voorgenomen toevoeging van fysieke 
activiteit als uitkomstmaat voor patiënten met CI. Immers, verbetering van de fysieke 
activiteit maakt vanzelfsprekend onderdeel uit van de leefstijl. Aangezien het erg lastig is 
om diepgeworteld gedrag te veranderen, moet een andere onderzoeksfocus zich richten 
op het verkrijgen van inzicht in de factoren die het beweeggedrag van CI patiënten 
bepalen. Het voorgestelde model in figuur 1 kan ondersteunen in het vergaren van inzicht 
en het identificeren van determinanten die bepaald gedrag kan verklaren. 
Ten derde kan het effect van specifieke spierkrachttraining van de onderste 
extremiteiten op loopafstand en looppatroon verder worden onderzocht. Spierkracht 
levert een belangrijke bijdrage aan zowel de loopsnelheid als balans (en daarmee het 
valrisico),72 en het lijkt dan ook logisch om spierkrachttraining toe te voegen aan een GLT 
programma. Echter, eenduidig wetenschappelijk bewijs hiervoor ontbreekt. Voorgestelde 
suggesties zijn wel in lijn van de huidige trend waarop GLT ingevuld wordt, namelijk in 
de vorm van een gevarieerd aanbod aan oefenvormen.73 Longitudinale EMG registratie 
(d.w.z. een nulmeting gevolgd door een interventie en follow-up meting) kan behulpzaam 
zijn bij het bepalen van het effect van GLT op de spierkracht en het looppatroon, aangezien 
tijdens gepaarde metingen EMG amplitudes wel geïnterpreteerd mogen worden als zijde 
spierkracht. 
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De resultaten van dit proefschrift leverden bewijs voor specifieke veranderingen in 
het looppatroon bij claudicanten, met name op het niveau van de contact- en afzetfase. 
Aangezien deze veranderingen duidelijk verband hielden met de loopsnelheid, dient een 
vierde onderzoeksfocus te liggen op studies naar de mogelijkheden om de loopsnelheid 
te verbeteren. Dit zou vervolgens kunnen leiden tot een verbetering van het looppatroon. 
Conclusies van dit proefschrift
1. Gesuperviseerde looptherapie (GLT) is een veilige behandeling bij patiënten met 
claudicatio intermittens (CI).
2. GLT leidt tot een grotere loopafstand in vergelijking met andere conservatieve 
behandelopties.
3. Vrouwen met CI hebben de neiging om minder te profiteren van GLT als het gaat 
om een verbeterde maximale loopafstand. 
4. Diabetespatiënten met CI hebben ook baat bij GLT.
5. De ‘minimaal relevante verschillen’ van de loopband bepaalde maximale 
loopafstand voor verbetering en verslechtering, zijn respectievelijk +305 en +147 
meter. De positieve waarde van het relevant verschil voor een verslechtering van de 
loopafstand geeft aan dat zelfs een kleine verbetering blijkbaar niet afdoende is in 
de ogen van de patiënt.
6. De correlaties tussen de fysieke inspanningscapaciteit (FIC) en dagelijkse fysieke 
activiteit (FA) bij patiënten met CI zijn zwak tot matig. Dit betekent dat FIC en 
FA, hoewel enigszins met elkaar overeenkomend, beschouwd moeten worden als 
verschillende entiteiten.
7. Patiënten met CI lopen langzamer en vertonen een korte afzetfase en afgenomen 
enkelbewegingen in vergelijking met gezonde controles. Daarentegen zijn er geen 
verschillen in aanspanningsduur van de tibialis anterior en mediale gastocnemius 
spieren. Echter, tijdens lopen met door ischemie geïnduceerde pijn, zijn de 
elektromyografische amplitudes wel significant hoger dan tijdens pijnvrij lopen. 
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VALORISATIE
Introductie 
Claudicatio intermittens (CI) is de meest voorkomende uitingsvorm van perifeer 
arterieel vaatlijden (PAV) en wordt gekenmerkt door inspanning gebonden pijn in de 
benen, welke verdwijnt na een periode van rust.1 De loopafstand is daardoor beperkt 
en bijkomend kan sprake zijn van een verminderd uithoudingsvermogen, verlies van 
spierkracht, verhoogd valrisico en angst voor pijn en/of inspanning.2-4 Uit onderzoek 
blijkt verder dat patiënten met PAV een verminderde kwaliteit van leven rapporteren en 
slechter scoren op functionele testen.5 Om klachten te maskeren gaan patiënten tijdens de 
noodzakelijke rustpauzes soms voor een winkeletalage staan. CI wordt daarom ook wel 
‘etalagebenen’ genoemd. 
PAV is vrijwel altijd het gevolg van atherosclerose (slagaderverkalking).6 De 
bloedvaten van en naar de benen raken vernauwd en/of verstopt, waardoor de toevoer 
van bloed en daarmee zuurstof naar de spieren (bij inspanning), tekort schiet. Nog vaak 
wordt vergeten dat atherosclerose een systeemziekte is. Niet alleen de bloedvaten in de 
benen zijn aangedaan, maar ook de kransslagaders rond het hart en de slagaders naar en 
van de hersenen. Daardoor hebben patiënten met PAV een aanzienlijk verhoogd risico op 
een hart- en/of herseninfarct, ten opzichte van mensen zonder PAV. Dit gaat gepaard met 
een aanzienlijke morbiditeit. Bovendien is de levensverwachting verkort met ongeveer 
10 jaar.7
Veelvoorkomend gezondheidsprobleem 
In Nederland krijgen jaarlijks ruim 25.000 mensen de diagnose CI te horen. Wereldwijd 
ligt het aantal mensen met PAV net boven de 200 miljoen.8 In het afgelopen decennium 
is het aantal patiënten met bijna een kwart gestegen. De grootste toename wordt gezien 
in de laag- en middeninkomenslanden, waar onder invloed van de toenemende welvaart 
geassocieerde ziekten als obesitas en diabetes mellitus steeds vaker voorkomen.8 
Voor de gezondheidszorg als geheel heeft de behandeling van PAV een groot aandeel 
in de totale zorgkosten, welke naar verwachting de komende jaren alleen verder zullen 
stijgen. Terecht werd recent een oproep gedaan aan overheden, relevante organisaties 
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en de private sector om met een oplossing te komen voor de maatschappelijke en 
economische consequenties van PAV.8 
Gesuperviseerde looptherapie als totaalbehandeling voor CI
Gesuperviseerde LoopTherapie (GLT), dat wil zeggen onder begeleiding van een 
fysiotherapeut trainen, is de eerste keus behandeling voor patiënten met CI en wordt 
in (inter)nationale richtlijnen  van zowel de eerste als tweede lijn geadviseerd.7, 9 Studies 
die GLT vergeleken met een loopadvies en/of een vasculaire interventie (zoals: een 
dotter, stent of bypass operatie) hebben overtuigend bewijs geleverd dat GLT de meest 
kosteneffectieve behandeling is.10-13 Recent werd de toegevoegde waarde van GLT ten 
opzichte van een vasculaire interventie ook aangetoond door haar positieve effecten op 
balans en het valrisico.14 Daarnaast heeft GLT invloed op het gehele cardiovasculaire 
systeem, waaronder het contralaterale been welke ten tijde van de therapie mogelijk 
nog asymptomatische is.15, 16 Een GLT programma van (slechts) 12 weken reduceert de 
mortaliteit en morbiditeit door cardiovasculaire oorzaken daardoor aanzienlijk.17
Op dit moment wordt slechts een minderheid van de patiënten met CI verwezen voor 
GLT, zo bleek uit een analyse van Nederlandse verzekeringsgegevens.18 Deze analyse liet 
ook zien dat wanneer 80% van de patiënten met CI wordt verwezen voor GLT en deze 
GLT wordt vergoed, een kostenbesparing van 33 miljoen gerealiseerd kan worden.18 Met 
het oog op noodzakelijk besparingen in de zorg en het toenemend aantal patiënten met 
CI, zou GLT toch een aantrekkelijke behandeling moeten zijn. 
Onterechte barrière door onzekerheid rondom veiligheid 
Er bestaat onzekerheid onder zowel fysiotherapeuten als verwijzend artsen over de 
veiligheid van GLT voor (bepaalde) CI patiënten (bijvoorbeeld bij patiënten met cardiale 
comorbiditeit). Deze onzekerheid wordt gevoed door adviezen uit (inter)nationale 
richtlijnen om CI patiënten voor aanvang van de behandeling cardiopulmonaal te 
screenen.7, 19 Vanzelfsprekend is veiligheid van therapie een belangrijk thema en dient het 
risico op complicaties in verhouding te staan tot de noodzaak van behandeling. Daarnaast 
moeten alternatieve behandelvormen overwogen worden. 
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Gedegen wetenschappelijk bewijs ten aanzien van de veiligheid van GLT ontbrak 
echter en vormde een duidelijke barrière om patiënten te verwijzen voor GLT. In dit 
proefschrift (hoofdstuk 3) werd aangetoond dat GLT een veilige behandeling is, zonder 
een noemenswaardig aantal complicaties.20 Daarentegen gaat de alternatieve invasieve 
behandeling (dotter, stent, bypassoperatie) gepaard met door literatuur ondergeschreven 
complicaties als bloedingen, trombo-embolische events en infecties.21 Ingegeven door de 
resultaten uit dit proefschrift werd het advies tot cardiale screening voor aanvang van 
GLT geschrapt uit de herziene richtlijn van het Koninklijk Nederlands Genootschap voor 
Fysiotherapie (KNGF, 2014).22 
‘Claudicatiotherapeut’ 
GLT is eigenlijk geen goede benaming meer voor wat een daartoe getrainde fysiotherapeut 
onder deze noemer moet gaan leveren. Want naast intervaltraining op de loopband, bestaat 
behandeling van CI uit oefeningen ter verbetering van het algehele uithoudingsvermogen, 
spierkracht, coördinatie, balans en meer specifiek het looppatroon. In de hoofdstukken 
8 en 9 van dit proefschrift werden naar aanleiding van de gevonden verschillen in het 
looppatroon van patiënten met claudicatio intermittens, concrete adviezen geformuleerd 
voor fysiotherapeuten. Er werd gesuggereerd dat verbetering van het looppatroon een 
positief effect kan hebben op de efficiëntie van lopen, waardoor de actieradius vervolgens 
positief wordt beïnvloed. Op deze manier draagt dit proefschrift bij aan de inhoudelijke 
verbetering van GLT.  
De behandeling dient zich daarnaast te richten op aanwezige cardiovasculaire 
risicofactoren, als stoppen met roken, meer bewegen, stimuleren van een verantwoord 
dieet en een gezond gewicht. In de komende jaren dient het accent nog meer op 
beïnvloeding van leefstijl te worden gericht, want uiteindelijk bepaalt leefstijl (en in het 
bijzonder de fysieke activiteit) de prognose (risico op vroegtijdig overlijden) van patiënten 
met CI.23 De claudicatiotherapeut wordt daarmee een gespecialiseerde leefstijlcoach, die 
als onderdeel van de totaalbehandeling ook medicatie compliance controleert en waar 
nodig non-compliance rapporteert aan de verwijzende arts. Idealiter de huisarts, want 
CI is een eerstelijns aandoening die op dit moment nog teveel door vaatchirurgen wordt 
gezien. 
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Wetenschappelijk bewijs voor de meerwaarde van leefstijl coaching tijdens GLT is 
nog niet beschikbaar. Maar dat lijkt een kwestie van tijd. Recent onderzoek bij patiënten 
met CI toonde aan dat een kortdurende interventie met motiverende gespreksvoering, 
een positief effect had op het dagelijkst loopgedrag.24 Bovendien lijkt met name herhaalde 
gespreksvoering effectief en hield het effect tot twee jaar na de interventie stand.25 Laat 
juist een GLT traject met bijna 50 contactmomenten gedurende een jaar de perfecte 
gelegenheid zijn om motiverende gesprekvoering toe te passen. 
ClaudicatioNet 
In 2011 werd het landelijk netwerk van fysiotherapeuten voor de behandeling van 
patiënten met CI opgericht. Op dit moment bestaat landelijke dekking van regionale 
netwerken en zijn ruim 1.400 therapeuten aangesloten.26 Naast de scholingseisen volgen 
deelnemers tijdens het specialisatietraject tot claudicatiotherapeut onder andere een 
driedaagse cursus motiverende gespreksvoering. Hierin wordt geleerd om patiënten te 
stimuleren tot verandering (van leefstijl) door te praten over verandering. Waar hulp 
van de huisarts gewenst is, kan dat via een verzoek aan de huisarts met toelichting, aan 
de patiënt worden meegegeven. Stoppen met roken, een gezond dieet, verantwoord 
gewicht, maar ook medicatie compliance worden zo een gezamenlijke actie van patiënt, 
claudicatiotherapeut én de huisarts. Met voortdurende scholing wordt getracht deze 
kwaliteit van zorg te waarborgen. 
Uit oogpunt van transparantie zijn deelnemende therapeuten zichtbaar op de 
landelijke website via een persoonlijk portfolio en wordt vanaf 1 januari 2016 via het 
elektronisch patiëntendossier geanonimiseerde data verzameld over therapieresultaten. 
Met deze gegevens kan GLT verder verbeterd worden door te leren van fysiotherapeuten 
die bovengemiddelde resultaten behalen. Met behulp van intervisie kan deze kennis en 
kunde worden overgedragen.
Geïndividualiseerde behandeling 
Vanwege de sterke associatie tussen leefstijlfactoren en mortaliteit is verandering van 
leefstijl een belangrijke pijler van de behandeling van CI. Verandering van gedrag en 
diepgewortelde gewoontes (verslaving) is echter bijzonder moeilijk.27 Daarnaast is 
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matige motivatie voor GLT onder patiënten niet onvoorstelbaar, gezien de alternatieve 
behandeling die geen inspanning van de patiënt vraagt en wel een snelle en effectieve 
oplossing verzorgt. 
Het is bekend dat mensen verschillende coping strategieën gebruiken om problemen 
op te lossen. Het is voor te stellen dat mensen voor gedragsverandering ook verschillende 
stijlen hanteren. Voortbordurend op de resultaten van hoofdstuk 7 uit dit proefschrift 
werd in de algemene discussie (hoofdstuk 10) een model geïntroduceerd waarmee 
patiënten op basis van twee uitkomstmaten geclassificeerd kunnen worden. Door 
vervolgens, bij voorkeur prospectief, gegevens te verzamelen van deze patiënten kan 
aanvullend inzicht verworven worden van de kenmerken (demografie, motivatie, 
ziektegeschiedenis) die mogelijk een rol spelen bij bepaald gedrag. Een vervolgstap van 
dit onderzoek zou een studie kunnen zijn naar geïndividualiseerde zorg die past bij de 
kenmerken van een bepaalde categorie van patiënten. Op deze manier kan GLT wellicht 
verder geoptimaliseerd worden. 
Hoe nu verder?
Structurele bekostiging is essentieel voor het slagen van GLT. Financiering zou 
bijvoorbeeld gerealiseerd kunnen worden vanuit het basispakket van de zorgverzekering. 
Volgens het stepped-care principe worden alle patiënten met CI in eerste instantie 
verwezen voor GLT en pas wanneer onvoldoende resultaat wordt geboekt, kan een 
invasieve behandeling overwogen worden. 
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DANKWOORD
Graag wil ik een aantal personen bedanken voor de directe of indirecte bijdrage aan het 
tot stand komen van dit proefschrift.
Allereerst de deelnemers aan mijn onderzoeken, zowel de patiënten met claudicatio 
intermittens als gezonde proefpersonen. Zonder uw belangeloze inzet in naam van de 
wetenschap was dit proefschrift er niet geweest. Hartelijk dank hiervoor! 
Professor dr. J.A.W. Teijink, beste Joep. ‘Ambitieuze studenten met interesse in onderzoek’, 
zo luidde de oproep op het studentenprikbord waar ik ruim drie jaar geleden op reageerde. 
Twee dagen na het versturen van mijn brief zat ik al aan jouw bureau en weer een uur 
verder was mijn promotieonderzoek beklonken. Jij grapte toen al over de flikflak die ik 
door de gang zou maken na de afronding van mijn proefschrift. Onze kennismaking 
was illustratief voor jouw werkwijze en de rest van mijn promotietraject. Je grenzeloze 
energie, enthousiasme en daadkracht inspireren mij enorm. Ik prijs mijzelf gelukkig met 
de kansen en het vertrouwen dat ik heb gekregen om in alle vrijheid onderzoek te doen en 
mijn eigen plannen uit te kunnen werken. Maar ook je adviezen en support toen duidelijk 
werd dat ik mijn carrière wilde vervolgen binnen de Kindergeneeskunde heb ik enorm 
gewaardeerd. Joep, dank voor alles! Zullen we die flikflak nu maar eens gaan doen?
Dr. M.R.M. Scheltinga, beste Marc. Ik ken weinig mensen die in jouw ongekende tempo 
artikelen lezen en van kritische opmerkingen voorzien. Een perfecte match met de strakke 
planning zoals ik die voor ogen had. Naast scherpe inhoudelijke opmerkingen, heb je met 
recht een ‘taalbult’, zoals je dat zelf weleens treffend omschreef. Artikelen liepen na jouw 
aanvullingen als een trein en taal-technisch heb ik enorm veel van je geleerd. Ik heb 
bewondering voor de passie waarmee je onderzoek doet en hoop in de toekomst jonge 
onderzoekers op dezelfde manier enthousiast te kunnen maken.
Dr. K. Meijer, beste Kenneth. Ik was op zoek naar een inhoudelijk expert op het gebied 
van gangbeeldanalyse. Via Frans Brooijmans kwam ik bij jou terecht en zonder twijfel 
besloot je om als copromotor in dit project te stappen. Ik heb onze bijeenkomsten in 
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Maastricht als zeer leerzaam ervaren en wil je bedanken voor de inhoudelijke bijdrage 
aan mijn onderzoek naar het looppatroon van patiënten met claudicatio intermittens. 
Medeauteurs van diverse artikelen, dank voor jullie bijdrage aan het tot stand brengen 
van een aantal mooie publicaties. 
Leden van de beoordelingscommissie, hartelijk dank voor de beoordeling van mijn 
manuscript.
Paranimfen: 
Lieve Ilse, er zijn weinig mensen die mij zo goed kennen als jij. Vanaf de dag dat 
we elkaar leerden kennen als studiegenoten aan de opleiding Fysiotherapie zijn we 
onafscheidelijk. Tegenwoordig helaas wat meer in de figuurlijke zin van het woord. Ik 
heb geen enkel moment getwijfeld om jou te vragen, mij tijdens de verdediging van dit 
proefschrift bij te staan. Bedankt voor je interesse in mijn onderzoek, maar vooral ook 
voor je wijze raad, lieve woorden, altijd attente appjes en bijzondere momenten die wij 
samen hebben beleefd. 
Lieve Daniëlle, ik weet nog dat jij tijdens mijn sollicitatiegesprek per ongeluk binnen 
liep. Als vanzelfsprekend werd ik aan jou voorgesteld als nieuwe collega en twee dagen 
later maakte jij mij wegwijs in de website van ClaudicatioNet. Daarna volgde een tijd 
van coschappen waardoor ik slechts af en toe in het ziekenhuis was en wij elkaar vooral 
zagen bij de basiscursussen die we door het hele land gaven. Maar jij was en bent altijd 
geïnteresseerd gebleven in zowel mijn onderzoek als sociale leven daarbuiten. Binnen de 
vaatclub zijn we ‘partners in crime’ en met recht ben jij dan ook mijn vaatmaatje! Fijn dat 
jij op dit bijzondere moment naast me wil staan.
Collega onderzoekers (uit de kelder): Geert, Emmeline, Martin, Thijs, Maikel, Gijs en 
Boudewijn. Vaak werd er hard gewerkt, soms ook goed ontspannen. Tijdens de eerste 
promovendiborrel van het Catharina Ziekenhuis, een paar dagen vóór mijn vertrek uit 
het Catharina Ziekenhuis, werd ik mij er pas echt van bewust hoe uniek, fijn en effectief 
onze (veel besproken) kelder is. Ik wens een ieder veel succes met het afronden van zijn/
haar promotieonderzoek. 
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Vaatclub: Marc, Philippe, Eva, Olga, Anja, Yvonne, Jolien, Edith, Bianca, Saskia, Lotte, 
Bart-Jeroen, Gert-Jan, Hugo, Rutger, Pieter, Yannick, David, Emiel, Marijn, Regine, 
Nicole en Sjaak. Heerlijk om bij zo’n leuke club te mogen horen! De tripjes naar Budapest 
en Porto, de vaatdagen in Noordwijkerhout en de jaarlijkse vaatuitjes waren onvergetelijk 
en ga ik zeker missen. Het gaat jullie allemaal goed!
Nicole, bedankt voor je adviezen bij het opstellen van mijn onderzoeksprotocollen en 
dank ook voor alle hulp bij het afronden van mijn proefschrift. 
David en Marijn, mijn opvolgers in de perifere onderzoekslijn. Heel veel succes! 
ClaudicatioNet: Loes, Yvonne, Robert, Steven, Tobias, Ben, Simon, Frans, Harm en alle 
fysiotherapeuten aangesloten bij ClaudicatioNet. Ik vind het een eer om mee te mogen 
denken en doen in dit unieke landelijke netwerk. Met veel plezier heb ik vele cursussen 
gegeven aan altijd enthousiaste deelnemers. Voor alle patiënten met claudicatio 
intermittens hoop ik dat de ClaudicatioNet plannen uiteindelijk werkelijkheid mogen 
worden.  
Maatschap Chirurgie Catharina Ziekenhuis, dank voor de mogelijkheid om in dit 
prachtige ziekenhuis onderzoek te mogen doen. Medewerkers Polikliniek Chirurgie, 
bedankt voor de ondersteuning tijdens het includeren van potentiële studiepatiënten. 
Arts-assistenten en semi-artsen Chirurgie, alle geluk met jullie carrières. 
Frans, zonder twijfel wil ik ook jou persoonlijk bedanken. Toen ik je belde om te praten over 
mijn onderzoeksplannen was jij meteen bereid om je praktijk, inclusief meetopstelling, 
24/7 voor mij open te stellen zodat ik mijn metingen kon doen. Het was een voorrecht om 
in jouw gezellige praktijk, waar we op vrijdagmiddag regelmatig een glas wijn dronken, 
te gast te zijn. Ik bewonder je sportiviteit, je energie en de manier waarop je op geheel 
eigen wijze je praktijk runt. Ook heb ik genoten van onze gezamenlijke ‘optredens’ tijdens 
ClaudicatioNet cursussen en op het jaarcongres. Gelukkig mogen we in maart nog een 
keer. Veel geluk met het afronden van jouw eigen promotieonderzoek. 
Beste Roel, toen ik belde met een vraag over de synchronisatie van mijn meetopstelling 
was je meteen bereid om mee te denken. Sterker nog, om half 2 ’s nachts mailde jij met 
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een mogelijke oplossing nadat je de complete handleiding van een veel te ingewikkelde 
synchronisatiebox had doorgenomen. Jij knutselde de befaamde kabel waarmee 
uiteindelijk metingen bij zo’n 100 personen zijn verricht. Zonder jouw technische kennis 
en hulp was dat niet gelukt. Enorm bedankt! 
Studenten: 
Annemieke, wat heb ik het met jou getroffen. In het kader van de LoopPad studie 
voerden we samen meer dan 70 metingen uit om het looppatroon van patiënten met 
claudicatio intermittens in kaart te brengen. ’s Ochtends, ’s avonds en in het weekend, 
jij was altijd bereid om te komen. Van dichtbij maakte je de frustraties mee toen het 
meetsysteem maar niet leek te functioneren en samen sprongen we een gat in de lucht 
toen het uiteindelijk was gelukt. Ik kijk met veel plezier terug op alle serieuze metingen, 
maar ook op de gezellige en hilarische momenten daar omheen. De kers op de taart 
was het congres in Maastricht waar we beiden een presentatie mochten geven. Wat een 
topweekend was dat! Ik bewonder je inzet en motivatie en wil je nogmaals bedanken voor 
al je hulp. 
Ingeborg en Robbin, jullie beiden wil ik bedanken voor de bijdrage aan de MovePAD 
studie. Zonder jullie hulp was het zeker niet gelukt om in zo’n korte tijd een uitgebreid 
pakket aan metingen te verrichten bij meer dan 50 patiënten. De vlotte publicatie die 
daarop volgde komt jullie meer dan toe. 
Dierbare vriendinnen: Patricia, Kyra en Roos. Als we elkaar zien, vragen jullie altijd 
met oprechte interesse naar mijn promotieonderzoek. Als we elkaar niet zien, omdat ik 
weer eens te druk ben met onderzoek en werk, is ook dat altijd goed. Wat fijn om zulke 
vriendinnen te hebben! Met het afronden van dit proefschrift is er hopelijk weer wat meer 
tijd om samen door te brengen. 
BMW-chicks: Sanne K, Sanne F, Marjan, Loes, Karin en Noortje. Samen begonnen 
we aan de studie Biomedische Wetenschappen en woonden we allemaal op kamers in 
Nijmegen. Vele etentjes, stapavonden, feestjes, kroegentochten en volleybaltoernooien 
volgden. Ruim acht jaar later wonen we verspreid over het land, hebben we uiteenlopend 
werk, is de eerste promotie voltrokken, de eerste bruiloft gevierd en de eerste puppy 
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aangeschaft! Het aantal etentjes, feestjes en borrels is helaas wat minder geworden, maar 
als we elkaar zien, is het onveranderd gezellig en wordt er onverminderd veel over onze 
favoriete onderwerpen gesproken. Maar wat is het fijn om elkaar ook zo goed te begrijpen 
wanneer het tijdens mijn onderzoek soms wat minder ging. Ik hoop dat er nog meer 
promoties, bruiloften en baby’s mogen volgen.
Team ‘A’: Loes, Esther, Evelien en Suzanne. Met elkaar begonnen we als coassistenten en 
wat was het leuk om de eerste ervaringen en verhalen uit het ziekenhuis met elkaar te delen. 
Samen begonnen we daarna als dokters aan hele verschillende, stuk voor stuk ambitieuze 
trajecten. We hebben eindeloos over elkaars keuzes gesproken en sollicitatiegesprekken 
samen voorbereid. Dank voor al jullie adviezen, interesse en onze fijne vriendschap. Ik 
hoop dat we onze succesreeks nog lang mogen voortzetten. 
Feestcommissie (‘4, 5, 6 feest’): Joyce en Kathelijn! Na onze succesvolle organisatie van 
het vriendenweekend in de Ardennen, was er geen twijfel over mogelijk dat de organisatie 
van mijn promotiefeestje bij jullie in goede handen zou zijn. Ik waardeer jullie oprechte 
interesse in al mijn bezigheden. Samen gaan wij er een mooie avond van maken.
Vrienden uit Eindhoven. Gelukkig zijn er genoeg feestjes om af en toe te ontspannen. Nu 
dit proefschrift is afgerond, ga ik proberen weer wat vaker van de partij te zijn. 
Lieve pap en mam, broer Kay, schoonzus Nadine, oma’s, opa en schoonouders Ad en 
Lenie. In zowel aandacht als tijd doe ik jullie allen soms te kort. De onvoorwaardelijke 
steun bij alle keuzes die ik maak, waardeer ik daarom des te meer. Het is fijn om in alle 
drukte en hectiek te weten dat ik bij mijn familie altijd terecht kan.
Liefste Niels, onbeschrijfelijk dankbaar ben ik voor je liefde, het vertrouwen en de vrijheid 
die je mij geeft om al mijn dromen waar te maken. Ik houd van ons leven en kijk uit naar 
onze droom samen!
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“Gesuperviseerde looptherapie is een 
veilige en de meest kosteneffectieve 
behandeling voor patiënten met claudicatio 
intermittens. Idealiter richt gesuperviseerde 
looptherapie zich naast het vergroten van 
de loopafstand, balans en spierkracht op 
(ongezonde) leefstijlfactoren. Stimuleren 
van fysieke dagelijkse activiteit, stoppen 
met roken en een verantwoord eetpatroon 
worden zo onderdeel van de algemene 
‘claudicatiobehandeling’. Dergelijke aanpak 
moet zorgen voor een meer duurzame 
behandeling van deze patiëntengroep.”
Lindy Gommans
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